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ABSTRACT
Drug-induced liver injury (DILI) is the most frequent cause for withdrawal of approved drugs 
and attrition of drug development. Although the cellular mechanisms of DILI leading to overt 
tissue and organ damage are still not frilly defined, model hepatotoxins such as 
acetaminophen (paracetamol; APAP) have been used in animal models to provide important 
insight into the relationship between chemical structure, drug metabolism and cellular 
response. The overall extent of APAP injury is thought to be dependent on the activation of 
cell-cell signalling pathways, in particular between hepatocytes and cells of the innate 
immune system. However, the extent of the role of the innate immune and inflammatory 
response in the modulation of liver injury remains poorly defined, with conflicting evidence 
in the literature. The work presented in this thesis has used model hepatotoxins APAP and 
galactosamine (GalN) and the innate immune stimulator lipopolysaccharide (LPS) as tools to 
explore the mechanism of inflammation associated with DILI with the aim to further 
understand the various inflammatory pathways during DILI and their contribution to the 
progression of liver injury.
Male C57BL/6 mice were used to investigate the inflammatory response associated with 
APAP, GalN and LPS exposure. Inflammation was measured as serum levels of TNF-a, IL-6 
and IL-ip by ELISA and neutrophil infiltration as assessed by histological analysis. 
Hepatotoxicity in the APAP model was characterised by a dose and time-dependent increase 
in serum ALT and was confirmed by histological analysis (0-1000mg/kg; 0-24hr). Significant 
elevations in levels of TNF-a, IL-6 and IL-lp were observed in the serum of mice following 
APAP overdose (530mg/kg; 0-24hr). Overnight fasting of mice led to a greater hepatotoxic 
and inflammatory response compared to non-fasted mice post APAP treatment. The LPS 
model was characterised by having no hepatotoxicity, as serum ALT activity remained at 
control levels (control - 41.37±8.45U/1; LPS - 50.57±5.56U/1; 5mg/kg; 24hr) and having a 
potent inflammatory response as determined by cytokine release (TNF-a - 
513.13±50.15pg/ml; IL-6 - 1201.12±157.20pg/ml; IL-ip - 227.08±39.93pg/ml; 5mg/kg; 
24hr) and neutrophil infiltration. The GalN model was characterised by mild hepatotoxicity 
(ALT activity 875,30±144.81U/1; 800mg/kg; 24hr) and a mild inflammatory response, with 
increase in cytokines (TNF-a - 56.44±5.68pg/ml; IL-6 - 63.22±8.41pg/ml; IL-ip - 
40.72±3.64pg/ml; 800mg/kg; 24hr) and neutrophil infiltration. Concurrent administration of 
suppressors of either metabolism (DMSO), or the innate immune response (aspirin, ethyl 
pyruvate and anti-HMGBl antibody) was also investigated. DMSO inhibited APAP 
metabolism, whereas aspirin had no effect on APAP toxicity or the inflammatory response. 
Delayed administration of ethyl pyruvate reduced toxicity and sermn HMGB1 content post 
APAP. Expression of RAGE mRNA over a 24hr time course was measured in whole livers of 
fasted and fed mice treated with APAP by RT-PCR. Full-length (flRAGE), endogenous 
secretory (esRAGE) and total (tRAGE) isoforms of RAGE increased in fed mice between Ihr 
and 3hr. Fasted mice showed a more prolonged increase in expression of all 3 isoforms of 
RAGE, culminating in a peak increase at 5hr. Western blot analysis determined that there 
were no changes in RAGE protein expression in whole liver over a 24hr period of APAP
/v
exposure. In situ hybridisation revealed a nuclear* accumulation of RAGE mRNA in 
hepatocytes following APAP exposure.
In summary, the studies described in this thesis have provided further evidence for the role of 
inflammation during DILI by using and developing a variety of in vivo models. These models 
assessed both basic and novel mechanisms of inflammation, such as cytokine release, hepatic 
neutrophil infiltration and RAGE expression, and tested potential therapeutic inhibitors such 
as aspirin and EP.
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1.1 INTRODUCTION
Adverse reactions to drugs are one of the main causes of hospital admission (Pirmohamed et 
al.s 2004), leading to patient morbidity and mortality and are largely responsible for drug 
attrition during development (Park et al, 2005). Whilst adverse drug reactions affect every 
organ system within the body, the liver is one of the most commonly affected organs. Drug- 
induced liver injury (DILI) has proven to be a major problem for both the pharmaceutical 
industry and regulatory authorities and is the most frequent cause for withdrawal of approved 
drugs and attrition of drug development. 10.2% of 548 new chemical entities approved 
between 1975 and 1999 in the United States acquired a new black box warning or were 
withdrawn (Lasser et al., 2002).
It has been reported that 50% of acute liver failure cases in the United States are as a result of 
drug-induced liver toxicity, with more than 800 drugs associated with hepatotoxicity 
(Dossing et al., 1993; Ostapowicz et al., 2002). The liver is the main site for metabolism of 
endogenous and exogenous compounds, making it a common target for drug-induced 
toxicities. One of the liver’s main physiological roles is the clearance and metabolism of 
xenobiotics into hydrophilic metabolites in order to facilitate their excretion. However, drug 
metabolism can lead to the formation of chemically reactive species that have the potential to 
damage cellular macromolecules. Although the cellular mechanisms of DILI leading to overt 
tissue and organ damage are still not folly defined, it appears to involve 2 pathways; direct 
hepatotoxicity and adverse immune responses. Model hepatotoxins have been used in animal 
models to provide important insight into the relationship between chemical structure, drug 
metabolism and cellular response. One classically studied drug used to examine the 
mechanisms of hepatotoxicity is acetaminophen (paracetamol; APAP).
APAP is a popular analgesic that is safe at therapeutic doses but can produce centrilobular 
hepatic necrosis in cases of overdose, which may lead to acute liver failure. APAP 
hepatotoxicity has been well characterised in animal models, where it has been defined that 
toxicity is mediated through the formation of an electrophilic reactive metabolite N-acetyl-p- 
benzoquinonimine (NAPQI) (Mitchel et al., 1973a), which depletes intracellular stores of 
hepatic glutathione (GSH) and initiates covalent binding to cellular macromolecules. This
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leads to cellular dysfunction and oxidative stress and may eventually lead to cellular damage 
and death. In most instances in DILI, it appeal’s that hepatocyte damage and death can trigger 
the activation of other cells, which can initiate an inflammatory response. This event may 
overwhelm the liver’s capacity to repair and regenerate, thereby contributing to the 
pathogenesis of liver injury.
Despite intense research, the extent of the role of the innate immune and inflammatory 
response in the modulation of liver injury remains poorly defined. It is reported that 
hepatocyte stress or damage can result in the release of signals that stimulate activation of 
other cells, particularly those of the innate immune system such as Kupffer cells (KC), 
natural killer cells and NKT cells. These cells can contribute to the progression of liver injury 
by producing proinflammatory mediators and chemokines to further recruit inflammatory 
cells such as neutrophils to the liver (Laskin et ah, 1986; Luster et ah, 2001; Liu et ah, 2004; 
Holt et ah, 2006; Ishida et ah, 2006; Jaeschke et ah, 2006). In contrast to this, innate immune 
cells also represent a major source of hepatoprotective factors such as IL-6 and IL-10 as it has 
been demonstrated that transgenic mice lacking these are more susceptible to APAP-induced 
liver injury. Thus, a balance of proinflammatory and hepatoprotective mediators produced 
after activation of the innate immune response could determine the susceptibility and extent 
of liver injury after toxic insult.
The contribution of the signals released by dying hepatocytes to the severity and progression 
of DILI is also of interest. The release of high mobility group box 1 protein (HMGB1) by 
necrotic cells, but not apoptotic cells, has been implicated as an important factor in 
connecting necrotic cell death with the innate inflammatory response (Scaffidi et ah, 2002). 
HMGB1 is classed as a damage-associated molecular pattern molecule (DAMP) that acts as a 
‘danger’ signal to cells of the innate immune system following cell damage (Hori et ah, 1995; 
Yu et ah, 2006; Tian et ah, 2007). HMGB1 can trigger an inflammatory response by 
signalling through its receptors; toll-like receptors (TLRs) and the receptor for advanced 
glycation end products (RAGE). These signalling pathways could provide a potential target 
for investigating the role of the innate immune and inflammatory response to the 
pathogenesis of DILL
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The overall aim of this thesis was to assess the contribution of the inflammatory response in 
the progression of DILI by targeting certain points in the signalling pathway between dying 
hepatocytes and cells of the innate immune system. The hepatotoxins APAP and 
galactosamine (GalN) and the innate immune stimulator lipopolysaccharide (LPS) have been 
investigated to further understand the mechanisms behind drug-induced inflammation and 
hepatotoxicity. Targeting the signalling pathway between dying hepatocytes and 
inflammatory cells will provide help in the understanding of how hepatotoxins trigger an 
inflammatory response which can ultimately exacerbate the initial liver injury.
1.2 ADVERSE DRUG REACTIONS
Adverse drug reactions (ADRs) represent a significant health problem and are a major cause 
of patient morbidity and mortality. In the United States it was estimated that in 1994, over 
100,000 patients died from ADRs (Lazarou et al., 1998). A prospective analysis of hospital 
admissions from two large Merseyside general hospitals in the UK, conducted over a 6 month 
period during 2001-2002 showed that ADRs accounted for 1225 (6.5%) out of 18,820 
admissions. 28 (2.3%) of those patients admitted due to ADRs, died as a direct consequence 
of the reaction (Pirmohamed et al., 2004). The projected annual cost of such admissions to 
the National Health Service (NHS) was £466m. ADRs are largely responsible for the high 
attrition rate of potential new drugs within the pharmaceutical industry. It was reported that 
10.2% of 548 new chemical entities approved between 1975 and 1999 in the United States 
acquired a new black box warning or were withdrawn (Lasser et al., 2002).
ADRs can be classified in terms of their clinical, pharmacological and chemical 
characteristics (Park et al., 1998) (Table 1.1). Type A reactions are predictable from the 
known pharmacology of the drug and are usually dose-dependent. These can usually be 
avoided by dose reduction and are rarely life-threatening. An example of a type A reaction is 
bleeding with anticoagulants such as warfarin. In contrast, type B reactions cannot be 
predicted from the basic pharmacology of the drug, are often independent of dose and are 
usually uncommon and therefore referred to as idiosyncratic. Although less common than 
type A reactions, type B reactions have the potential to be serious and even life-threatening. 
Examples of type B reactions include halothane hepatitis and anticonvulsant hypersensitivity.
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Type C reactions can be predicted by the chemical structure of the drug or metabolite. An 
example of this type of reaction is paracetamol hepatotoxicity. The different types of ADRs 
are diverse and are known to affect every organ system in the body. As a result of patient 
morbidity and mortality, drug-induced liver injury (DILI) has proven to be a major problem 
for both the pharmaceutical industry and regulatory authorities, as it is the most frequent 
cause for post marketing withdrawal of medications despite pre-clinical and clinical 
screenings (Jaeschke et al., 2002).
Table 1.1: Classification of ADRs (Park et al., 1998)
Reaction Type Characteristics Examples
A - Augmented Predicted from drug pharmacology 
Dose-dependent
Resolve by dose diminution
Hypotension with 
antihypertensives and 
haemorrhage with anticoagulants
B - Idiosyncratic Not predictable from the drug 
pharmacology
Not dose-dependent
Patient-specific
Metabolism or immune components 
dictate individual susceptibility
Halothane hepatitis and 
anticonvulsant hypersensitivity
C - Chemical Can be predicted or rationalised from 
the chemical behaviom* of the drug 
or its metabolite
Paracetamol hepatotoxicity
1.3 DRUG-INDUCED LIVER INJURY
While ADRs can affect every organ system in the body, the liver represents a primary target 
for adverse drug reactions due to its central role in biotransformation and excretion of foreign 
compounds. Drug-induced liver injury (DILI) is attributed to a significant cause of patient 
morbidity and mortality (Lee et al., 2005) and accounts for more than 50% of acute liver 
failure in the United States, 39% of which includes hepatotoxicity caused by APAP 
(Ostapowicz et al., 2002). DILI is a major cause of drug attrition dining development and the 
most frequent reason for the withdrawal of approved drugs from the market (Lee, 2003). An
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estimated 1000 drugs have been implicated in causing liver damage on more than one 
occasion (Kaplowitz., 2004).
DILI can affect all cells of the liver which can lead to a variety of pathological conditions, 
including acute and chronic hepatitis, fibrosis/cirrhosis, cholestasis and hepatic artery/vein 
damage (Larrey et ah, 2000). The predominant forms of DILI are acute hepatitis and 
cholestasis, of which the former is characterised by a marked increase in aminotransferases 
coinciding with hepatocellular necrosis (Gunawan., 2004). Current methods for the detection 
of liver damage are through the measurement of serum or plasma aminotransferases, which 
are enzymes released from the liver during necrosis. They are universally important 
indicators for studies ranging from preclinical animal studies to post-marketing patient 
monitoring (Amacher., 1998). One of the most commonly measured enzymes is alanine 
aminotransferase (ALT), with severe liver damage represented by levels exceeding 1000U/1 
(Beckett et ah, 1985). A major limitation to using this enzyme as a marker of liver toxicity is 
that it is not an early biomarker, as it is only present once overt liver toxicity and necrosis 
have occurred.
1.3.1 Mechanisms of DILI
The mechanism of DILI appears to involve 2 pathways, direct hepatotoxicity and immune 
mediated damage. The pathogenesis of DILI can be related to the chemical properties of the 
parent drug or its metabolite. DILI in some instances can be initiated by bioactivation of 
drugs to chemically reactive metabolites, which have the ability to interact with cellular 
macromolecules leading to cellular dysfunction. The impairment of hepatic cellular function 
can ultimately lead to cell death and possible liver failure. Hepatic cellular death and 
dysfunction have the ability to initiate immunological response, triggering both innate and 
adaptive immune response. Hepatocyte damage or stress can result in the release of signals 
that stimulate the activation of other cells, particularly those of the innate immune system 
such as Kupffer cells (KC), natural killer cells and NKT cells. These cells can contribute to 
the progression of liver injury by producing proinflammatory mediators and chemokines to 
further recruit inflammatory cells such as neutrophils to the liver (Blazka et al., 1995; Blazka 
et al., 1996; Ishida et al., 2002).
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1.3.2 Physiological role of drug metabolism
Drug metabolism is the process by which drug molecules are chemically altered by 
enzymatic biotransformation, usually into more hydrophilic metabolites in order to facilitate 
their excretion. The liver is the principle organ and quantitatively the most important site of 
drug metabolism. Xenobiotics are usually non-polar, lipophilic chemical compounds that are 
readily absorbed in the gastrointestinal tract. Metabolism is important to increase the 
hydrophilicity and facilitate their excretion in the urine or bile. Drug metabolism can be 
divided into 3 phases; phase I (functionalisation/bioactivation), phase II 
(conjugation/detoxification) and phase III (transport/excretion) (Pachkoria et ah, 2007). Phase 
I reactions result in the exposure or incorporation of a functional group that is then a target 
for phase II conjugation reactions to form a highly polar conjugate (Guengerich & Shimada., 
1991). Phase I reactions do not necessarily occur before phase II reactions. A drug can be 
metabolised by phase II metabolism without having previously being involved in phase I 
metabolism, providing there is a suitable functional group present on the parent compound 
(Gibson, 1994). Phase III metabolism involves the transport of drug conjugates across 
membranes (Pachkoria et ah, 2007). While metabolism results in detoxification of many 
xenobiotics, some drugs are bioactivated to reactive and potentially toxic metabolites (Grillo 
et ah, 2003). An imbalance between the three phases could lead to an increase of reactive 
metabolites resulting in liver toxicity (Pachkoria et ah, 2007).
1.3.3 Phase I metabolism and involvement in DILI
Phase I metabolic reactions are also known as functionalisation reactions and incorporate or 
unmask functional groups, such as hydroxyl groups (-OH), primary amines (-NH2), 
sulphydryl (-SH) and carboxylic acids (-COOH) by oxidation, reduction, hydrolysis or 
hydration reactions to facilitate phase II reactions (Gibson, 2001). Phase I drug metabolism 
enzymes include the microsomal cytochrome P450 monoxygenase system (CYP450) 
enzymes which are found in high abundance in the liver and catalyse the majority of phase I 
oxidation reactions (Timbrell, 2000). The CYP450 family are membrane-associated enzymes 
located on the inner mitochondrial membrane or in the endoplasmic reticulum of cells (Meyer 
et al., 1996; Guengerich et ah, 2003). They have been referred to as ‘mixed function
9
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oxidases’ due to their wide substrate specificities. The primary role of CYP450 enzymes is to 
act as a detoxification pathway and to metabolise endogenous and exogenous compounds. 
However, there is the possibility that reactions catalysed by CYP450 enzymes may result in 
liver injury as they may generate metabolites that are more reactive and toxic than the parent 
compound. This can result in liver damage in several ways. Metabolism of drug molecules 
can generate free radicals, leading to an increase in cellular’ oxidative stress. The exposure or 
incorporation of functional groups can lead to generation of electrophiles that may be 
detrimental to biological systems by potentially reacting with electron rich macromolecules 
such as proteins, DNA and RNA by covalent interactions. The chemical modification of these 
cellular macromolecules has the potential to render it toxic such as tissue necrosis, cellular 
apoptosis, chemical carcinogenesis and hypersensitivity.
1.3.4 Phase 11 metabolism and involvement in DILI
Phase II metabolism involves the conjugation of a hydrophilic chemical moiety to a drug 
molecule, thereby increasing its polarity and water solubility to aid excretion (Timbrell, 
2000). The addition or exposure of a functional group by phase I reactions enables the 
conjugation of an endogenous substrate to form a highly polar and non-reactive conjugate, 
that can be more readily excreted than the parent compound. Phase II reactions consist of a 
diverse group of enzymes such as UDP-glucuronosyltransferases (UGT), N- 
acetyltransferases (NAT), sulphotransferases (SULT) and glutathione S-transferases (GST) 
(McCarver & Hines., 2002). An important function of phase II enzymes is the detoxification 
of reactive molecules that may be generated by phase I drug metabolism (Park et al., 2005). 
This enables the excretion of drugs into the urine or bile. Phase II reactions include 
glucuronidation, sulphation, acetylation, methylation, amino acid conjugation and glutathione 
(GSH) conjugation (Zamek-Gliszczynski et al., 2006).
GSH conjugation represents one of the most protective processes in the liver in the 
detoxification of reactive species generated as a result of metabolism. GSH is an endogenous 
tripeptide (y-glutamylcysteinylglycine) consisting of glutamate, cysteine and glycine amino 
acids and is the most abundant non-protein cellular thiol, present in millimolar 
concentrations. It is an important antioxidant, reductant and scavenger within the cell (Hayes
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et al., 1999) and exists in two forms, oxidised (GSSG) and reduced (GSH). GSH can 
conjugate either directly with a reactive electrophilic species or by facilitation through GST 
forming a thioether bond between the cysteine residue of GSH and the electrophile (Coles et 
al., 1988). GSTs are a family of enzymes located in the cytosol and microsomes. Cytosolic 
GSTs (95%) are encoded by at least 5 gene families whereas the membrane bound 
microsomal GSTs are encoded by one gene (Meister and Anderson, 1983; Dirven et al., 
1995). The conjugation process with GSH is of particular importance when sulphation and 
glucuronidation pathways become saturated (Timbrell, 2000; Gibson, 2001). In cases where 
GSH depletion occurs, such as that seen with highly reactive metabolite exposure, other thiol 
groups, especially those on critical proteins become vulnerable to attack with subsequent 
oxidation, cross-linking and formation of covalent adducts. Protein sulphydryl groups appear 
to be the most susceptible nucleophilic target for electrophilic attack. Often these sulphydryl 
groups are critical for enzyme function. GSH depletion has been shown to be a prerequisite 
for the onset of toxicity (Mitchel et al., 1973b). An example of this is during APAP 
hepatotoxicity, when synthesis of new GSH is not capable of replenishing GSH used through 
conjugation or oxidation to GSSG (Mitchel et al., 1973b). Although Phase II metabolism is 
principally a detoxification pathway there is still a potential for bio activation, which can lead 
to DILI. UGT catalyses the conversion of carboxylic acid containing drugs, such as non­
steroidal anti-inflammatory drugs (NSAID), to acyl glucuronides that have the potential to 
bind covalently to plasma and hepatic proteins (Zhou et al., 2005).
1.3.5 Phase III metabolism and involvement in DILI
Phase III involves hepatic drug removal, involving a number of drug transporter proteins 
(Ishikawa, 1992). Mizuno et al. (2003) cloned and characterised plasma membrane-bound 
hepatocyte transporters and revealed that many drugs enter and exit hepatocytes by energy- 
dependent transporters rather than by diffusion. These transporters play a role in the 
transportation and removal of endogenous and exogenous compounds (Borst et al., 2002). 
The predominant transporters involved in drug uptake belong to the solute carrier (SLC) 
transporter superfamily, located on the sinusoidal plasma membrane. Examples include 
organic anion transporters (OAT) (Reichel et al, 1999), organic cation transporters (OCT) 
(Zhang et al., 1998) and sodium taurocholate cotransporting polypeptide (NTCP) (Hagenbuch
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et al., 1994). The transporters involved in the excretion of drugs and their metabolites from 
hepatocytes are members of the ATP-binding cassette (ABC) transporter superfamily located 
on the biliary canalicular plasma membrane, where they mediate the excretion of drugs into 
bile, or on the sinusoidal membrane, where they mediate efflux back into the circulation 
(Dean et al., 2001; Kerb et al., 2001). Examples of these include multi-drug resistance protein 
(MDR), breast cancer resistance protein (BCRP) and bile salt export pump (BSEP). Inhibitors 
of these export proteins or genetic polymorphisms which alter protein function have the 
potential to induce cholestatic injury. The liver injury produced by compounds such as 
sulindac, flucloxacillin and terbinafine is attributable to the inhibition of canalicular bile salt 
transporter (Bolder et al, 1999; Iverson and Uetrecht, 2001; Lakehal et al., 2001).
1.3.6 Drug-induced cell death
The mechanisms leading to drug-induced cell death are still not fully understood but what is 
known is that the occurrence of hepatic cell necrosis and apoptosis are events which follow 
the capacity of the liver to respond to toxic insults (Grattagliano et al, 2002).
Apoptosis is a mechanism of programmed cell death that is executed during normal 
physiological regulation of cell number (Kerr et al, 1972) and can occur when a cell is 
damaged beyond repair to prevent the spread of damaged DNA to live cells. Hallmarks of 
apoptosis include membrane blebbing, cell shrinkage, chromatin condensation and DNA 
fragmentation (Robertson and Orrenius, 2000). The cells fragment into apoptotic bodies that 
are phagocytosed by adjacent cells and macrophages for lysosomal degradation, minimising 
the leakage of cellular components into the extracellular space and preventing the induction 
of subsequent inflammatory responses (Savill et al, 2003). Many stimuli can initiate 
apoptosis such as tumour necrosis factor alpha (TNF-a) or Fas ligand (FasL) that engage with 
death receptors on the cell surface (Ashkenazi et al, 1998; Latta et al, 2000). Usually these 
stimuli lead to activation of a cascade of cysteine-aspartate proteases (caspases), which 
cleave cellular proteins after an aspartate residue (Cohen, 1997) leading to the degradation of 
the cell
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Unlike apoptosis, necrosis is regarded as the accidental or uncontrollable form of cell death 
and is a much less orderly process. Necrosis occurs as a consequence of acute cellular injury 
and results in the release of intracellular contents after cellular membrane damage. With 
respect to DILI, the release of intracellular contents can trigger an inflammatory response, 
leading to exacerbation of injury (Robertson and Orrenius, 2000). Necrosis is characterised 
by mitochondrial swelling, loss of plasma membrane integrity and nuclear DNA being 
randomly cleaved as a consequence of cellular' degradation. APAP is a model hepatotoxin 
that has been shown to result in necrotic hepatocyte cell death (Jaeschke et ah, 2003a).
The processes of apoptosis and necrosis during liver injury are not mutually exclusive, as the 
typical response of tissues and cells to injurious stresses and other death signals is a mixture 
of events associated with apoptotic and necrotic cell death which can occur in parallel or 
sequentially.
1.4 ACETAMINOPHEN HEPATOTOXICITY
Acetaminophen (Paracetamol; APAP) is a widely used analgesic and antipyretic which is safe 
at therapeutic doses of 4g/day (Bray, 1993) but is associated with acute liver failure (ALF) 
caused by massive centrilobular necrosis after an overdose (Davidson et ah, 1966; Vermeulen 
et ah, 1992). The main mechanism of action is considered to be through the inhibition of 
cycloxygenase (COX) activity and a reduction in prostaglandin synthesis (Dotting et ah, 
2000; Boutaud et al., 2002). APAP-induced hepatotoxicity continues to be a significant cause 
of patient morbidity and mortality and is the single biggest cause of acute liver failure in the 
UK and USA (Ostapowicz et al., 2002; Hawkins et al, 2007; Khashab et al., 2007). APAP 
hepatotoxicity has been widely studied as it provides a clinically relevant tool in which to 
study the toxicological consequences of drug metabolism in in vitro and in vivo models.
1.4.1 Role of drug metabolism in APAP hepatotoxicity
APAP is extensively metabolised in the liver (Mitchel et al., 1973a; Lee et al., 1996). At 
therapeutic doses, around 55% and 30% of APAP is bioinactivated to glucuronide and
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sulphate conjugates, by UDP-glucuronosyltransferase (UGT) and sulphotransferase (ST), 
respectively (Howie et al., 1977). These metabolites can then be rapidly excreted in the urine 
(Nelson, 1990). A small proportion of the therapeutic dose of APAP (5-10%) is bioactivated 
to the reactive metabolite N-acetyl-p-benzoquinonimine (NAPQI) by several CYP450s, 
primarily CYP2E1 and also CYP3A4 and CYP1A2 (Dalilin et al., 1984; Raucy et al., 1989; 
Thummel et al., 1993). NAPQI is conjugated to GSH resulting in its detoxification and is 
excreted in the urine as cysteine and mercapturate conjugates (Mitchel et al., 1973a) (Figure 
1.1).
During overdose, the glucuronidation and sulphation pathways become saturated, forcing a 
greater fraction of the dose to become metabolised via the oxidative pathway. This results in 
an increase in the formation and subsequent accumulation of NAPQI, exceeding the cellular' 
stores of hepatic GSH and new GSH synthesis, leading to depletion of hepatic GSH (Mitchel 
et al., 1973a; Mitchel et al., 1973b; Potter et al., 1973; Dalilin et al, 1984; Davies et al, 1986; 
Lee at al, 1996). The accumulation of NAPQI has been shown to result in binding of NAPQI 
to cellular proteins (Guengerich et al, 1985). As a result of binding to cellular proteins, 
NAPQI is capable of damaging the cell through oxidative stress, mitochondrial dysfunction 
and DNA damage. The covalent modification of proteins and the oxidation of protein thiols 
are believed to correlate with APAP-induced toxicity (Davis et al, 1974; Potter et al, 1974; 
Roberts et al, 1987; Bartolone et al, 1988). The standard treatment for APAP intoxication is 
the administration of N-acetylcysteine (NAC), which replaces hepatic GSH after depletion 
and prevents toxicity. NAC is most beneficial if given within 16hrs after APAP overdose. 
Without NAC the depletion of GSH stores and covalent binding of proteins by NAPQI will 
not only result in cellular toxicity (David Josephy, 2005) but also activate the cellular 
adaptive defence response during drug exposure (Park et al, 2005).
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Figure 1.1: Metabolism and toxicity of APAP.
At therapeutic doses APAP is detoxified to glucuronide and sulphate metabolites, with a 
small proportion (5-10%) bioactivated to the electrophilic reactive metabolite NAPQI, which 
is then conjugated with GSH and detoxified. During overdose, the glucuronidation and 
sulphation pathways become saturated leading to increased formation of NAPQI. 
Intracellular stores of GSH are depleted leading to an accumulation of NAPQI, which can 
lead to covalent binding of cellular macromolecules and toxicity.
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1.4.2 Cellular defence in response to APAP bioactivation and bioinactivation
The depletion of hepatic GSH enables NAPQI to covalently modify and inhibit the function 
of various critical proteins within the hepatocyte, which can lead to cellular dysfunction and 
cell death. The covalent modification or functional inhibition of critical proteins such as y- 
glutamyl cysteine ligase, catalytic subunit (GCLC) (Kitteringham et al, 2000), 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (Dietze et al, 1997) and Ca2+/Mg2+ 
ATPase (Tsokos-Kuhn et al., 1988) can severely impair hepatocyte function. The covalent 
modification of these proteins by NAPQI has been hypothesised to contribute to 
mitochondrial dysfunction and disruption of ATP and Ca2+ homeostasis (Jaeschke et al., 
2003a) and is thought to be a critical step in the development of cell death observed following 
APAP overdose.
One of the major tiers of cell defence involves the upregulated expression of cytoprotective 
genes, a process mediated by certain transcription factors. In addition to inducing direct 
cellular damage, oxidants can activate transcription factors, which regulate the production of 
inflammatory mediators (Dambach, 2006). The massive chemical stress mediated by an 
APAP overdose leads to an immediate adaptive defence response in the hepatocyte. This 
involves various mechanisms, including the nuclear translocation of redox-sensitive 
transcription factors such as nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf-2), 
which ‘sense5 chemical danger and orchestrate cell defence (Goldring et al., 2004). Nrf2 is 
essential for the antioxidant responsive element (ARE)-mediated induction of phase II 
detoxifying and oxidative stress enzyme genes (Itoh et al., 1999). In the absence of cellular 
stress the cytoplasmic protein kelch-like ECH-associated protein 1 (Keapl) directly binds to 
Nr£2 and represses transactivation by promoting proteasome-dependent degradation of the 
protein. Exposure to oxidative or chemical stress enables Nrf2 to evade the Keapl-mediated 
degradation process, and accumulates within the nucleus to activate ARE target genes (Itoh et 
al, 1999; Goldring et al, 2004) (Figure 1.2). With respect to APAP, Nr£2 genes of immediate 
significance are those involved in glutathione synthesis such as GCLC, GSTs, 
glucuronyltransferases, and heme oxygenase (OH). Importantly, it has been observed that 
nuclear translocation occurs at nontoxic doses of APAP and at time-points before overt 
toxicity is observed. However, with increasing doses of APAP, there is progressive 
dislocation of nuclear translocation, transcription, translation, and protein activity
16
Chapter 1
(Kitteringham et al., 2000) as the rate of drug bioactivation overwhelms cell defence through 
the modification and inhibition of critical proteins.
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Figure 1.2: Cellular defence by Nrf2-ARE pathway in response to APAP.
Formation of NAPQI in hepatocytes results in GSH depletion and adduct formation. This 
leads to release of Nrf2 from its cytoplasmic inhibitor, Keap 1, which then translocates to the 
nucleus. Nrf2 in the nucleus activates the antioxidant response element (ARE), resulting in 
the enhanced transcription of a variety of genes involved in cell defence (adapted from Park 
et al., 2005).
Nuclear factor-icB (NF-kB) is the name given to a family of transcription factors formed by 
the hetero- or homodimerisation of proteins from the Rel family (Lawrence et al., 2001). 
There are 5 Rel proteins: p50, p65 (RelA), c-Rel, p52, and RelB (Hayden et al., 2006). NF- 
kB is a major regulator of the innate and adaptive immune response, and thus serves an 
important role in immune and inflammatory responses through the regulation of genes 
encoding pro-inflammatory cytokines, adhesion molecules, chemokines, growth factors, and
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inducible enzymes which include cyclooxygenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS). In resting cells, NF-kB is localised within the cytosol as a dimeric complex, 
usually comprising p50 and p65 subunits (Hayden et al., 2006). The cytoplasmic NF-kB 
exists in an inactive form due to binding to an inhibitor protein, IkB (Baeuerle and 
Baltimore., 1988; Li et al., 2002). NF- kB activation is mediated by a number of cell surface 
receptors, including TNF-a receptor, interleukin-1 receptor, toll-like receptors (TLRs) and 
receptor for advanced glycation end products (RAGE). Activation of NF-kB by stimulation 
of the cell through these receptors in response to a variety of stimuli such as reactive oxygen 
species (ROS), the bacterial endotoxin lipopolysaccharide (LPS) or proinflammatory 
cytokines, is a result of the phosphorylation of IkB, which targets the molecule for 
ubiquitination and then subsequent proteosomal degradation (Hayden et al., 2004). 
Phosphorylation of IkB is mediated by an enzyme complex called IkB kinase (IKK), which 
phosphorylates critical serine residues within IkB. IKK is a dimer consisting of two different 
subunits, IKKa and IKK|3, which is held in an IKK complex with a regulatory subunit called 
NF-kB essential modifier (NEMO) (Scherer et al. 1995; Mercurio et al. 1997; Mercurio et al. 
1999; Ben-Neriah 2002). Consequently, the nuclear localisation signal (NLS) of NF-kB is 
revealed, permitting translocation of NF-kB into the nucleus, where it can bind to the 
promoter region of various target genes (Figure 1.3). NF-kB is activated during APAP- 
induced hepatotoxicity (Blazka et al., 1996a, 1996b; Bauer et al., 2000; Chiu et al, 2003a, 
2003b) suggesting that transcription factors may be involved in the inflammatory response to 
this hepatotoxicant. Notably, exposure of mice to hepatotoxic doses of APAP causes the NF- 
KB-dependent upregulation of pro-inflammatory mediators, including IL-1J3 and TNFa, and 
the anti-inflammatory cytokine IL-10 in the liver (Dambach et al. 2006).
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Figure 1.3: NF-kB signal transduction pathway.
In the absence of inflammatory activity, the transcription factor NF-kB is retained in the 
cytoplasm by the protein inhibitor IkB. Proinflammatory stimuli such as LPS, IL-1 or TNF-a 
activate the protein kinase complex IKK, resulting in the degradation of IkB and translocation 
of NF-kB into the nucleus (adapted from Perkins 2007).
1.4.3 APAP-induced hepatic cell death
APAP has been shown to result in necrotic hepatocyte cell death (Jaeschke et al., 2003a) and 
it is generally accepted that necrosis is the final and ultimate form of hepatic cell death in 
APAP-induced hepatotoxicity in animals and in man. However, some reports suggest hepatic 
apoptosis can also occur following APAP metabolic activation (Ferret et al., 2001; Henderson 
et al., 2007; Kon et al., 2007) and may even play a key role in modulation of APAP
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hepatotoxicity (Ray et al., 1996; El-Hassan et al, 2003). Despite intense research, the role of 
apoptosis remains controversial with some reports suggesting that apoptosis may not feature 
in APAP hepatotoxicity due to overwhelming oxidative stress and rapid depletion of ATP in 
the hepatocyte, conditions which are not favourable for caspase activation, a prerequisite for 
apoptosis (Lawson et al., 1999; Ruepp et al., 2002; Cover et al., 2005; Gimawan et al., 2006).
1.4.4 Effect of fasting on APAP-induced hepatotoxicity
As mentioned previously, GSH depletion is known to be a prerequisite for the onset of 
toxicity (Mitchel et al., 1973b). Fasting has been shown to substantially reduce intracellular 
hepatic GSH levels, resulting in a markedly increased susceptibility to the toxic effects of 
APAP (Pessayre et al., 1979). A reduced hepatic content of GSH, required to detoxify the 
reactive metabolite, has been documented in chronic alcoholics and has been postulated to be 
a factor responsible for the liver injury described in alcoholic patients following therapeutic 
doses of APAP (McClain et al., 1980; Jewell et al., 1986; Seeff et al., 1986). Malnourished 
individuals may therefore have a compromised detoxification capacity due to decreased 
levels of hepatic GSH and become more susceptible to APAP hepatotoxicity.
1.5 INNATE IMMUNOLOGICAL RESPONSE TO APAP HEPATOTOXICITY
1.5.1 Sterile inflammation and damage-associated molecular pattern molecules
Inflammation is the first line of response to tissue damage. Blood flow is increased, and both 
nucleated blood cells and fluid extravasate from the vessels into the affected tissue. 
Neutrophils, followed later by macrophages are recruited to provide a first line of defence 
against intruding microorganisms, and to clear the debris (Ramaiah et al., 2007). 
Inflammation is considered a dual process since it can have two functionally different 
characteristics, one that can lead to tissue regeneration and another that can produce damage. 
Inflammation is part of a physiological process for repairing damage, however, when this 
process is not controlled and inflammation spreads, it loses its repairing and regenerating 
function and which may cause damage (Nathan, 2002; Aller et al., 2006). Molecules
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generated to kill microbes, such as reactive oxygen species and proteases, leak from live and 
dying leukocytes and kill normal cells (Rock et al., 2008). Recent studies have shown that 
dying cells trigger inflammation even in the absence of microbial infection, known as sterile 
inflammation (Chen et ah, 2007). Sterile inflammation occurs as a result of recognition of 
intracellular proteins released by necrotic cells, known as alarmins or damage-associated 
molecular' patterns (DAMPs) which results in the recruitment of neutrophils. DAMPs are 
host-derived proteins that are released following tissue injury or cell death and have the 
ability to activate a proinflammatory response. These include heat-shock proteins (HSPs) 
(Vabulas et al, 2001; Quintana et al, 2005), DNA (Jahr et al, 2001), ATP (Mariathasan et 
al, 2006), and high mobility group box-1 (HMGB1) (Hori et al, 1995; Yu et al, 2006; Tian 
et al, 2007). Under normal physiological conditions, DAMPs are usually sequestered 
intracellularly and therefore hidden from recognition by cells of the innate immune system, 
however when released into the extracellular’ enviromnent by necrotic cells they can trigger 
an immune response (Rubartelli et al, 2007). One of the DAMPs identified to be released 
during APAP hepatotoxicity was HMGB1 and treatment of mice with HMGB1-specific 
antibodies ameliorated hepatic inflammatory cell recruitment (Scaffidi et al, 2002).
In summary, during an inflammatory response induced by released cellular contents, the 
tissue site is rapidly infiltrated by leukocytes, consisting initially of neutrophils followed by 
accumulations of macrophages and production of proinflammatory cytokines and 
chemokines. There is an increasing awareness that dining APAP hepatotoxicity, 
nonparenchymal cells of the liver and cells of the innate immune system, namely neutrophils, 
Kupffer cells and natural killer/natural killer with T cells (NK/NKT cells) may be involved in 
the pathogenesis (Jaeschke et al, 2005; Liu et al, 2006) (Figure 1.4). The use of gene knock­
out animals (Ishida et al, 2002; Bourdi et al, 2007) and the depletion of certain cell types (Ju 
et al, 2002; Liu et al, 2004; Liu et al, 2006) have highlighted the critical role played by the 
innate immune system in the modulation of hepatotoxicity.
1.5.2 Role of neutrophils in APAP hepatotoxicity
APAP-induced liver injury has been histopathologically characterised by centrilobular 
necrosis and infiltration of leukocytes, mainly polymorphonuclear leukocytes (neutrophils).
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Hepatic infiltration and activation of neutrophils is an early response to tissue injury, cellular 
stress or systemic inflammation and is a hallmark of the inflammatory process, which may 
contribute to the development of APAP-induced liver injury (Luster et ah, 2001; Ishida et al., 
2006; Jaeschke et al., 2006). Increasing evidence has implicated neutrophils as the main type 
of leukocyte involved in the pathogenesis of APAP-induced liver injury (Jaeschke et al., 
2002; Liu et al., 2006). A study showed that depletion of neutrophils using an anti-Gr-1 
antibody significantly protected mice against APAP-induced liver injury, as evidenced by 
markedly reduced serum ALT levels and centrilobular hepatic necrosis, and improved mouse 
survival (Liu et al., 2006). Another study demonstrated that the magnitude of liver injury 
induced by APAP correlated with hepatic neutrophil number and myeloperoxidase activity, 
suggesting that neutrophil recruitment in the liver was involved in the pathogenesis of APAP- 
induced liver injury (Ishida et al., 2002). The authors went on in a more recent study to show 
that neutrophils expressed CXCR2 and inducible NO synthase (iNOS), which can produce 
NO, a potent injurious mediator for APAP-induced liver injury (Ishida et al, 2006). There are 
however, conflicting views concerning the role of neutrophils in APAP-induced liver injury 
(Lawson et al., 2000). One study suggested that although the numbers of neutrophils were 
increased in the liver of APAP-challenged animals, neutrophils did not contribute to the 
initiation and progression of APAP-induced liver injury. The inflammation observed after 
overdose was stated as not being severe enough to cause additional damage (Lawson et al., 
2000). Enhanced Mac-1 (CDllb/CD18) expression and L-selectin (CD62L) shedding are 
characteristic for activation of neutrophils (Jutila et al, 1989). However, it was shown that 
there was neither Mac-1 upregulation nor L-selectin shedding of circulating neutrophils after 
APAP administration suggesting that there was no activation of neutrophils during APAP- 
induced toxicity (Lawson et al, 2000).
1.5.3 Role of Kupffer cells in APAP hepatotoxicity
Kupffer cells are resident macrophages of the liver and constitute 80-90% of all tissue- 
resident macrophages in the body, representing 15% of the total liver cell population 
(Bouwens et al, 1986). Predominantly, they are localised in the lumen of the hepatic 
sinusoids in the periportal and centrilobular regions of the liver lobule (Bouwens et al, 1986). 
They play an important role in the normal physiology and homeostasis of the liver, but can 
also participate in the acute and chronic responses of the liver to toxic compounds. The
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activation of Kupffer cells has been previously attributed to APAP hepatotoxicity (Laskin et 
ah, 1986; Michael et ah, 1999; Ito et ah, 2003) by the release of an array of cytokines and 
reactive oxygen species. This was evident in a study that used gadolinium chloride (GdCL3), 
which selectively reduces the capacity of Kupffer cells to produce superoxide (Liu et ah, 
1995). Pretreatment of mice with GdCLs completely eliminated oxidative stress and liver 
injury during the first Sin* post APAP-dose (Michael et ah, 1999). However, subsequent 
studies using GdCL3 found that little to no protection was afforded against APAP 
hepatotoxicity (Ju et ah, 2002; Ito et ah, 2003; Knight et ah, 2004). Moreover, another report 
contradicted the theory of hepatotoxicity potentiation by Kupffer cells with the authors 
demonstrating a hepatoprotective role (Ju et ah, 2002). This was highlighted through the near 
complete depletion of Kupffer cells, using liposome-entrapped clodronate, resulting in 
increased susceptibility of mice to APAP hepatotoxicity. This was thought to be a result of 
the Kupffer cell depletion leading to the elimination of the formation of several 
hepatoregulatory cytokines and mediators including IL-6 and IL-10. The conclusion was that 
the dominant effect of Kupffer cell activation after APAP is not to cause cytotoxicity by 
oxidant formation but rather to limit toxicity by production of a number of hepatoregulators 
that serve to potentially coimteract proinflammatory stimuli and support liver regeneration. 
The discrepancies between reports are based on the use of different agents to deplete or 
inhibit Kupffer cell function (Ju et ah, 2002) and serve to highlight the complexity of the role 
Kupffer cells play in APAP-induced liver injury.
1.5.4 Role of natural killer and natural killer T cells in APAP hepatotoxicity
It was previously reported that the depletion of natural killer (NK) cells and NK cells with T- 
cell receptors (NKT cells) in the liver had a protective effect against APAP hepatotoxicity 
(Liu et ah, 2004). In this study, mice were depleted of both NK and NKT cells by an anti- 
NK1.1 antibody and treated with 500mg/kg APAP. The authors found that the increase in a 
large number of cytokines and chemokines including interferon-y (IFN-y) and monocyte 
chemoattractant protein-1 (MCP-1) after APAP treatment was significantly reduced. Also, 
they observed a decrease in Fas ligand (FasL) expression and a reduction in neutrophil 
accumulation in the liver. The effect of APAP on cytokines, chemokines, FasL expression 
and neutrophil accumulation was also reproduced in IFN-y deficient mice (Ishida et ah, 2002;
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Liu et al., 2004). It was concluded that NK and NKT cells were mainly responsible for IFN-y 
production and the subsequent severity of liver injury after APAP (Liu et al., 2004). 
However, it was later implicated in a conflicting report that the use of dimethyl sulfoxide 
(DMSO) to solubilise APAP was the major factor in the contribution of NKT and NK cells to 
the overall extent of APAP-induced liver injury (Masson et al., 2008).
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Figure 1.4: Overview of the effect of the release of intracellular contents from necrotic 
hepatocytes and activated immune cells in the modulation of DILI.
Necrotic hepatocytes passively release HMGB1 into the extracellular space and blood. 
Activation of innate immune cells (Kupffer cells, neutrophils and NK/NKT cells) by HMGB1 
and other DAMPS triggers the further release of HMGB1 and inflammatory cytokines, 
therefore modulating the overall pathogenesis of DILI (adapted from Adams et al., 2010).
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1.6 CIRCULATING MEDIATORS OF INFLAMMATION INVOLVED IN DILI
In addition to the intracellular biochemical events there is growing evidence that suggests that 
the innate immune system can contribute to the severity and progression of APAP-induced 
liver injury through the recruitment of inflammatory cells into the liver and production of 
cytokines downstream of bioactivation (Blazka et al.5 1995; Laskin et ah, 2001; Liu et ah, 
2004). The generation of inflammatory mediators such as cytokines, chemokines, reactive 
oxygen and nitrogen species released by Kupffer cells and macrophages have been implicated 
in APAP hepatotoxicity by exacerbating cell damage as a result of initiating an overly 
aggressive inflammatory process (Luster et ah, 2001; Liu et ah, 2004). Cytokines are small, 
soluble protein mediators produced by mostly all cell types in response to various stimuli 
including other cytokines. They play important roles in the normal physiology of cells and 
are commonly associated with the immune response, inflammation, tissue injury or repair, 
and organ dysfunction (Simpson et ah, 1997; DeCicco et ah, 1998). Many cytokines, such as 
TNF-a, IL-lp and IL-6, have been implicated as key mediators of APAP hepatotoxicity. An 
understanding of the role of cytokine responses in APAP hepatotoxicity is therefore 
important to the future development of novel therapies for APAP toxicity.
1.6.1 Tissue necrosis factor-a (TNF-a)
TNF-a is a proinflammatory cytokine that aids in tissue regeneration by stimulating apoptosis 
and cell proliferation but also can exacerbate cell damage by initiating an overly aggressive 
inflammatory response. It is produced by a number of different cells in the liver, including 
Kupffer cells (Decker et ah, 1990), endothelial cells (Ranta et ah, 1999) and hepatocytes 
(Gonzalez-Amaro et ah, 1994). Production of TNF-a is an early event in a hepatic 
inflammatory response and triggers the release of a cascade of cytokines that recruit and 
activate inflammatory cells (Bradham et ah, 1998; Luster et ah, 2001). TNF-a has been 
shown to increase inflammatory cell infiltration by promoting recruitment and adhesion of 
neutrophils to endothelial cells (Fiers., 1991). The biological effects of TNF-a are mediated 
by two receptors, TNFR1 and TNFR2, both of which are structurally related but are involved 
in different distinct signalling pathways (Tartaglia et ah, 1991; Tartaglia et ah, 1993; 
Bradham et ah, 1998). The receptors are co-expressed on the surface of many cell types with
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TNFR1 being heavily expressed on Kupffer cells and hepatocytes (Faubion and Gores., 
1999). TNF-a signalling via TNFR1 is the main signalling pathway leading to an 
inflammatory response (Douni et al., 1998; Peschon et al, 1998). TNF-a has been implicated 
to have a role in the exacerbation of APAP hepatotoxicity as it was shown to be produced 
after APAP challenge and was responsible for the progression of APAP hepatotoxicity 
(Blazka et al., 1995; Blazka et al., 1996; Goldin et al, 1996). It was demonstrated that TNF-a 
is generated between 4-24hr after APAP overdose, and the administration of antibodies 
targeted against TNF-a attenuated APAP-induced liver injury (Blazka et al, 1995). In 
contrast, one study showed that antibodies to TNF-a had no effect on liver damage induced 
by APAP (Simpson et al, 2000). Similarly, no difference in APAP-induced liver injury was 
observed between TNF-a KO mice and wild-type mice (Boess et al, 1998). The differences 
between these reports were suggested to be due to the doses of APAP used and the 
sensitivities of different mouse strains used in these studies (Gardner et al, 2003). Due to the 
dual role played by TNF-a in tissue repair and tissue damage it appears that its role in APAP 
hepatotoxicity depends on the balance and kinetics of TNF-a production as well as other 
mediators in the liver (Gardner et al, 2003).
1.6.2 Interleukin 6 (IL-6)
IL-6 is a multifunctional cytokine that has pro- and anti-inflammatory properties that regulate 
the immune response, haematopoiesis, the acute-phase response and inflammation (Hirano et 
al, 1998; Heinrich et al, 2003). 11-6 has been shown to have a pathogenic proinflammatory 
role in animal models of experimental autoimmune diseases such as insulin-dependent 
diabetes mellitus, inflammatory bowel disease and rheumatoid arthritis (Ishihara et al, 2002). 
In contrast, IL-6 has been shown to protect against liver injury caused by carbon tetrachloride 
(CC14) (Kovalovich et al, 2000), ethanol (Hong et al, 2002), ischaemia/reperfusion 
(Camargo et al, 1997) and APAP (James et al, 2003; Masubuchi et al, 2003). Studies have 
reported the upregulation of IL-6 in animal models of hepatic injury (Luckey et al, 2002) 
including APAP treated mice (Bourdi et al, 2002a; James et al, 2003). Other investigations 
using IL-6 KO mice suggest that IL-6 is important in hepatocyte regeneration following 
APAP hepatotoxicity (James et al, 2003; Masubuchi et al, 2003). In these studies it was 
demonstrated that in the absence of IL-6 in APAP treated mice, toxicity was increased 
compared to wild-type mice. The pro- and anti-inflammatory role of IL-6 in APAP
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hepatotoxicity may be determined by the level of expression of the cytokine as one report 
suggested that IL-6 can be a protoxicant in a model of APAP-induced liver injury when it is 
overexpressed (Bourdi et al5 2002a). This study demonstrated that using IL-10/IL-4 KO mice, 
IL-6 expression levels were elevated and mice were highly susceptible to APAP 
hepatotoxicity. The enhanced sensitivity of these mice to APAP was diminished when IL-6 
levels were reduced using an anti-IL-6 antibody. They concluded that the deficiency of IL-10 
and IL-4, which downregulates IL-6, lead to high levels of IL-6 and subsequent sensitisation 
of mice to APAP hepatotoxicity.
1.6.3 Interleukin 1 (IL-la/IL-lp)
There are two distinct forms of IL-1, IL-la and IL-lp, both of which are pleiotropic 
cytokines that mediate a range of biological activities such as proinflammatory responses, the 
immune response and haematopoiesis (Dinarello et al., 1991). IL-la and IL-lp stimulate the 
IL-1 receptor (IL-1R) which itself has different types. The type I IL-1 R is a transmembrane 
protein that is expressed predominantly by T cells, fibroblasts, and endothelial cells. IL-1R 
type II is a transmembrane protein found on B lymphocytes, neutrophils, monocytes, large 
granular leukocytes and endothelial cells (Kuno et al, 1994). IL-1 has been implicated in the 
injury process of APAP toxicity in experimental animals. In one report, IL-1R KO mice were 
more than 90% protected against APAP hepatotoxicity based on plasma ALT activities (Chen 
et al., 2007). However, when a combination of neutralising antibodies against IL-1R, IL-la 
and IL-lp was used, the protective effect was reduced to 30%. An earlier study also indicated 
that antibodies against IL-la protect against APAP hepatotoxicity in mice (Blazka et al., 
1995; Blazka et al., 1996).
1.6.4 High mobility group box protein X (HMGB1)
The chromosomal protein HMGB1 is a member of the high mobility group box family 
(HMGB; previously known as amphoterin or HMG), which include HMGB2 and HMGB3 
(Muller et al., 2001; Degryse et al., 2003; Lotze et al., 2005). HMGB1 was first identified 
over 30 years ago and later determined as an abundant nonhistone protein present in nuclei 
and cytoplasm of almost all eukaryotic cells (Goodwin et al., 1973; Muller et al., 2004). Its
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main intranuclear function is to modulate chromatin structure to facilitate transcription 
(Bianchi et al., 2004). HMGB1 is a 25kDa protein whose structure is composed of two 
homologous DNA-binding domains (Box A and B), and a negatively charged C-terminal 
domain made up of a carboxylic acid tail composed of aspartic and glutamic acids (Bonaldi et 
ah, 2003) (Figure 1.5). The acidic tail has important functional roles such as the modulation 
of the acetylation of HMGB1 by histone acetyltransferases (Pasheva et ah, 2004).
The nuclear role of HMGB1 has been widely studied. It has been found to be loosely 
associated with chromatin of cells and participates in DNA replication, gene transcription and 
repair as well as the regulation of chromatin structure (Chen et al., 2004; Yang et al., 2005). 
The change in structure enables multiple interactions between DNA and proteins such as p53, 
NF-kB and steroid hormone receptors (Bianchi et al., 2007), The functional importance of 
HMGB1 as a regulator of gene transcription has been determined by HMGB1 knockout mice, 
which die shortly after birth due to hypoglycaemia and show a defect of the transcriptional 
function of the glucocorticoid receptor (Calogero et al., 1999; Knapp et ah, 2004). Expression 
of the recombinant B box has been highlighted as the domain responsible for the 
proinflammatory cytokine function, inducing the release of IL-6 and TNF-a whereas the 
recombinant A box acts as a specific antagonist by attenuating HMGB1-induced macrophage 
secretion of these proinflammatory cytokines (Yang et ah, 2002; Li et al., 2003). HMGB1 
undergoes post-translational modifications including phosphorylation, acetylation, 
methylation (Bianchi et ah, 2007) and oxidation (Hoppe et al., 2006). The processes leading 
to these modifications and their functional consequences remain largely unknown. Post- 
translational modifications of HMGB1 appear to be important for its subcellular localisation 
and may regulate its proinflammatory activity (Lotze et al., 2005).
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Figure 1.5: Schematic representation of the structural domains of HMGB1.
HMGB1 is a tripartite structure composed of two homologous DNA-binding domains (named 
A-box and B-box), and a negatively charged acidic C-terminus. The two nuclear localisation 
signal sequences (NTS) undergo acetylation and are involved in nuclear transport. HMGB1 
can activate the receptor of advanced glycation end products (RAGE) through the RAGE- 
binding domain located at the amino acids 150-183 (adapted from Ulloa and Messmer., 
2006).
HMGB1 has been shown to play an important pathogenic role in a wide range of 
inflammatory diseases such as sepsis (Andersson et al., 2003; Sunden-Cullberg et al., 2005), 
rheumatoid arthritis (Taniguchi et al., 2003), inflammatory lung disease (Abraham et al., 
2000) and systemic lupus erythematosus (SEE) (Urbonaviciute et al., 2008). HMGB1 has 
been identified as a late mediator of endotoxin lethality as murine and human 
macrophages/monocytes can release large amounts of HMGB 1 days after being stimulated by 
exposure of the bacterial endotoxin, lipopolysaccharide (EPS) (Wang et al., 1999). HMGB1 
is secreted from monocytes/macrophages within 16-36hr following stimulation with EPS, 
TNF-a, or IE-1(3, which is in contrast to the secretion of the proinflammatory cytokines TNF- 
a and IE-1(3 which is within minutes of EPS stimulation both in vitro and in vivo (Wang et 
al., 1999; Andersson et al., 2000; Bianchi et al., 2007). Antibodies directed towards 
neutralising HMGB1 have shown to protect against EPS-induced lethality even when 
administered 24 hours after EPS stimulation.
HMGB1 can be actively secreted by stimulated immune cells or by passive release during 
necrotic cell death but not by apoptosis (Scaffidi et al., 2002; Rovere-Querini et al., 2004) 
HMGB1 is released in a delayed manner from activated macrophages or monocytes 
compared with the earlier production and secretion of TNF-a and IL-1 in response to
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stimulation with LPS, pro-inflammatory cytokines such as TNF-a, IL-lp, IFN-y and other 
signalling molecules (Wang et al, 1999; Chen et ah, 2004; Erlandsson Harris, 2004). 
HMGB1 is relocalised from the nucleus to cytoplasmic organelles after stimulation by LPS or 
pro-inflammatory cytokines (Gardella et al, 2002). In most cells, HMGB1 is continuously 
shuttled between the nucleus and the cytoplasm due to two non-classical nuclear export 
signals (NES1 and NES2) but nuclear accumulation is favoured (Bonaldi et al, 2003). It was 
discovered that activation of macrophages/monocytes as a result of LPS stimulation, or 
forced hyperacetylation by acetylases, leads to acetylation of two specific clusters of lysine 
residues on HMGB1 that causes it to accumulate in the cytoplasm as its nuclear re-entry is 
blocked but not its nuclear export (Bonaldi et al., 2003; Bianchi et al, 2004; Wahamaa et al, 
2007). Moreover, once the HMGB1 is cytosolic, it is moved further by accumulating in 
secretory lysosomes which are specialised organelles that are abundant in haematopoietic 
cells (Bonaldi et al, 2003). The HMGB1-containing secretory lysosomes can then fuse with 
the cell membrane and exocytosis is induced by cellular activation by 
lysophosphatidylcholine (LPC), a bioactive lipid generated by phospholipase A2 that 
promotes inflammatory effects (Gardella et al, 2002). The release of HMGB 1 for its role as 
an inflammatory cytokine is not solely dependent on activated inflammatory cells as it can 
also be released by necrotic cells in a hypo-acetylated form. Cells that undergo necrosis or are 
damaged lose the integrity of their membranes, which causes their soluble intracellular 
contents such as proteins to leak out (Bianchi et al, 2004). HMGB1 is passively released 
from necrotic cells as a soluble molecule which is capable of inducing inflammatory 
responses both in vivo and in vitro (Scaffidi et al, 2002; Dumitriu et al, 2005). Wild-type 
necrotic cells promoted a strong inflammatory response from macrophages whereas HMGB 1 
null necrotic cells had a reduced ability to signal inflammation. HMGB1 might be a critical 
molecule that allows innate immune cells both to respond to injury, and to further induce 
inflammation.
This is in contrast to apoptotic cells, which do not release significant quantities of HMGB 1, 
as these cells retain HMGB1 in their nuclei, which become firmly bound to chromatin, due in 
part to chromatin hypoacetylation (Scaffidi et al, 2002). The mechanism in which HMGB1 is 
retained in apoptotic cells was shown to involve the underacetylation of histones, with the 
affinity of HMGB1 for DNA to be higher with a lower degree of acetylation. If apoptotic 
cells are prevented from modifying their chromatin, HMGB1 will no longer be retained and
30
Chapter 1
the cells become as inflammatory as necrotic cells (Scaffidi et al., 2002). This difference 
between the types of cell death might underlie important differences in the ability of 
apoptotic and necrotic cells to promote an inflammatory response (Lotze et al, 2005). Having 
two distinct mechanisms of release demonstrates that HMGB1 can act as an early initiator (by 
means of passive release from necrotic cells) and a late promoter (by means of the late, active 
release by activated macrophages/monocytes) of inflammation (Wang et al., 1999; 
Erlandsson Harris, 2004).
Once released, HMGB1 targets innate immune cells through Toll-like receptors (TLR) and 
the receptor for advanced glycation end-products (RAGE) (Stern et al., 2002; Yu et al., 2006; 
Palumbo et al., 2007). Binding of HMGB1 to RAGE, TLR2 and 4 can lead to recruitment of 
inflammatory cells by acting as a chemoattractant and secretion of proinflammatory 
cytokines, therefore having the potential to modulate the overall extent of liver injury. 
Interaction of HMGB1 with these receptors could provide a critical link between tissue 
damage and activation of the innate immune response and provide a novel area of therapeutic 
intervention for the treatment of DILI. Antibodies directed towards neutralising HMGB1 
have been shown to be successful in attenuating the inflammatory response associated with 
APAP hepatotoxicity (Scaffidi et al., 2002) and LPS-induced lethality in mice (Wang et al., 
1999). Administration of ethyl pyruvate also was shown to attenuate systemic inflammatory 
responses and improve survival in mice subjected to lethal peritonitis by inhibiting HMGB1 
release from activated immune cells (Ulloa et al., 2002). As well as inhibiting HMGB1, 
targeting its receptors may also help reduce the inflammatory response associated with APAP 
hepatotoxicity.
1.7 RECEPTOR MEDIATORS OF INFLAMMATION
1.7.1 Toll-Like receptors (TLRs)
Toll-like receptors (TLRs) are highly conserved proteins that recognise specific molecular 
patterns that are present in a variety of endogenous and exogenous stimuli and play a crucial 
role in the induction of an immune response (Aderem et al., 2000). TLR signalling can be
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activated by molecules released by injured tissue, namely damage-associated molecular 
patterns (DAMPs), which include HMGB1. TLR proteins transduce signals through a family 
of cytosolic adapter proteins such as MyD88. After receptor engagement, MyD88 recruits 
members of the death domain-containing serine/threonine IL-lR-associated kinase (IRAK) 
family which leads to the activation and nuclear translocation of NF-kB (Park et ah, 2004; Yu 
et ah, 2006). Toll-like receptor 2 and 4 (TLR2 and TLR4) have been implicated in HMGB1 
signalling in neutrophils and macrophages (Park et ah, 2004; Yu et ah, 2006). Recent 
findings implicated the involvement of TLR2 and TLR4 in HMGB1 signalling using 
transfection experiments of murine macrophage cell lines with dominant negative constructs 
of the toll-like receptors (Park et ah, 2004). The macrophage cell lines showed a decrease in 
activation (by a reduction in NF-kB nuclear translocation) on stimulation with HMGB1 
however it was shown that wild-type and TLR2 knockout mice responded similarly to 
HMGB1 suggesting that TLR4 is the more predominant receptor (Kokkola et ah, 2005). Such 
findings indicate that TLR2 and TLR4 are the major receptors for HMGB1 but other 
receptors such as RAGE also play a contributory role (Park et ah, 2004).
1.7.2 Receptor for advanced glycation end products (RAGE)
RAGE is a 45-55kDa multiligand member of the immunoglobulin superfamily of cell surface 
molecules capable of interacting with a broad spectrum of ligands such as advanced glycation 
endproducts (AGEs), SlOOB/calmodulin, amyloid p-peptides and HMGB1 (Schmidt et ah, 
2000; Bucciarelli et ah, 2002; Stern et ah, 2002). In normal adult tissues, RAGE is expressed 
at low levels, except in the lung where it is abundant; however, it becomes rapidly 
upregulated at sites where its ligands accumulate and can produce a sustained cellular 
activation through multiple intracellular signalling pathways (Raucci et ah, 2008). Its 
involvement in inflammation has been suggested by many findings. First, RAGE is 
upregulated in all inflammatory lesions studied, including rheumatoid arthritis (Hofmann et 
ah, 2002), inflammatory kidney disease (Abel et ah, 1995), arteriosclerosis (Hofmann et ah, 
2001) and inflammatory bowel disease (Hofmann et ah, 1999). As a receptor of various 
ligands, RAGE has been implicated as a receptor on macrophages and a variety of tumour 
cells that mediate the cytokine activity of HMGB1 and is expressed on endothelium, smooth 
muscle cells, monocytes/macrophages, neurons and tumour cells (Brett et ah, 1993; Stern et
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al., 2002; Fiuza et al., 2003; Yang et al., 2005). The part of HMGB1 responsible for 
interaction with RAGE has been defined as amino acids 150-183, just before the C-terminal 
acidic tail (Dumitriu et al., 2005). RAGE is composed of a number of distinct protein 
domains; an extracellular region composed of three immunoglobulin-like domains, including 
an Ig-like V-type domain, which contains the ligand binding site, and two Ig-like C2-type 
domains. After the extracellular domain there follows a single transmembrane-spanning 
domain and a short 43-amino acid cytoplasmic tail (Figure 1.6).
Figure 1.6: Schematic representation of the structural domains of RAGE.
RAGE contains an intra-cellular domain, a short transmembrane domain and an extracellular 
domain consisting of three immunoglobulin-like regions, one ‘V’ type followed by two ‘C 
types (adapted from Hudson et al., 2008).
It has been identified that RAGE has several isoforms deriving from alternative splicing. 
RAGE exists as a full-length isoform that is bound to the cell surface membrane, which 
contains the extra- and intracellular domains and soluble isoforms. One variant is a secreted 
form that lacks the transmembrane domain called soluble RAGE (sRAGE). It has been 
identified that the primary splicing mechanism of producing sRAGE is from the alternative 
splicing of intron 9/exon 10 of the RAGE gene (Yonekura et al., 2003). The other mechanism 
responsible for producing the circulating pool of sRAGE derives from membrane-bound full- 
length RAGE by proteolytic processing (Galichet et al., 2008; Raucci et al., 2008). sRAGE 
appears to function as a decoy receptor that neutralises the signalling of circulating ligands. 
Due to this, recombinant sRAGE has been used extensively and successfully in animal 
models for the treatment of inflammation-mediated diseases, including type II collagen-
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induced arthritis (Hofmann et ah, 2002) and diabetic atherosclerosis (Park et al.5 1998; Goova 
et ah, 2001).
Engagement of a ligand with RAGE results in the activation and transduction of multiple cell 
signalling mechanisms, such as the mitogen-activated protein (MAP) kinase family (p38, Erk 
1/2 and jnk) and GTPases (Rac and CDC42) (Stern et ah, 2002; Ishihara et ah, 2003). One of 
the main signalling pathways is the activation of Rac and CDC42, which are guanosine 
triphosphatases that regulate cell motility and neurite outgrowth. The other pathway involves 
the subsequent activation and nuclear translocation of NF-kB via several MAPKs (Yang et 
ah, 2005). Binding of HMGB1 to RAGE on murine macrophages and human neutrophils 
causes the phosphorylation of the p38 and p42/44 kinases, c-Jun N-terminal kinase and 
Erk 1/2 (extracellular-signal-regulated kinase) which leads to activation of the NF-kB 
signalling pathway which promotes cell survival and cytokine production such as TNF-a, IL- 
6 and IFN-y (Li et ah, 2003; Park et ah, 2003; Lotze et ah, 2005; Yang et ah, 2005; Ulloa et 
ah, 2006). In endothelial cells, HMGB1-RAGE induces a transient phosphorylation of MAP 
kinases and expression of adhesion molecules resulting in amplification of the inflammatory 
response (Kokkola et ah, 2005). Activation of these MAP kinases was also found to be 
RAGE independent, as no differences in signalling were observed in RAGE null mice 
(Kokkola et ah, 2005; Ulloa et ah, 2006). Despite there being no differences in signalling in 
RAGE null mice, HMGB1 induced secretion of pro-inflammatory cytokines was reduced by 
70%. This suggests that although RAGE has been determined to be important for 
inflammatory responses, other receptors such as TLRs are involved in HMGB1 signalling 
(Ulloa et ah, 2006). One unique feature of RAGE-induced NF-kB activation is the positive 
feedback loop in which the RAGE signal is maintained and amplified. Due to its ability to 
sustain cellular activation, RAGE can function as a master switch, converting short-lasting 
proinflammatory responses into long-lasting cellular dysfunction (Bierhaus et ah, 2001). 
Targeting RAGE and blocking signalling could be a useful therapeutic treatment in 
dampening down the inflammatory response in drug-induced hepatotoxicity. Moreover, a 
recent study demonstrated that blockade of RAGE led to increased survival and a reduction in 
oxidative stress in APAP-treated animals (Ekong et ah, 2006).
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1.8 AIMS OF THESIS
The innate immune response has been shown to play an important role in the exacerbation of 
liver injury during APAP hepatotoxicity downstream of drug metabolism (Ju et ah, 2002; Liu 
et al., 2004; Liu et ah, 2006). However, despite intense research, inconsistencies and 
conflicting reports remain on the extent of the role of the innate immune and inflammatory 
response in the modulation of liver injury, with the key signalling pathways connecting dying 
hepatocytes and the inflammatory response needing further elucidation. The overall aim of 
this thesis was to assess the contribution of the inflammatory response in the progression of 
DILI by using appropriate animal models and utilising model hepatotoxins that can address 
and define the signalling pathways from activated immune and necrotic cells that lead to an 
inflammatory response. By this, we could test the hypothesis that the inflammatory response 
exacerbates APAP-induced liver injury via signalling between damaged hepatocytes and cells 
of the imiate immune system.
The aims to answer the following questions and hypotheses of this thesis are:
• To define and characterise a suitable set of in vivo models of DILI and inflammation 
that could produce an inflammatory response which could be assessed and 
characterised by a chosen set of observable or measurable parameters.
o What is the effect of overnight fasting on hepatotoxicity and the inflammatory 
response in a model of APAP-induced liver injury? Does fasting exacerbate 
these responses?
• To further evaluate the contribution of the innate immune response in the 
pathogenesis of APAP-induced liver injury by firstly identifying the role dimethyl 
sulfoxide (DMSO) may play in modulation of immune cell accumulation. Secondly, 
by using aspirin as a pharmacological inhibitor of the Nalp3 inflammasome in our 
models of hepatotoxicity and inflammation.
o Does DMSO have an effect on APAP-induced hepatotoxicity and 
inflammation by promoting neutrophil recruitment?
o Can aspirin help protect against DILI by inhibiting the associated 
inflammatory response?
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• To further explore the signalling events triggered by DILI by investigating the effect 
of ethyl pyruvate (EP) as a pharmacological inhibitor of early (TNF-a, IL-6 and IL- 
1P) and late (HMGB1) inflammatory cytokines on the pathogenesis of APAP-induced 
liver injury.
o Can EP protect against APAP hepatotoxicity by inhibition of the inflammatory 
response? Does EP prevent cytokine release in our models?
o How does the effect of EP compare to the effect of complete inhibition of 
HMGB1 by the use of an anti-HMGBl antibody?
• To evaluate the expression of the HMGB1 receptor RAGE in the tissues of APAP- 
treated mice and its relationship to the pathophysiology of APAP hepatotoxicity at the 
mRNA, protein and tissue level.
o Is RAGE upregulated in response to danger signals such as HMGB1 that are 
released by necrotic cells during APAP-induced liver injury?
The studies in this thesis have been undertaken in an attempt to provide more information on 
the role of the innate immune and inflammatory response during DILI. The investigations are 
to assess the contribution of inflammation by targeting certain points in the signalling 
pathway between dying hepatocytes and cells of the innate immune system. The overall 
objective is to aid the development of effective methods of therapeutic intervention by 
understanding the relationship between inflammation and toxic outcome.
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CHAPTER TWO
DEVELOPMENT OF AN INTEGRATED ANIMAL MODEL OF INFLAMMATION 
IN DRUG-INDUCED HEPATOTOXICITY
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2.1 INTRODUCTION
Currently, sufficient data to support an unequivocal role for inflammation in some cases of 
DILI are lacking, and in many cases, mechanistic details are unknown. Evidence to support 
the hypothesis that DILI triggers the activation of the innate immune system has been 
obtained from experimental in vivo models. The advantages of investigating inflammation in 
animal models of DILI are the stable genetic, molecular and immunological backgrounds of 
inbred strains. This lack of variation enables a more complete exploration and determination 
of possible inflammatory mechanisms contributing to the overall pathophysiology.
A widely studied model of DILI has been APAP-induced liver injury in mice. Evidence 
suggests that the initial hepatocellular damage caused by NAPQI may lead to the release of 
cellular* contents known as Damage-Associated Molecular Patterns (DAMPs). These include 
HMGB1 and heat-shock proteins (HSP), which act as signals that activate cells of the innate 
immune system (Yu et ah, 2006; Bianchi et al., 2007). This in turn leads to hepatic 
infiltration of inflammatory cells, which may contribute to the progression of liver injury by 
producing proinflammatory mediators such as cytokines and chemokines, as well as reactive 
oxygen and nifrogen species (Jaeschke et al., 2005; Ishida et al., 2006; Liu et al., 2006). 
Several different models of APAP-induced liver injury are being investigated, in which 
inflammation has been modulated in an attempt to explore the contribution of different 
processes of inflammation and their roles in DILI (Ju et al., 2002; Blazka et al., 1995; Liu et 
al., 2006). The variations between these models have however, lead to conflicting reports 
regarding the roles and contribution of particular immune and inflammatory mediators.
Many cell types have been implicated in determining the extent of liver injury, such as 
Kupffer cells (Ju et al., 2002), NK and NKT cells (Liu et al., 2004) and neutrophils (Liu et 
al., 2006). Neutrophils accumulating in areas of hepatocyte necrosis in the liver after APAP 
overdose were first recognised by Mitchell et al., 1973, but the relevance of this accumulation 
to the pathophysiology is still unclear* (Cover et al, 2006). Increasing evidence has implicated 
neutrophils as the main type of leukocyte involved in the pathogenesis of APAP-induced 
liver injury (Jaeschke et al., 2002; Liu et al., 2006). A study showed that depletion of 
neutrophils using an anti-Gr-1 antibody significantly protected mice against APAP-induced
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liver injury, as evidenced by markedly reduced serum ALT levels and centrilobular hepatic 
necrosis, and improved mouse survival (Liu et ak, 2006). Another study demonstrated that 
the magnitude of liver injury induced by APAP correlated with hepatic neutrophil number 
and myeloperoxidase activity, suggesting that neutrophil recruitment was involved in the 
pathogenesis of APAP-induced liver injury (Ishida et al., 2002). These findings are in 
contrast to other studies with conflicting views concerning the role of neutrophils in APAP- 
induced liver injury (Lawson et al., 2000; Cover et al, 2006). One study suggested that 
although the numbers of neutrophils were increased in the liver from APAP-challenged 
animals, neutrophils did not contribute to the initiation and progression of APAP-induced 
liver injury. The inflammation observed after overdose was stated as not being severe enough 
to cause additional damage (Lawson et al, 2000).
The involvement of various proinflammatory mediators such as TNF-a (Ishida et al, 2004; 
Blazka et al, 1995), IL-6 (Bourdi et al, 2007) and IL-lp (Imaeda et al, 2009) in promoting 
tissue damage has been demonstrated. These and other cytokines are released into the 
bloodstream from the liver during hepatic toxic injury, with rapid changes in cytokine levels 
occuning within a few hours following DILI and may precede the formation of visible 
histological liver necrosis and release of serum ALTs (Lacour et al, 2005).
In addition to APAP, other model hepatotoxins have been used in animal models to 
investigate the role inflammation plays during DILI, such as ethanol (Adachi et al, 1994; 
Arteel et al, 1996; Yin et al, 1999; Wheeler et al, 2001), halothane (Bourdi et al, 2002b) 
and galactosamine (GalN) (Tiegs et al, 1990; Nowak et al, 2000). The bacterial endotoxin 
LPS, a potent inducer of inflammation, has been widely used in scientific investigations for 
many year's as a tool to induce and study inflammatory responses (Roth et al, 1997). LPS 
administration induces systemic inflammation that mimics many clinical features of sepsis, 
including increases in the blood of proinflammatory cytokines such as TNF-a and IL-1 
(Wichterman et al, 1980; Michie et al, 1988). The release of these mediators can lead to the 
activation and recruitment of innate immune cells in the liver, which propagate tissue 
damage. Neutralizing antibodies against TNF-a or IL-1 in LPS-treated animals has resulted in 
improved outcomes for this model (Tracey et al, 1987; McNamara et al, 1993). LPS has 
recently been used as an adjuvant to model hepatotoxins such as APAP, in order to test if
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inflammation can increase sensitivity to DILI. In one study, low doses of APAP (100- 
400mg/kg, i.p) administered 2hr after a dose of LPS (44x106 EU/kg) to fasted C57BL/6 mice 
was shown to produce a leftward shift of the dose-response curve for APAP-induced liver 
injury (Maddox et al, 2010). The authors observed no hepatotoxicity with LPS alone 
although there was significantly greater TNF-a production. Histopathologic examination 
revealed centrilobular necrosis with marked neutrophilic accumulation only in livers of mice 
treated with LPS and APAP (Maddox et al., 2010). GalN has also been used as a model 
hepatotoxin (Izu et al., 2007) or as an accompaniment to LPS in a hepatotoxic and endotoxic 
shock model in mice (Galanos et al, 1979; Nowak et al., 2000). High doses of GalN induce 
fatal liver injury that histologically resembles human hepatic failure (Keppler et al., 1968) 
and induces an inflammatory response in the liver that resembles the reaction seen clinically 
in viral hepatitis (Medline et al., 1970). Moreover, when given concurrently with a low dose 
of LPS, GalN highly sensitizes animals to develop lethal liver injury resembling fulminant 
hepatitis (Galanos et al., 1979). GalN’s mechanism of toxicity is different to that of APAP, 
causing hepatic necrosis by UTP depletion, leading to inhibition of RNA synthesis (Decker 
and Keppler, 1974). In addition, GalN induces oxidative stress, causes membrane damage, 
and can lead to a number of pathological disorders (El-Mofty et al., 1975; Han et al., 2006). 
The involvement of inflammation in the pathogenesis of GalN hepatotoxicity has been 
previously demonstrated, for example, one study showed that glycine protected against GalN 
toxicity as it inhibited the activation of Kupffer cells and subsequent cytokine release 
(Stachlewitz et al., 1999). Both LPS and GalN are useful tools to produce experimental 
inflammation in animals, with different mechanisms of cellular injury to those of APAP.
Given the complexity of interplay between chemically mediated toxicity and inflammation, 
and the differences observed between strains of mice, species and in vivo model pre­
treatments, further investigation is required to define the precise role of cytokines and 
inflammatory cells in response to injury or as part of the inflammatory response.
The aims of the studies presented in this chapter were firstly to define a set of different in 
vivo models of DILI which could produce a comparable inflammatory response as 
detennined by a chosen set of inflammatory parameters. Inflammation was determined in our 
models by neutrophil accumulation in the liver and by measurement of serum levels of the
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cytokines TNF-a, IL-6 and IL-lp. The type of immune activation that APAP causes was 
characterised, and the model inflammatory stimulator LPS and hepatotoxin GalN were 
investigated as tools with which to compare the mechanism of toxicity and inflammation to 
that of APAP. Both have been shown to trigger an inflammatory response in mice, but 
without requiring metabolic activation into a toxic reactive metabolite, which is the main 
mechanism of APAP toxicity. These models would give mechanistic data to understand the 
nature of the immune response to APAP. The parameters of toxicity (serum ALT, histology), 
metabolism (hepatic GSH content) and inflammation (neutrophil accumulation, serum TNF- 
a, IL-6 and IL-lp) were defined for each model. The effect of increasing the dose of APAP 
on inflammatory cell accumulation was also investigated; testing the hypothesis that 
increased toxicity would drive APAP-induced necrosis and promote a more vigorous 
inflammatory response. The final aim of this chapter was to assess the effect fasting had on 
the APAP model of toxicity and inflammation after recent evidence suggested that fasting 
could inhibit APAP-induced apoptosis by ATP depletion, thereby promoting an inflammatory 
response (Antoine et al., 2010). The purpose of developing and defining these models was to 
aid the investigation of particular pathways of inflammation downstream from initial cellular 
injury and evaluate if modulation of these pathways could reduce the level of overall injury.
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2.2 MATERIALS AND METHODS
2.2.1 Materials
Infinity ALT liquid kits were purchased from ALPHA Laboratories (Eastleigh, U.K). Unless 
otherwise stated, all other chemicals and materials were purchased from Sigma-Aldrich 
(Poole, U.K).
2.2.2 Experimental animals
The protocols described were in accordance with criteria outlined in a licence granted under 
the Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool 
Animal Ethics Committee. Animals were purchased from Charles River laboratories and had 
a 5 day acclimatisation period prior to experimentation. Animals were also maintained in a 
12hr light/dark cycle with free access to food and water.
2.2.3 Animal dosing regime
Male C57BL/6 mice (18-23g) were either fasted overnight with free access to water or had 
free access to food and water prior to experimentation. Mice were administered a single i.p. 
injection of APAP (O-lOOOmg/kg) in 0.9% saline then were euthanized after 5hr. Other 
groups received APAP (530mg/kg) in 0.9% saline and were euthanized between 0-24hrs. 
Some mice received LPS (0-5mg/kg i.p.) in 0.9% saline or GalN (0-1500mg/kg i.p.) in 0.9% 
saline and were then euthanized between 0-24hr post dose. Control animals received 0.9% 
saline. Treatment groups consisted of 4-5 individual animals.
2.2.4 Assessment of hepatotoxicity in treated male C57BL/6 mice
Animals were sacrificed by CO2 inhalation and confirmed by cervical dislocation. Blood was 
collected via cardiac puncture and allowed to clot overnight at 4°C. Livers were removed, 
rinsed in ice cold 0.9% saline and a section was fixed in 10% neutml buffered formalin. The
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rest of the liver was snap frozen in liquid nitrogen. Serum was separated by pulse 
centrifugation from blood and alanine transaminase (ALT) levels were determined.
2.2.5 Determination of hepatic glutathione levels in C57BL/6 mouse whole liver during 
drug-induced hepatotoxicity
Liver samples were prepared by homogenisation of 30-50 mg of tissue from the major lobe in 
5-sulfosalicyclic acid (200pi; 6.5 % w/v) and GSH stock buffer (800pl; 143mM NaH2P04, 
6,3mM EDTA, pH 7.4) and the protein was allowed to precipitate on ice for 10 min prior to 
centrifugation (14000rpm for 5 min). Liver protein samples were dissolved in 1ml 1M NaOH 
prior to protein content determination. Supernatants containing GSH and samples for protein 
determination were stored at -80°C until analysis. Total GSH content was measured 
spectromically (412nm) by a kinetic reaction that took place between total GSH and GSH 
reductase on a Dynatech Laboratories UV-visible absorbance MRX microtiter-plate reader 
(Vandeputte et al., 1994). The results were compared to GSH standards (0-80nm/ml). Levels 
of GSH were normalised to hepatic protein content using Bio-Rad protein assay reagent 
according to the manufacturer’s instructions.
2.2.6 Preparation of histology sections
Histological specimens were prepared in the Histology Laboratory, Veterinary Laboratory 
Services, School of Veterinary Science, University of Liverpool. Slices (3-4mm) of the major 
lobe of the liver were immersed in neutral buffered formalin (10%, Sigma) for 24hr. 
Transverse sections were taken from the formalin fixed sample, and placed cut side down 
into a pre-labelled histology cassette. Tissue samples were processed using a tissue processor 
(Tissue-TEK Vacuum Infiltration Processor). The tissue processor removes water from the 
tissues and replaces it with paraffin wax which solidifies tissue and enables it to be cut. 
Briefly, the tissue was dehydrated with a series of increasing concentrations of ethanol to 
remove free and bound water. They were then submersed and washed in xylene which 
removes the ethanol. The tissue specimens were then removed from their cassette and 
embedded into a mould of molten paraffin wax with the trimmed side down. The cassette was 
then placed on top of the mould and topped up with wax and allowed to solidify. 3-5 pm thick
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sections were cut and floated onto a clean water bath (45°C) to remove creases. The sections 
were retrieved with a charged microscope slide and allowed to dry in an oven.
2.2.7 Histological and immunohistological staining of liver sections
For histological assessment, sections were stained with haematoxylin and eosin (HE). For the 
assessment of hepatocellular* glycogen contents, sections from selected livers were stained 
with the Periodic Acid Schiff (PAS) reaction. On selected cases, immunohistology for the 
confirmation of apoptosis was performed by staining for cleaved caspase-3 as previously 
described (Antoine et al., 2009). All stains were performed by technical staff in the Histology 
Laboratories, Veterinary Laboratory Services, School of Veterinary Science, University of 
Liverpool.
2.2.8 Histological examination of C57BL/6 mouse liver
The histological examination was undertaken in collaboration with Prof A Kipar, Veterinary 
Pathology, School of Veterinary Science, University of Liverpool. HE-stained sections were 
examined and the degree of hepatocyte loss and necrosis was scored according to the criteria 
in table 2.1. Leukocyte infiltration was assessed and recorded. PAS-stained sections were 
used to assess the hepatocellular* glycogen content, and sections stained for cleaved caspase-3 
served to confirm hepatocyte death via apoptosis. The histological assessment was 
undertaken blindly by Prof A Kipar*.
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Table 2.1: Scoring of histological changes in murine livers (based on Antoine et al, 2009)
Score Definition
0 Normal - no evidence of hepatocyte necrosis
1 Hepatocyte loss and necrosis - minimal to mild
Focal
Limited to centrilobular region
Less than lA of affected lobules are necrotic
Associated with vacuolar- degeneration or haemorrhages
2 Hepatocyte loss and necrosis - mild to moderate
Focal or multifocal
Extends from central to midzonal lobular- region
Vi of affected lobules are necrotic
Associated with vacuolar degeneration or haemorrhages
3 Hepatocyte loss and necrosis - moderate to severe
Multifocal
May extend from centrilobular* region to portal area
More than Vi to % affected lobules are necrotic
Associated with vacuolar degeneration or haemorrhages
4 Hepatocyte loss and necrosis - severe
Multifocal
More than % affected lobules are necrotic
Associated with vacuolar- degeneration or haemorrhages
5 Massive Hepatocyte loss and necrosis — severe, involving entire 
lobules
Hepatocyte loss extends from central vein to portal area
Hepatocyte loss extends to adjacent lobules (multilobular necrosis) 
Associated with vacuolar degeneration or haemorrhages
2.2.9 Measurement of cytokines in serum from animals dosed with LPS, GalN and 
APAP using Luminex Analysis
Serum was collected from control and treated animals. Concentrations of TNF-a, IL-6 and 
IL-lp were measured using the Bio-Plex Assay kit (Bio-Rad Laboratories, Inc).
A filter plate was wet with 100j.il of Assay Buffer per well, then a vacuum manifold was 
applied to the bottom of the plate. The bottom of the plate was then dried thoroughly by 
blotting on a clean paper towel. The coupled magnetic beads were vortexed at medium speed 
for 30sec then 50pl were added to each well. The plate was washed twice with lOOpl of 
Wash Buffer and the vacuum manifold. The standards and samples were gently vortexed for 
1-3 sec before 50pl were added to the appropriate well. The plate was covered with a sheet of 
sealing tape to prevent liquid escaping from the wells. The plate was then placed on a plate
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shaker and covered in aluminium foil to protect from light. The plate was shaken at room 
temperature at l,100rpm for 30sec, and then at 300rpm for 30min. During incubation, lx 
detection antibodies were prepared by dilution of lOx detection antibodies with Detection 
Antibody Diluent. After incubation was complete, the sealing tape was removed and 
discarded. lOOpl of Wash Buffer was added to each well and removed by the vacuum 
manifold. This last wash step was repeated 3 times, blotting excess liquid in between on a 
clean paper towel. The lx detection antibodies were gently vortexed for 1-3sec before 25pl 
were added to each well. The plate was covered and vortexed briefly (l,100rpm for 30sec) 
before being incubated on the shaker at room temperature (300rpm for 30min). During 
incubation, lx streptavidin-phycoerythin (streptavidin-PE) was prepared by dilution using 
Assay Buffer. After incubation, the sealing tape was carefully removed and discarded. The 
plate was washed 3 times with lOOpl Wash Buffer using the vacuum manifold. The 
streptavidin-PE (lx) was vortexed vigorously for 3-5sec before 50pi was added to each well. 
The plate was once again covered and incubated on the plate shaker at room temperature, this 
time for lOmin. After the streptavidin-PE incubation, the sealing tape was carefully removed 
and discarded. The plate was washed 3 times with 100pl Wash Buffer using the vacuum 
manifold. 125 pi of Assay Buffer was added to each well. The plate was covered with a new 
sheet of sealing tape. The plate was shaken at room temperature at l,100rpm for 30sec. The 
sealing tape was then removed before reading the plate on a Luminex 100 system. The results 
were acquired using Bio-Plex Manager software, a standard curve and 5-parameter logistics 
was used to analyse the data. The lower range of the assay is <5.8 pg/ml for TNF-a, 
<0.74pg/ml for IL-6 and <10.36pg/ml for IL-1J3. Levels below these values were assigned a 
value of zero.
2.2.10 Statistical analysis
All results are expressed as mean ± standard deviation (S.D). Values to be compared were 
analysed for non-normality using a Shapiro-Wilk test. The unpaired t-test was used when 
non-normality was indicated. A Mann-Whitney U test was used for non-parametric data. 
Comparisons between multiple groups were performed with one-way ANOVA or, where 
appropriate, by two-way ANOVA, followed by a post hoc Bonferroni test. All calculations 
were performed using SPSS statistical software, results were considered significant when 
/K0.05.
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2.3 RESULTS
2.3.1 LPS model of hepatic inflammation in C57BL/6 mice
The dose and time dependent nature of LPS-induced effects on the liver and the associated 
inflammation was investigated in male C57BL/6 mice to assess the usefulness of LPS as a 
tool to induce inflammation and compare to other model hepatotoxins. In male C57BL/6 
mice, there was no statistically significant change in serum ALT activity compared to control 
animals (41.37±8.45U/1) after administration of LPS over a dose range (0-5mg/kg) at 24hr 
post dose (Figure 2.1 A). There was also no significant effect on hepatic GSH content induced 
by LPS at 24hr post dose compared to control levels (73.68±9.53nmol/mg) (Figure 2.IB). No 
significant effect on serum ALT activity was observed with LPS over the time course 
investigated (0-24hr) (Figure 2.1C) or on hepatic GSH content (Figure 2.ID). With a dose 
level of 5mg/kg, there was a significant increase in the serum level of TNF-a at 24hr 
(513.13±50.15pg/ml) (Figure 2.2A). IL-6 also increased at 24hr after LPS 
(1201.12±157.20pg/ml) (Figure 2.2B) as well as levels of IL-lp (227.08±36.93) (Figure 
2.2C). The histological evaluation undertaken on the livers of animals dosed with LPS 
(5mg/kg) and euthanized after 0 to 24hr revealed no evidence of hepatocyte necrosis (score 0, 
see Table 2.1) but identified neutrophil influx of variable degree from 3hr post dosing on. 
There was also some evidence of potential hepatocyte damage represented by the loss of 
glycogen from 3hr post dosing onwards.
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Figure 2.1: LPS 24hr dose response and time course.
The dose effect of LPS (0-5mg/kg) on serum ALT activity (A) and hepatic GSH content (B) 
was assessed at 24hr. The time dependent effects of LPS (5mg/kg) on serum ALT activity (C) 
and hepatic GSH content (D) were assessed over 0-24hr. Data is given as mean ± SD of 4 
mice per group. Statistical significance was assigned relative to saline treated controls.
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Figure 2.2: Serum cytokine levels in male C57BL/6 mice after LPS exposure.
Male C57BL/6 mice were administered LPS (5mg/kg; 24hr) and serum levels of TNF-a (A), 
IL-6 (B) and IL-lp (C) were determined. Data is given as mean ± SD of 3 mice per group. 
Statistical significance was assigned relative to saline treated controls. ***p < 0.001.
5/
Chapter 2
Table 2.2: Histological findings after LPS treatment. The time dependent effects of LPS 
(5mg/kg) were assessed over 0-24hr, using the scoring scheme of table 2.1. The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed in each of 4 animals per group.
Time post 
dosing
Score Histological findings
Ohr 0 Diffuse glycogen in hepatocytes; no histological abnormality is 
recognised (NHAIR)
0.5hr 0 Diffuse glycogen in hepatocytes; NHAIR
Ihr 0 Diffuse glycogen; NHAIR
3 In* 0 Reduced hepatocellular glycogen; increased numbers of 
neutrophils (NL) between hepatic cords; several central veins 
with some NL in lumen; scattered small NL aggregates between 
hepatic cords; focal mixed cellular infiltration, relatively large, 
extending focally from one central vein
5hr 0 Markedly reduced or no hepatocellular* glycogen; several 
leukocytes in central veins and a few around them; scattered 
small random NL aggregates and generally increased leukocytes 
between hepatic cords .
24hr 0 No glycogen; several leukocytes in central veins and a few 
around them (Figure 2.3); scattered small random NL aggregates 
and generally increased leukocytes between hepatic cords
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Figure 2.3: Histological findings in a C57BL/6 mouse at 24hr post LPS (5mg/kg) 
treatment.
Several neutrophils are present within the lumen and attached to endothelial cells of central 
veins (CV) (long arrows) and in the immediately adjacent parenchyma (short arrow). HE 
stain.
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2.3.2 GalN model of hepatotoxicity and inflammation in C57BL/6 mice
The dose dependent effects of GalN were investigated in C57BL/6 mice at 5In post 
treatment. GalN induced a dose dependent increase in serum ALT activity which was 
significant from control levels at 600mg/kg (83.16±15.43U/1) and 800mg/kg 
(197.78±26.08U/1) (Figure 2.4A). No significant change in hepatic GSH levels was observed 
compared to control levels over the dose range (Figure 2.4B). In order to determine the 
threshold of toxicity for GalN, the dose range was increased above 800mg/kg (0-1500mg/kg) 
and the time point for assessment extended to 24hr. A time course of the effect of GalN at 
800mg/kg (0-24hr) was also performed. As before, GalN induced a dose dependent increase 
in serum ALT activity that was significant from control levels above 400mg/kg (Figure 
2.5A). Increasing the time point to 24hr resulted in a greater level of serum ALT activity 
being observed at 600mg/kg (542.76±163.95U/1) and 800mg/kg (825.34±127.03U/1) 
compared to those corresponding doses at 5hr (83.16±15.43U/1 and 197.78±26.08U/1, 
respectively). No significant change in the level of hepatic GSH content was observed at 24hr 
across the dose range (Figure 2.5B). GalN induced a time dependent increase in toxicity 
(serum ALT activity) with a dose of 800mg/kg. Serum ALT activity was significantly 
increased from control levels at 5hr (339.08±51.84U/1) and 24hr (875.30±144.81U/1) post 
GalN dose (Figure 2.5C). No significant change in hepatic GSH content was observed across 
the time course (Figure 2.5D). With a dose level of 800mg/kg, there was a significant 
increase in the serum level of TNF-a (56.44±5.68pg/ml) (Figure 2.6A), IL-6 
(63.22±8.41 pg/ml) (Figure 2.6B) and IL-ip (40.72±3.64) at 24hr (Figure 2.6C). The 
histological examination did not reveal any histological changes at low doses 24hr post 
treatment. With higher doses, random small areas of mixed cellular infiltrates with associated 
individual hepatocyte apoptosis and necrosis was observed (Figure 2.7; 24hrs 1500ing/kg; 
Table 2.3). The effect of a GalN dose that induced serum cytokine levels (800mg/kg) was 
studied over a period of 0-24hr post dosing. Up to 3hr post treatment, no histological 
abnormalities were detected. At 5hr, all animals showed evidence of slight hepatocellular 
dissociation and exhibited scattered apoptotic hepatocytes (Figure 2.8). A slight increase of 
neutrophils was seen between hepatic cords. At 24hr, multifocal random areas of hepatocyte 
necrosis, apoptosis, neutrophil and macrophage infiltration were seen (Table 2.4).
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Figure 2.4: GalN-induced hepatotoxicity.
The dose effect of GaIN (0-800mg/kg) on serum ALT activity (A) and hepatic GSH content 
(B) was assessed at 5hr in male C57BL/6 mice. Data is given as mean ± SD of 5 mice per 
group. Statistical significance was assigned relative to saline treated controls. **p< 0.01 and
***p< 0.001.
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Figure 2.5: GaIN 24hr dose response and time course.
The dose effect of GaIN (0-1500mg/kg) on serum ALT activity (A) and hepatic GSH content 
(B) was assessed at 24hr in C57BL/6 mice. The time dependent effects of GaIN (800mg/kg) 
on serum ALT activity (C) and hepatic GSH content (D) were assessed over 0-24hr. Data is 
given as mean ± SD of 5 mice per group. Statistical significance was assigned relative to 
saline treated controls. ***^> < 0.001.
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Figure 2.6: Serum cytokine levels during GalN-induced hepatotoxicity in male C57BL/6 
mice.
Male C57BL/6 mice were administered GaIN (800mg/kg; 24hr) and serum levels of TNF-a 
(A), IL-6 (B) and IL-lp (C) were determined. Data is given as mean ± SD of 3 mice per 
group. Statistical significance was assigned relative to saline treated controls. **p< 0.01 and 
***/?< 0.001.
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Table 2.3: Histological findings after GalN treatment. The dose effect of GalN (0- 
1500mg/kg) on male C57BL/6 mouse livers was assessed at 24hr. The histological evaluation 
was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary Science, 
University of Liverpool). The listed findings represent a summary of the changes observed in 
each of 5 animals per group.
GalN Dose Score Histological findings
Omg/kg 0 Diffuse glycogen in hepatocytes; no histological abnormality is
recognised (NHAIR)
200mg/kg 0 Diffuse glycogen in hepatocytes; scattered small mixed cellular 
aggregates with occasional necrotic hepatocytes (as in control 
animals)
40 Omg/kg 0 Diffuse glycogen in hepatocytes; scattered small mixed cellular 
aggregates with occasional necrotic hepatocytes (as in control 
animals)
600mg/kg 0 Diffuse glycogen in hepatocytes; disseminated small mixed 
leukocyte aggregates between hepatic cords (more intense than 
in controls and at lower doses)
800mg/kg 0 Diffuse glycogen; disseminated small mixed cellular* aggregates 
with occasional necrotic hepatocyte; some random areas of 
coagulative necrosis with haemorrhage and neutrophil infiltrate, 
surrounded by rim of hepatocytes with loss of glycogen
lOOOmg/kg 0 Diffuse glycogen in hepatocytes; disseminated small mixed 
cellular aggregates with occasional necrotic hepatocyte; some 
random areas of coagulative necrosis with haemorrhage and 
neutrophil infiltrate, surrounded by rim of hepatocytes with loss 
of glycogen
1500mg/kg 0 Multifocal random areas with mixed leukocytes (neutrophils, 
macrophages, lymphocytes) with occasional apoptotic and 
necrotic hepatocytes (Figure 2.7A); some disseminated 
individual necrotic and apoptotic hepatocytes (Figure 2.7B)
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Figure 2.7: Histological findings in a C57BL/6 mouse at 24hr post GalN treatment 
(1500mg/kg).
(A) Focal area of leukocyte infiltration with some necrotic/apoptotic hepatocytes (arrow). HE 
stain. (B) Staining for cleaved caspase-3 identifies scattered apoptotic hepatocytes (arrows). 
Peroxidase anti-peroxidase method. Pananicolaou’s haematoxylin counterstain.
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Table 2.4: Histological findings at different time points after GalN treatment. The time 
dependent effects of GalN (800mg/kg) were assessed over 0-24hr post dose. The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool), The listed findings represent a summary of the changes 
observed in each of 4 animals per group.
Time post
dosing
Score Histological findings
Ohr 0 Diffuse glycogen; no histological abnormality is recognised
(NHAIR)
0.5hr 0 Diffuse glycogen; (NHAIR)
llir 0 Diffuse glycogen; (NHAIR)
3hr 0 Diffuse glycogen; (NHAIR)
5 hr 0 Diffuse glycogen; slight hepatocellular dissociation; scattered 
apoptotic cells and bizarre mitotic figures in hepatocytes (Figure 
2.8); occasional neutrophils between hepatic cords
24hr 0 Diffuse glycogen, but with patchy glycogen loss in association 
with multifocal random, variable sized (rel. large) focal areas of 
neutrophil and macrophage infiltration and hepatocyte 
necrosis/apoptosis; some leukocytes in central veins
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Figure 2.8: Histological findings in a C57BL/6 mouse at 5hr post GalN treatment 
(800mg/kg).
(A) Scattered apoptotic hepatocytes (small arrow) and hepatocytes with bizarre mitotic 
figures (large arrows) are seen. HE stain. (B) Closer view of apoptotic hepatocytes (arrow). 
HE stain. (C) Staining for cleaved caspase-3 confirms that dying hepatocytes undergo 
apoptosis (arrow). Peroxidase anti-peroxidase method. Pananicolaou’s haematoxylin 
counterstain.
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2.3.3 Effect of increasing APAP dose on hepatotoxicity and neutrophil recruitment in 
male C57BL/6 mice
APAP induced a dose dependent increase in serum ALT activity at 24hr which was 
significant from control levels at 530mg/kg (2126.09±263.42U/1) (Figure 2.9A). There was 
also a significant increase in toxicity at 530mg/kg from 300mg/kg. There was no significant 
decrease in hepatic GSH content between control and dosed groups at 24hr with GSH levels 
returned to control levels (Figure 2.9B). At 24hr there were no surviving mice subjected to a 
750mg/kg dose of APAP, therefore ALT and GSH values were not included. The histological 
examination identified the typical APAP-induced centrilobular hepatocyte loss in all animals 
at a dose of 530mg/kg and 750mg/kg. After 300mg/kg, mild typical lesions were apparent in 
one mouse. In mice treated with 530mg/kg affected areas generally showed mild to moderate 
neutrophil infiltration at this stage (Figure 2.10). Remaining hepatocytes in affected areas 
exhibited marked hydropic degeneration and coagulative necrosis (Figure 2.10) and there 
were occasional apoptotic cells (Table 2.5).
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Figure 2.9: APAP-induced hepatotoxicity in male C57BL/6 mice.
The dose effect of APAP (0, 300, and 530mg/kg) on serum ALT activity (A) and hepatic 
GSH content (B) was assessed at 24hr. Data is given as mean ±S.D of 5 mice per group. 
Statistical significance was assigned relative to saline treated controls. ***/? < 0.001.
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Table 2.5: Histological findings in mice after APAP treatment (dose response). The dose 
effect of APAP (0-750mg/kg) on male C57BL/6 mouse livers was assessed at 24hr post dose. 
The histological evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, 
School of Veterinary Science, University of Liverpool). The listed findings represent a 
summary of the changes observed and the range of scores and average score in each of 5 or 6 
(750mg/kg) animals per group.
APAP dose Score
[average!
Histological findings at 24hr after dosing
Omg/kg 0 Diffuse glycogen; no histological abnormality is recognised 
(NHAIR)
300mg/kg 0(-l)
[0.1]
Diffuse glycogen; NHAIR (4/5); one animal with centrilobular 
glycogen loss, hydropic degeneration and necrosis/apoptosis of 
hepatocytes and moderate neutrophil infiltration in affected 
areas
5 3 Omg/kg 1-4
[2.7]
Extensive centrilobular cell loss, hydropic degeneration, 
necrosis and apoptosis of remaining hepatocytes, with mild to 
moderate neutrophil infiltration in affected areas (Figure 2.10)
75 Omg/kg* 2-3
[2.83]
Centrilobular hepatocyte loss with scattered necrotic cells; no 
inflammatory infiltration
* The animals died maximally lOhr after dosing
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Figure 2.10: Histological findings in a C57BL/6 mouse at 24hr post APAP treatment 
(530mg/kg).
(A) There is extensive centrilobular cell loss with hydropic degeneration of remaining cells in 
affected areas, central vein (CV). (B) Closer view of (A), highlighting infiltration of 
neutrophils in affected areas (arrows). HE stains.
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2.3.4 Effect of increasing APAP dose on survival of male C57BL/6 mice
Male C57BL/6 mice were administered either a 300mg/kg, 530mg/kg or 750mg/kg dose of 
APAP then euthanized at 24hr post dose. The 750mg/kg dose of APAP resulted in a 
significant increase in mortality starting at the 8hr mark (-66% survival) with 0% survival at 
11 hr (Figure 2.11). Mice subjected to a dose of 530mg/kg APAP displayed 100% survival 
until 19hr (-91%) and had -83% survival by 24hr. The lower dose of APAP (300mg/kg) and 
control mice each had 100% survival at 24hr.
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Figure 2.11: Kaplan-Meier Survival Curve.
Male C57BL/6 mice treated with APAP (0, 300, 530 and 750mg/kg) and percent (%) survival
was recorded over 24hr (Saline, solid line----- ; APAP 300mg/kg, dotted line •**•; APAP
530mg/kg, large dashed line----- ; APAP 750mg/kg, small dashed line----- ).
i
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2.3.5 APAP model of hepatotoxicity and inflammation in C57BL/6 mice
In male C57BL/6 mice a dose dependent increase in serum ALT activity was observed at 
dose levels of 530mg/kg and above at 5hr (Figure 2.12A). APAP induced a dose dependent 
decrease in total hepatic GSH content which was significant from control levels at doses of 
150mg/kg and above at 5hr (Figure 2.12B). The time dependent effects of APAP-induced 
hepatotoxicity, metabolism and cytokine release were also determined. Serum ALT activity 
was significantly increased from control levels at 3hr (1004.74±252.56U/1), 5hr 
(2056.82±214.47U/1) and 24hr (2702.49±231.65U/1) post APAP (530mg/kg) dose (Figure 
2.12C). A significant decrease in hepatic GSH content was observed 30min post APAP dose 
(3L94±3.76mnol/mg) compared to vehicle control mice (73.57±2.88nmol/mg) (Figure 
2.12D). Hepatic GSH content decreased further at Ihr (25,42±7.28nmol/mg) and reached 2% 
of control at 3hr (1.68±0.85nmol/mg) post APAP dose. Hepatic GSH content increased at 5hr 
post dose (17.78±8.77nmol/ml) and returned to control levels at 24hr (69.75±7.86nmol/ml). 
Serum TNF-a was significantly increased from control levels at 3hr (67.52±9.07pg/ml), 5hr 
(74.37±7.13pg/ml) and 24hr (75.86±7.94pg/ml) post APAP dose (Figure 2.13A). Serum IL-6 
levels were significantly increased at Ihr (40.49±14.21pg/ml), reaching their peak level at 
24hr (104.53±13.07pg/ml) (Figure 2.13B). Serum IL-lp was significantly increased at 5hr 
(25.31±4.46pg/ml), with levels returning to those of control at 24hr (18.18±2.54pg/ml) 
(Figure 2.13C). Both the APAP dose response and time course studies showed the typical 
APAP-associated centrilobular cell loss (Table 2.6 and Table 2.7). At 5hr post dosing, there 
was no evidence of inflammatory cell recruitment in the liver. This was seen at 24hr with a 
dose of 530mg/kg, although with variable intensity (slight to moderate), and was represented 
by the presence of neutrophils within centrilobular areas of hepatocyte loss (Figure 2.10; 
Table 2.7)
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Figure 2.12: APAP-induced hepatotoxicity in male C57BL/6 mice.
The dose effect of APAP (0-1000mg/kg) on serum ALT activity (A) and hepatic GSH 
content (B) was assessed at 5hr. The time dependent effects of APAP (530mg/kg) on serum 
ALT activity (C) and hepatic GSH content (D) were assessed over 0-24hr. Data is given as 
mean ± SD of 5 mice per group. Statistical significance was assigned relative to saline treated 
controls. **p< 0.01 and ***p< 0.001.
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Figure 2.13: Serum cytokine levels during APAP-induced hepatotoxicity in male 
C57BL/6 mice.
The time dependent effects of APAP (530mg/kg) on serum levels of TNF-a (A), IL-6 (B) and 
IL-lp (C) were determined in male C57BL/6 mice over 0-24hr. Data is given as mean ± SD 
of 3 mice per group. Statistical significance was assigned relative to saline treated controls. 
**p<0.01 and ***/?< 0.001.
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Table 2.6: Histological findings in mice at 5hr after APAP treatment (dose response). The 
dose effect of APAP (0-1000mg/kg) on male C57BL/6 mouse livers was assessed at 5hr. The 
histological evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of 
Veterinary Science, University of Liverpool). The listed findings represent a summary of the 
changes observed and the range of scores and average score in each of 5 animals per group.
APAP dose Score
[averagel
Histological findings at 5hr post dose
Omg/kg 0 Diffuse glycogen in hepatocytes; no histological abnormality
is recognised (NHAIR)
150mg/kg 0 Diffuse glycogen in hepatocytes; NHAIR
300mg/kg 0 Centrilobular hepatocellular glycogen loss (small rim) with 
occasional hepatocellular hydropic degeneration
5 3 Omg/kg 3-4
[3.42]
Hydropic degeneration of remaining cells in areas of cell 
loss; generally reduced amount of glycogen in hepatocytes in 
unaffected areas
600mg/kg 3-4
[3.58]
Zones of cell loss surrounded by small rim with loss of 
glycogen and hydropic degeneration; remaining hepatocytes 
unaltered with glycogen
75 Omg/kg 2-4
[3]
Hydropic degeneration of non-necrotic cells surrounding 
necrosis; some remaining unaltered hepatocytes immediately 
periportal; no glycogen
lOOOmg/kg 3-5
[4.14]
Marked hydropic degeneration of remaining hepatocytes in 
affected areas; variable degree of hydropic degeneration of 
hepatocytes outside affected areas; no glycogen
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Table 2.7: Histological findings in mice after APAP treatment (time course). The time 
dependent effects of APAP (530mg/kg) were assessed over 0-24hr. The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed and the range of scores and average score in each of 4 animals per group.
Time post 
dosing
Score
[averagel
Histological findings
Ohr 0 Diffuse glycogen in hepatocytes; no histological abnormality 
is recognised (NHAIR)
Ihr 0 Diffuse glycogen in hepatocytes; NHAIR
3hr 1-3
[1.25]
Hydropic degeneration of remaining cells in affected areas; 
loss of glycogen of hepatocytes surrounding affected areas; 
no or very occasional apoptotic hepatocytes in affected areas
5hr 1-4
[2.75]
Hydropic degeneration of remaining cells in affected areas; 
loss of glycogen of hepatocytes surrounding affected areas
24hr 1 Hydropic degeneration and coagulative necrosis of remaining 
centrilobular hepatocytes; small rim of glycogen loss around 
affected areas; some centrilobular neutrophils
2.3.6 Effect of fasting on APAP-induced hepatotoxicity and inflammation in C57BL/6 
mice
The effects of overnight fasting on APAP-induced hepatotoxicity, metabolism and 
inflammation were explored in male C57BL/6 mice. Serum ALT activity increased in a time 
dependent manner compared to control, with a significant increase observed at 3br 
(1470.74±345.02U/1), 5hr (2240.83±425.04U/1) and 24hr (3597.04±299.46U/1) (Figure 
2.14A). There was a significant decrease in hepatic GSH content observed at 30min post 
APAP dose (15.29±4.83nmol/mg) which continued to decrease until 3hr where levels 
reached 5% of control (2.02±0.14nmol/mg) (Figure 2.14B). Hepatic GSH levels began to 
increase at 5hr and were returning to control levels at 24hr (29,94±3.77nmol/mg). Serum 
TNF-a was significantly increased from control levels at 3hr (145.32±17.84pg/ml), 5hr 
(123.94±23.73pg/ml) and 24hr (249.8l±39.55pg/ml) post APAP dose (Figure 2.15A). Serum 
IL-6 levels followed a similar pattern to TNF-a levels and were significantly increased at 3hr
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and above (119.67±16.31pg/ml), reaching their peak at 24hr (194.31±35.72pg/ml) (Figure 
2.15B). Serum IL-lp was significantly increased at Ihr (38.90±4.56pg/ml), reaching peak 
levels at 5hr (65.10±9.08pg/ml) with a lower level at 24hr (48.72±6.63pg/ml) (Figure 2.15C). 
Animals that had been fasted prior to treatment showed complete hepatocellular glycogen 
depletion (Figure 2.16A). Hepatocellular glycogen was restored after 30min (Figure 2.16B), 
but appeared to be lost again Ihr post APAP dosing. At 3hr it was again restored which was 
apparent in treated animals in unaffected areas. Definite histological evidence of APAP- 
induced centrilobular hepatocyte loss was seen at 5hr post dosing, but there was evidence of 
hepatocyte damage already at 3hr post dosing, when centrilobular loss of hepatocellular 
glycogen was observed (Figure 2.17; Table 2.8).
A B
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* * *4000
H 3000 * * *
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Time (hr)
Figure 2.14: APAP-induced hepatotoxicity in fasted male C57BL/6 mice.
The time dependent effects of APAP (530mg/kg) on serum ALT activity (A) and hepatic 
GSH content (B) were assessed over 0-24hr. Data is given as mean ± SD of 4 mice per group. 
Statistical significance was assigned relative to saline treated controls. *p < 0.05 and ***/?< 
0.001.
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Figure 2.15: Serum cytokine levels during APAP-induced hepatotoxicity in fasted male 
C57BL/6 mice.
The time dependent effects of APAP (530mg/kg) on serum levels of TNF-a (A), IL-6 (B) and 
IL-ip (C) were determined in fasted male C57BL/6 mice over 0-24hr. Data is given as mean 
± SD of 4 mice per group. Statistical significance was assigned relative to saline treated 
controls. **/?< 0.01 and ***/?< 0.001.
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Table 2.8: Histological findings in fasted mice after APAP treatment (time course). The time 
dependent effects of APAP (530mg/kg) were assessed over 0-24hr. The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed and the range of scores and average score in each of 4 animals per group.
Time post
dose
Score
[average]
Histological findings
Ohr 0 No glycogen (Figure 2.16A); no histological abnormality is 
recognised (NHAIR)
0.5hr 0 Diffuse glycogen (relatively low amount; Figure 2.16B); one 
animal with centrilobular loss of glycogen
Ihr 0 No glycogen; one animal with centrilobular hydropic 
degeneration
3 hi* 0 Extensive centrilobular glycogen loss and hydropic 
degeneration (Figure 2.17)
5hr 3-4
[3.25]
Hydropic degeneration of remaining hepatocytes in affected 
areas
24hr 2-3
[2.1]
Hydropic degeneration, coagulative necrosis and apoptosis of 
remaining hepatocytes in affected areas
NB: Control animals exhibited no hepatocellular glycogen at Ohr. Hepatocellular glycogen
was restored from 0.5hr onwards
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Figure 2.16: Assessment of hepatocellular glycogen content in C57BL/6 mice at Ohr and 
0.5hr post APAP treatment (530mg/kg).
(A) At Ohr, no hepatocellular glycogen is observed. (B) At 0.5hr, hepatocellular glycogen is 
restored, although at generally low level. PAS reaction.
74
Chapter 2
Figure 2.17: Assessment of hepatocellular glycogen content in a C57BL/6 mouse at 3hr 
post APAP treatment (530mg/kg).
(A) Extensive centrilobular hepatocellular glycogen loss is observed. (B) Glycogen loss is 
associated with hydropic degeneration of individual centrilobular hepatocytes (arrows), 
central veins (CV). HE stain.
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2.3.7 Comparison of APAP-induced effects on fasted and non-fasted C57BL/6 mice
Following the assessment of APAP hepatotoxicity in fasted C57BL/6 mice, a comparison 
was made of APAP (530mg/kg) induced changes and basal factors with non-fasted C57BL/6 
mice at 5hr and 24hr post APAP dose. Table 2.9 illustrates that serum ALT activity was 
significantly higher in APAP treated fasted mice at 24hr (3597.04±299.46U/1) than fed mice 
(2709.49±231.65U/1). Basal levels of hepatic GSH content were higher in fed mice at 5hr 
(83.85±6.65nmol/mg) than in fasted (38.20±3.09nmol/mg) and also at 24hr. Levels of GSH 
were also lower in fasted mice at 5hr post APAP dose (4.18±0.70nmol/mg) than in fed 
(17.78±8.77nmol/mg) and a similar effect was seen at 24hr. Serum levels of TNF-a were 
significantly higher in fasted mice at 5hr post APAP dose (123.94±23.73pg/ml) than in fed 
(74.37±7.13pg/ml) as were levels of IL-6 (106.29±12.34pg/ml and 61.69±5.75pg/ml 
respectively) and IL-ip (65.10±9.08pg/ml and 25.31±4.46pg/ml respectively). Also at 24hr 
post APAP dose serum levels of TNF-a were significantly higher in fasted mice 
(249.8l±39.55pg/ml) than fed (75.86±7.94pg/ml) as were levels of IL-6 (194.3 l±35.72pg/ml 
and 104.53±13.07pg/ml respectively) and IL-ip (48.72±6.63pg/ml and 18.18d=2.54pg/ml 
respectively).
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Table 2.9: Summary and comparison of APAP induced effects in fasted and non-fasted male 
C57BL/6 mice (APAP 530mg/kg; 5hr and 24hr). Data is given as mean (±SD) of 4-5 mice 
per group. Statistical significance was assigned for non-fasted relative to fasted C57BL/6 
mice. < 0.05, **p< 0.01 and ***p < 0.001.
Fed Fasted
Control APAP Control APAP
5hr after dose
Age (weeks) 4-6 4-6 4-6 4-6
Starting body weight 
(g)
20.27(1.63) 19.67 (0.36)** 18.01 (1.49) 18.26 (0.41)
Serum ALT (U/l) 14.92(10.41) 2056.82 (214.47) 11.67(7.16) 2240.83 (425.04)
Hepatic GSH content 
(nmol/g)
83.85 (6.65)*** 17.78 (8.77)* 38.20(3.09) 4.18(0.70)
TNF-a (pg/ml) 3.30 (2.09) 74.37 (7.13)** - 123.94 (23.73)
IL-6 (pg/ml) " 61.69 (5.75)** - 106.29(12.34)
IL-ip (pg/ml) ** 25.31 (4.46)** - 65.10(9.08)
24hr after dose
Age (weeks) 4-6 4-6 4-6 4-6
Starting body weight 
(g)
20.25(1.23)** 21.48(1.05)*** 16.16(0.69) 15.67(1.32)
Serum ALT (U/l) 8.49 (7.28) 2709.49(231.65)** 12.39(6.81) 3597.04 (299.46)
Hepatic GSH content 
(nmol/g)
82.26 (5.48)*** 69.75 (7.86)*** 38.23 (4.60) 29.94 (3.77)
TNF-a (pg/ml) 3.60 (4.33)* 75.86 (7.94)*** 20.33 (5.10) 249.81 (39.55)
IL-6 (pg/ml) 4.20 (3.80) 104.53 (13.07)** 24.51 (8.10) 194.31 (35.72)
IL-ip (pg/ml) ' 18.18(2.54)** 14.35 (3.34) 48.72 (6.63)
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2.4 DISCUSSION
Despite intense research, the extent to which the innate immune response contributes to DILI 
remains disputed. Several different models of DILI in which inflammation has been 
modulated are being investigated in an attempt to dissect the processes of inflammation from 
those of direct hepatotoxicity. The use of different strains of mice, species, compounds, and 
their varying doses and pretreatments in in vivo models in the literature, while enabling 
greater insight into the innate immune and inflammatory responses in DILI, have led to 
conflicting reports regaining the roles these responses play in the progression of DILL
The aims of this chapter were therefore to define a set of in vivo models of DILI that could 
produce an inflammatory response which could be assessed and characterised by a chosen set 
of observable or measurable parameters. The inbred C57BL/6 strain of mice was chosen for 
the mouse model as it is a common strain used in the literature for APAP and LPS 
investigations. C57BL/6 mice have been used by many research groups studying the 
mechanisms of APAP toxicity and are commonly used for the generation and analysis of 
transgenic and knockout animal models (Chiu et al., 2003; Masubuchi et ah, 2003; Liu et ah, 
2004; Liu et ah, 2006; Bourdi et ah, 2007; Yee et ah, 2007; Zurita et ah, 2010). They have 
also been used to explore the effects of LPS on APAP-induced liver injury (Maddox et al., 
2010) and LPS/GalN-induced liver injury (Bahrami et ah, 1994; Nowak et ah, 2000). LPS 
and GalN were chosen as model hepatotoxins that can serve as mechanistic models to 
compare to APAP, both of which trigger an inflammatory response in mice, but with a 
biological disconnection to APAP since they do not require metabolic activation into a toxic 
reactive metabolite. To characterise the LPS, GalN and APAP models of hepatotoxicity and 
inflammation, markers of toxicity and necrosis (serum ALT and histology), APAP-mediated 
metabolism (hepatic GSH content) and inflammation (neutrophil accumulation and serum 
cytokines TNF-a, IL-6 and IL-1 (3) were evaluated in a time and dose dependent manner.
LPS is a bacterial endotoxin that can trigger a potent inflammatory response through 
numerous inflammatory pathways via activation of TLR4. These include intracellular 
signalling pathways and transcription factors such as p38 and NF-kB and inflammatory 
mediators such as cytokines and chemokines (Deng et ah, 2009). The release of these
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mediators can lead to the activation and hepatic infiltration of innate immune cells such as 
neutrophils, which propagate tissue damage. In C57BL/6 mice, no hepatotoxicity as 
determined by ALT activity or effect on total hepatic GSH content was observed across a 
dose response or time course with LPS (Figure 2.1). These results were consistent with other 
published findings (Maddox et al, 2010). At 24hr with a dose of 5mg/kg the serum protein 
levels of the cytokines TNF-a, IL-6 and IL-lp were significantly increased (Figure 2.2). 
These results confirm that administration of LPS to mice at the dose used in this study 
produces a systemic inflammatory response, as evidenced by the increase in serum levels of 
TNF-a, IL-6 and IL-lp. While this appeared to induce some influx of leukocytes into the 
liver, it was not associated with overt liver damage, since there was no evidence of 
parenchymal cell death. Despite there being no evidence of damaged hepatocytes, TNF-a and 
IL-6 has been observed in hepatocytes of mice treated with LPS (5mg/kg) at 24hr by 
immunohistochemical analysis (data not shown, personal communication with Prof Anja 
Kipar), suggesting that the cytokines detected in the serum are not only from activated 
leukocytes alone. This model therefore is characterised by a potent inflammatory response 
with no hepatotoxicity and is suitable as a positive control for inflammation.
GalN is a hepatotoxin frequently used to induce experimental liver injury (Keppler et al, 
1968). Excessive doses of GalN induce fatal liver injury that histologically resembles human 
hepatic failure, while transient acute liver injury is observed at lower doses (Keppler et al, 
1968). High doses of GalN are known to cause both hepatic necrosis by UTP depletion, 
leading to inhibition of RNA synthesis (Decker and Keppler, 1974) and apoptosis in rats and 
mice (Tsutsui et al, 1997; Itokazu et al, 1999; Stachlewitz et al, 1999; Gujral et al, 2003a). 
GalN was chosen as a model hepatotoxin because the mechanism of toxicity is different to 
APAP while GalN is known to produce an inflammatory response. The inflammatory 
response in the liver resembles the reaction seen in viral hepatitis (Medline et al, 1970), also 
antibodies to TNF-a have been shown to protect against GalN-induced hepatotoxicity in rats 
(Stachlewitz et al, 1999). The aim was to develop a GalN-induced hepatotoxicity model of 
inflammation in mice. In C57BL/6 mice, GalN hepatotoxicity (as determined by serum ALT 
activity) showed a dose dependent effect without any significant effect on total hepatic GSH 
content at Sin (Figure 2.3). The levels of serum ALT were significantly raised at dose levels 
of 600mg/kg and 800mg/kg. To be able to characterise GalN-induced hepatotoxicity fully at a 
detectable level, a more detailed dose response study and time course were assessed. The
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dose response measurements were extended from 5hr to 24hr to allow time for toxicity to 
occur. These results showed that serum ALT activity significantly increased in a dose 
dependent manner above the threshold of toxicity at doses of 600-1500mg/kg (Figure 2.4). 
Increasing the dose still had no significant effect on hepatic GSH content which is consistent 
with evidence that GalN is not metabolised into a toxic reactive metabolite therefore will not 
form a GSH conjugate level in the liver (Maley et al., 1968). GalN hepatotoxicity also 
showed time dependence as ALT activities were significantly raised at 5hr and 24hr and GSH 
content was not affected. From the dose and time course experiments the level of serum 
cytokines were assessed at 24hr at a dose of 800mg/kg. Levels of TNF-a} IL-6 and IL-ip 
were all significantly increased although one point to notice was that the levels were 
markedly lower in comparison to levels observed with LPS. The results suggest that this 
model is characterised by moderate hepatotoxicity and a moderate inflammatory response as 
assessed by cytokine release. The histological assessment confirmed GalN-associated 
hepatocyte necrosis and apoptosis at higher doses, with a mixed cellular inflammatory 
infiltrate.
The secondary aim was to characterise the neutrophilic inflammatory response after treatment 
of C57BL/6 mice with APAP. To define a degree of hepatotoxicity which may cause 
neutrophil infiltration a range of APAP doses (300mg/kg, 530mg/kg or 750mg/kg) were 
administered to male C57BL/6 mice (Figure 2.6). In administering a high dose, the 
hypothesis that extensive hepatocellular' necrosis would lead to infiltration and accumulation 
of immune cells was being tested. Figure 2.8 illustrates that the survival of mice after 
exposure to APAP was significantly decreased in the treatment groups of the high 
(750mg/kg) dose at 24hr compared to saline treated and low-dose (300mg/kg) APAP which 
had 100% survival. Mice receiving 750mg/kg survived up until 8-11 hr with none lasting to 
24 Irrs. The 530mg/kg dosed group had only a couple of mortalities after the 18hr mark, with 
the majority surviving the 24hr period, despite there being evidence of toxicity. Toxicity at 
24hr was dependent upon dose when assessed by serum ALT activity which was significant 
from control levels at doses above 530mg/kg (Figure 2.6). At the equivalent time point 
(24hr), the histological assessment of the liver did not identify a significant inflammatory cell 
influx and the hepatic GSH content was not significantly different from control levels which 
suggested that a physiological adaptation or regeneration had occurred within the liver, 
although the level of ALT activity was still high.
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The APAP model of hepatotoxicity and inflammation was further characterised by a detailed 
dose response and time course investigation in male C57BL/6 mice as illustrated by Figure 
2.9. APAP induced a dose dependent increase in hepatotoxicity as seen by an increase in 
serum ALT activity which was first significant at dose levels above 530mg/kg at 5hr 
compared to control levels. Hepatic GSH depletion occurred in a dose dependent manner 
starting at 150mg/kg. Hepatotoxicity due to APAP was observed as early as 3hr post APAP 
dose (530mg/kg) by serum ALT activity, which was preceded by depletion in hepatic GSH 
content first significant from control at 0,5hr post APAP dose (530mg/kg). These results 
confirm that in this model, GSH depletion is a prerequisite for the onset of toxicity following 
APAP overdose (Davis et al., 1974). To determine the time frame of the onset of 
inflammation in this model the serum protein levels of the cytokines TNF-a, IL-6 and IL-1[3 
were measured in parallel to toxicity. The levels of each cytokine appeared to mimic the 
pattern of serum ALT activity over the time course with levels of TNF-a and IL-6 reaching a 
peak at 24hr post APAP dose (530mg/kg) (Figure 2.10). IL-1J3 diverged from this pattern 
slightly in that levels peaked at 5hr post APAP (530mg/kg) and began to decrease at 24hr. At 
24hr post dosing, the histological assessment identified ongoing centrilobular hepatocyte 
necrosis and apoptosis as well as some recruitment of neutrophils into the affected areas. The 
latter was not observed at an earlier time point.
Fasting is used in pharmacological and toxicological experiments to assure more uniform 
drug absoiption (Strubelt et al., 1981). Overnight fasting of animals has been commonly used 
in studies of APAP-induced hepatotoxicity as fasting reduces hepatic GSH content and 
reduces its diurnal valuation (Jaeschke et al., 1985), enabling more uniform toxicity from 
moderate doses. Recent reports demonstrated that overnight fasting of mice can prevent 
APAP-induced apoptosis and lead to hepatocyte death almost exclusively by necrosis 
(Antoine et al., 2010). Evidence suggests that a biological consequence of fasting is depletion 
of hepatic glycogen stores which is used to generate cellular' ATP (Strubelt et al., 1981). 
Depletion of hepatic ATP levels can lead to a reduction of apoptotic cell death and switch to 
necrosis (Kim et al., 2003). Antoine et al, (2010) also demonstrated that infiltration of 
neutrophils into the liver was seen in fasted but not in fed CD-I mice after APAP treatment. 
This was also supported by an increase in serum TNF-a levels and total HMGB1. It was 
concluded that reduced ATP levels in hepatocytes of fasted animals prevents apoptosis and 
promotes necrotic cell death which leads to the release of total HMGB1, which triggers
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recruitment of inflammatory cells into the liver and formation of serum cytokines. The 
purpose of the next study was to investigate the impact of overnight fasting on APAP- 
induced hepatotoxicity and inflammation in C57BL/6 mice and assess if this was a more 
suitable model for inflammation than the previously characterised fed model. Similar in 
pattern to the fed model, APAP caused a time dependent elevation in hepatotoxicity as 
assessed by serum ALT activity, which was first significant at 3hr and continued to increase 
at the further time points of 5hr and 24hr (Figure 2.11). Hepatic GSH depletion preceded the 
increase in ALT at 0.5hr and began to return to control levels at 24hr. The serum levels of 
TNF-tx and IL-6 increased significantly at 3In post APAP dose (530mg/kg) and were 
preceded by a significant increase in IL-lp at Ihr (Figure 2.12). TNF-a and IL-6 both reached 
peak concentrations at 24hr post APAP, whereas IL-lp began to decrease nonetheless. The 
histological examination did not identify significant inflammatory cell influx into the liver at 
any time point.
Table 2.9 illustrates the comparison between the fasted and non-fasted C57BL/6 models of 
APAP-induced hepatotoxicity and inflammation. Serum ALT activity was significantly 
higher in fasted mice than fed at 24hr after APAP dose (530mg/kg). This result is supported 
by evidence in the literature that fasting of mice prior to dosing can increase the levels of 
hepatic necrosis and worsen liver injury in animal models (Strubelt et al., 1981). Basel 
control levels of hepatic GSH content in fed C57BL/6 mice were higher than in fasted mice at 
5hr and 24hr. This may account for the increased sensitivity of fasted mice to the toxic effects 
of APAP as seen by serum ALT activity as decreased hepatic GSH content may result in a 
lesser detoxification of APAP and therefore a higher amount of the reactive metabolite 
NAPQI, enhancing the hepatotoxicity of APAP. Overnight fasting of mice also had the effect 
of increasing the serum protein concentrations of cytokines TNF-a, IL-6 and IL-ip at both 
5hr and 24hr post APAP (530mg/kg) dose compared to fed mice. One reason for this could 
be a change in the predominant form of cell death. Fasting may lead to hepatocyte death 
almost exclusively by necrosis due to evidence that fasting leads to depletion of intracellular 
ATP (Lee et al., 1988), inhibiting the energy-dependent process of apoptosis. Increasing the 
level of necrosis would lead to the release of more inflammatory signals and mediators, 
promoting a greater inflammatory response. Further investigations are required to fully 
determine why fasting prior to experimental DILI elicits a greater inflammatory response in 
animals.
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The aims of the studies presented in this chapter were to utilise LPS, GalN and APAP as 
model hepatotoxins to enable the characterisation of the inflammatory response in in vivo 
models of hepatotoxicity. Defining the toxic and inflammatory parameters of these models 
will enable the investigation of various inflammatory pathways during DILI and their 
contribution to the progression of liver injury. Modulation of these pathways can help 
examine the overall effect on DILI by apportioning the level of toxicity caused by 
inflammation or the direct deleterious effects of the model hepatotoxins. As shown with these 
studies, the three model agents and the dietary conditions of the C57BL/6 strain of mice have 
produced models of varying levels of toxicity and inflammation. Each of the animal models 
are equally valid and the variation of each with regards to mechanisms of toxicity allow a 
more complete exploration and determination of possible inflammatory mechanisms 
contributing to the overall pathophysiology. With these defined and characterised models, the 
next course of action would be to investigate the innate immune and inflammatory responses 
in these models by using pharmacological agents that modulate the mechanism of 
inflammation.
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CHAPTER THREE
INVESTIGATION OF THE EFFECT OF DMSO AND ASPIRIN ON DRUG- 
INDUCED HEPATOTOXICITY AND MODULATION OF THE INFLAMMATORY
RESPONSE
84
Chapter 3
CONTENTS
3.1 INTRODUCTION 87
3.2 MATERIALS AND METHODS 90
3.2.1 Materials 90
3.2.2 Experimental animals 90
3.2.3 Animal dosing regime 90
3.2.4 Assessment of hepatotoxicity in treated male C57BL/6 mice 91
3.2.5 Determination of hepatic glutathione levels in C57BL/6 mouse whole liver during
drug-induced hepatotoxicity 91
3.2.6 Histological examination of C57BL/6 mouse liver 91
3.2.7 Measurement of cytokines in serum from animals dosed with EPS, GalN and APAP
using Limiinex Analysis 91
3.2.8 Measurement of HMGB1 in serum from animals dosed with EPS 92
3.2.9 Statistical analysis 92
3.3 RESULTS 93
3.3.1 Investigation into the effect of DMSO on APAP-induced hepatotoxicity 93
3.3.2 Investigation into the effect of aspirin on EPS-induced inflammation 97
3.3.3 Investigation into the effect of aspirin on GalN-induced hepatotoxicity and
inflammation 100
3.3.4 Investigation into the effect of aspirin on AP AP-induced hepatotoxicity and
inflammation 102
3.3.5 Investigation into the effect of aspirin on AP AP-induced hepatotoxicity and
inflammatory infiltration in fasted C57BL/6 mice at 1 Ohr 104
3.3.6 Investigation into the effect of aspirin on AP AP-induced hepatotoxicity and
inflammation in fasted C57BL/6 mice at 24hr 107
3.3.7 Investigation into the effect of aspirin on AP AP-induced hepatotoxicity and
inflammation in non-fasted C57BL/6 mice at 1 Ohr 110
85
Chapter 3
Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
inflammation in non-fasted C57BL/6 mice at 24hr 113
Comparison of the effects of aspirin on APAP-induced hepatotoxicity in fasted and 
non-fasted C57BL/6 mice 116
DISCUSSION 118
Chapter 3
3.1 INTRODUCTION
The mechanisms of APAP hepatotoxicity are well defined and characterised in experimental 
animals and humans (Mitchell et ah, 1973). In addition to the intracellular biochemical events 
there is growing evidence that suggests that the innate immune system can contribute to the 
severity and progression of APAP-induced liver injury through the production of cytokines 
and recruitment of inflammatory cells into the liver downstream of bioactivation (Blazka et 
ah, 1995; Laskin et ah, 2001; Liu et ah, 2004). The generation of inflammatory mediators 
such as cytokines, chemokines, reactive oxygen and nitrogen species released by 
inflammatory cells have been implicated in APAP hepatotoxicity by exacerbating cell 
damage as a result of initiating an overly aggressive inflammatory process (Luster et ah, 
2001; Liu et ah, 2004). It is therefore increasingly important to understand the mechanisms 
by which cells of the innate irmnune system are activated and recruited to the liver during 
DILI.
The formation and release of proinflammatory cytokines such as TNF-a and IL-1|3 during 
APAP-induced liver injury have been extensively investigated (Blazka et ah, 1995; Lawson 
et al., 2000) and the results presented in Chapter 2 provide supporting evidence of the 
presence of an inflammatory response in mice after APAP overdose. However, only recently 
have the initiating mechanisms of an inflammatory response been identified. The direct effect 
of APAP on hepatocytes may be an initiating event for an immune response as necrotic cells 
release endogenous molecules that alert the innate immune system of the danger associated 
with tissue damage. These molecules collectively termed damage-associated molecular, 
patterns (DAMPs) include HMGB1, heat shock proteins (HSPs) and DNA fragments 
(Bianchi et ah, 2007) and act as danger signals by activating a variety of pattern recognition 
receptors including TLRs, RAGE and NLRs. As a result, necrotic cells and several danger- 
signals directly trigger proinflammatory responses.
The liver contains a large number of various types of innate immune cells such as Kupffer 
cells, NK cells and NKT cells. Aside from the resident innate immune cells the release of 
DAMPs and formation of cytokines during the inflammatory response lead to hepatic 
infiltration and activation of neutrophils and monocytes in response to tissue injury (Lawson
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et al., 2000; Scaffidi et aL, 2002). Depletion of NK and NKT cells in the liver was reported to 
protect mice from APAP hepatotoxicity (Liu et al, 2004). Depletion of these cells 
substantially reduced the formation of cytokines and chemokines, notably IFN-y after APAP 
overdose and associated neutrophil accumulation in the NK/NKT cell depleted mice. There 
are however, conflicting reports concerning the role of NK cells and NKT cells in APAP- 
induced liver injury. One study provided evidence that NKT and NK cells only contributed to 
liver injury when dimethyl sulfoxide (DMSO) was used to solubilise APAP (Masson et al, 
2008). The report revealed that DMSO, both alone and with APAP, led to the activation of 
hepatic NKT and NK cells as shown by higher NKT cell numbers and that the effect of NKT 
cells in the exacerbation of APAP-induced liver injury was due to high levels of DMSO 
(Masson et al, 2008). The depletion of these cell types in mice did not alter APAP-induced 
injury unless the cells had been pre-activated with DMSO.
Neutrophils have also been implicated as having an active role in the pathogenesis of APAP 
hepatotoxicity (Ishida et al, 2006; Liu et al, 2006). Depletion of neutrophils with an anti­
granulocyte antibody significantly protected mice against APAP-induced liver injury as 
evidenced by reduced serum ALT levels and improved mice survival The involvement of 
neutrophils was also implied in a recent study that suggested APAP-induced hepatotoxicity is 
partially mediated by IL-lp, which can activate and recruit neutrophils, exacerbating injury 
(Imaeda et al, 2009). It was shown in this study that stimulation of TLR9 by DNA fragments 
during APAP-induced hepatotoxicity lead to the transcriptional activation of the IL-ip gene 
resulting in formation of pro-IL-ip. The pro-form of IL-lp is cleaved by activated caspase-1, 
whose activation is regulated by the Nalp3 inflammasome. Imaeda et al (2009) showed that 
APAP-induced liver injury was reduced in gene knockout mice of each individual component 
of the inflammasome and also by inhibition of inflammasome activation by aspirin. This 
suggested an important role of inflammasome activation of IL-lp formation in APAP- 
induced hepatotoxicity and potential therapeutic strategy to treat APAP hepatotoxicity. 
However, there are conflicting views regarding the importance of the inflammasome and the 
role of neutrophils. IL-lp signalling does not directly induce cell death in vivo (Sims and 
Smith, 2010) but causes liver injury through activation of inflammatory cells such as 
neutrophils (Bajt et al, 2001). However, conflicting reports suggest neutrophils are unlikely 
to cause injury after APAP overdose (Bauer et al, 2000; Cover et al, 2006; Lawson et al, 
2000). One study suggested that although the numbers of neutrophils were reported to be
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increased in the liver from APAP-challenged animals, neutrophils did not contribute to the 
initiation and progression of APAP-induced liver injury. The inflammation observed after 
overdose was stated as not being severe enough to cause additional damage (Lawson et ah, 
2000).
The overall extent of the contribution of the innate immune system to the progression of 
APAP-induced liver injury requires further investigation. The aims of the studies within this 
chapter were to identify the role DMSO may play in APAP hepatotoxicity by modulation of 
hepatic immune cell accumulation and whether in our animal model of APAP-induced liver 
injury the addition of DMSO could potentiate toxicity by initiating a greater inflammatory 
response. Secondly, one objective of this investigation was to further evaluate the 
contribution of the immune system in the pathogenesis of DILI by using aspirin as a 
pharmacological intervention of the Nalp3 inflammasome in our animal models characterised 
in Chapter 2.
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3.2 MATERIALS AND METHODS
3.2.1 Materials
Infinity ALT liquid kits were purchased from ALPHA Laboratories (Eastleigh, U.K). Unless 
otherwise stated, all other chemicals and materials were purchased from Sigma-Aldrich 
(Poole, U.K).
3.2.2 Experimental animals
The protocols described were in accordance with criteria outlined in a licence granted under 
the Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool 
Animal Ethics Committee. Animals were purchased from Charles River laboratories and had 
a 5 day acclimatisation period prior to experimentation. Animals were also maintained in a 
12hr light/dark cycle with free access to food and water.
3.2.3 Animal dosing regime
Male C57BL/6 (18-23g) mice were either fasted overnight with free access to water or had 
free access to food and water prior to experimentation. Mice received an i.p injection of 
APAP (530mg/kg) with a simultaneous i.p injection of DMSO (0-lml/kg) or l-4hr after 
APAP administration. Control animals received either 0.9% saline or solvent control in 0.9% 
saline as appropriate. Treatment groups contained 4-5 individual animals. Additionally, some 
mice were given aspirin via drinking water (0.06mg/ml, 0.3mg/ml, 0.6mg/ml or Img/ml) for 
three days and fasted overnight prior to either LPS (5mg/kg; ip), GalN (800mg/kg; ip) or 
APAP (530mg/kg; i.p).
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3.2.4 Assessment of hepatotoxicity in male C57BL/6 mice
Animals were sacrificed by CO2 inhalation and cervical dislocation and blood was collected 
by cardiac puncture. Hepatotoxicity was assessed by serum ALT activity and histology as 
described in Chapter 2.
3.2.5 Determination of hepatic glutathione levels in C57BL/6 mouse whole liver during 
drug-induced hepatotoxicity
Total hepatic GSH levels were detennined as described previously in Chapter 2. Levels of 
GSH were normalised to hepatic protein content using Bio-Rad protein assay reagent 
according to the manufacturer’s instructions.
3.2.6 Histological examination of C57BL/6 mouse liver
Hepatotoxicity and leukocyte infiltration was assessed as part of the histological examination 
of HE-stained sections as described in Chapter 2. The assessment was undertaken by Prof A 
Kipar, Veterinary Pathology, School of Veterinary Science, University of Liverpool.
3.2.7 Measurement of cytokines in serum from animals dosed with LPS, GalN and 
APAP using Luminex Analysis
Serum was collected from control and treated animals. Concentrations of IL-lp, IL-6 and 
TNF-a were measured using the Bio-Plex Assay kit (Bio-Rad Laboratories, Inc) as described 
in Chapter 2. The lower range of the assay is <5.8 pg/ml for TNF-a, <0.74pg/ml for IL-6 and 
<10.36pg/ml for IL-ip. Levels below these values were assigned a value of zero.
91
Chapter 3
3.2.8 Measurement of HMGB1 in serum from animals dosed with LPS
HMGB1 measurements were carried out using an ELISA according to the manufacturer’s 
instructions. A chicken anti-HMGBl antibody was used as a catcher antibody (Ijag/well 
compared to known standards using 3,3 ’,5,55-tetramethyl-benzidine turnover by a peroxidise- 
linked anti-HMGBl antibody. The limit of detection was O.lng/ml.
3.2.9 Statistical analysis
All results are expressed as mean ± standard deviation (S.D). Values to be compared were 
analysed for non-normality using a Shapiro-Wilk test. The unpaired t-test was used when 
non-normality was indicated. A Mann-Whitney U test was used for non-parametric data. 
Comparisons between multiple groups were performed with one-way ANOVA or, where 
appropriate, by two-way ANOVA, followed by a post hoc Bonferroni test. All calculations 
were performed using SPSS statistical software, results were considered significant when 
;?<0.05.
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3.3 RESULTS
3.3.1 Investigation into the effect of DMSO on APAP-induced hepatotoxicity
To investigate the effect of DMSO in APAP-induced hepatotoxicity by inhibition of APAP 
bioactivation or immune cell infiltration, mice were either simultaneously co-administered 
DMSO (1 ml/kg) or administered DMSO 2hr after APAP (530mg/kg) for 24hr (Figure 3.1). 
Significant toxicity as determined by serum ALT activity was observed in APAP treated mice 
(2468.65±380.78U/1) and DMSO 2hr post-APAP (2001.55±228.45U/1) compared to solvent 
control (Figure 3.1 A). No toxicity was evident when DMSO was dosed simultaneously with 
APAP (27.68±4.85U/1). At 24hr there was significant depletion of hepatic GSH content 
observed between control and APAP dosed groups (77.55±4.47nmol/mg and 
54.09±8.28nmol/mg respectively) (Figure 3.IB). GSH returned to control levels when dosed 
with APAP and DMSO concurrently (69.95±7.38mnol/mg) but was significantly lower than 
control when DMSO was dosed 2hr post-APAP (63.97±2.66mnol/mg). DMSO induced a 
dose dependent decrease in serum ALT activity at 5hr compared to solvent control (Figure 
3.2A). There was a significant decrease in toxicity in groups with DMSO levels greater than 
0.1 ml/kg (1348.27±325.14U/1) when compared to groups treated with APAP alone 
(2116.36±193.40U/1). There was significant toxicity in all DMSO and APAP treated groups 
compared to DMSO treated alone (15.28±5.13U/1). An increase in hepatic GSH levels was 
observed, notably from DMSO levels greater than O.lml/kg (23.04±7.04nmol/mg), with a 
significant increase at 0.5ml/kg (28.85±9.51nmol/mg) and above (Figure 3.2B). DMSO 
inhibited APAP-induced toxicity in a time dependent manner. When administered 
concurrently with APAP, DMSO completely abolished toxicity (45.83±9.11U/1) compared to 
APAP alone (1863.93±178.34U/1). DMSO administered Ihr post APAP dose also negated 
toxicity (136.28±18.04U/1), however when administered 2hr and 4hr post APAP dose there 
was a significant increase in ALT activity (361.02±119.46U/1 and 1277.07±230.74U/1 
respectively) (Figure 3.3A). APAP induced a significant decrease in hepatic GSH content 
(8.42±2.3 7nmol/mg) compared to control. DMSO administered concurrently with APAP or 
Ihr post APAP dose increased GSH content by around 52% compared to APAP alone 
(33.15±3.12nmol/mg and 32.21±1.89nmol/mg respectively) (Figure 3.3B). DMSO 
administrated 2hr and 4hr post APAP did not lead to an increase in GSH content compared to 
APAP alone.
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Figure 3.1: The effect of DMSO on APAP-induced hepatotoxicity.
Male C57BL/6 mice were administered APAP (530mg/kg; 24hr) ± DMSO (1 mg/ml; 0-2hr) 
and the effect on APAP induced serum ALT levels (A) and hepatic GSH content (B) was 
observed in the same group of mice. Data is given as mean ± SD of 5 mice per group. 
Statistical significance was assigned relative to solvent treated controls. * p < 0.05, **p < 
0.01, ***/?< 0.001.
The histological examination identified the typical APAP-induced changes in APAP-treated 
animals. These were completely lacking in animals co-treated with DMSO, whereas they 
were still present when DMSO was administered 2hr post APAP treatment. The degree and 
distribution of centrilobular hepatocyte loss was highly variable in these animals (Table 3.1).
Table 3.1: Histological findings after DMSO and APAP treatment. Male C57BL/6 mice were 
administered APAP (530mg/kg; 24hr) ± DMSO (Img/ml; 0-2hr) or DMSO alone. Animals 
were examined 24hr post treatment. The histological evaluation was undertaken by Prof Anja 
Kipar (Veterinary Pathology, School of Veterinary Science, University of Liverpool). The 
listed findings represent a summary of the changes observed in each of 5 animals per group.
Treatment Score
[ average]
Histological findings
Saline + DMSO 0 Diffuse glycogen; no histological abnormality is recognised
(NHAIR)
APAP 1-4
[22]
Centrilobular, mainly coagulative necrosis; highly variable 
degree; sometimes with neutrophil aggregates in centre
APAP +
DMSO Ohr
0 Diffuse glycogen; NHAIR
APAP +
DMSO 2hr
1-4
[1.91
Highly variable intensity of cell loss
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Figure 3.2: Dose dependent effect of DMSO on APAP-induced GSH depletion and 
toxicity.
Male C57BL/6 mice were administered APAP (530mg/kg; 5hr) simultaneously with DMSO 
(0-1 ml/kg) and the effect on APAP induced serum ALT levels (A, U/l) and hepatic GSH 
content (B, nmol/mg) was observed in the same group of mice. Data is given as mean ± SD 
of 5 mice per group. Statistical significance was assigned to groups with values that are 
higher or lower when compared to DMSO treated controls ***/?< 0.001 or compared to 
APAP alone (t/? < 0.05, tft/? < 0.001).
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Figure 3.3: Time course of the effect of DMSO on APAP-induced GSH depletion and 
toxicity.
Male C57BL/6 mice were administered APAP (530mg/kg; 5hr) and DMSO (1 ml/kg; 0-4hr 
post-APAP) and the effect on APAP induced serum ALT levels (A) and hepatic GSH content 
(B) was observed in the same group of mice. Data is given as mean ± SD of 5 mice per 
group. Statistical significance was assigned relative to groups with values that are higher or 
lower when compared to DMSO treated controls (***/? < 0.001) or compared to APAP alone 
(ttl7>< 0.001).
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3.3.2 Investigation into the effect of aspirin on LPS-induced inflammation
It was hypothesised that aspirin is capable of modulating inflammation by inhibiting the 
Nalp3 inflammasome and NF-kB activation. As it was reported that pretreatment with aspirin 
in the drinking water reduced APAP-induced liver injury (Imaeda et al., 2009), the effects of 
aspirin on the modulation of inflammation were investigated in the LPS mouse model 
characterised in Chapter 2. This study was repeated with the aspirin dose previously 
published (0.06mg/ml in drinking water; Imaeda et al., 2009). Aspirin in the drinking water 
caused no toxicity as assessed by serum ALT activity (48.10±15.93U/1) (Figure 3.4A). LPS 
administered alone or with aspirin did not cause toxicity (44.61±18.71U/1 and 
40.44±17.33U/1 respectively). Aspirin pretreatment did not alter hepatic GSH content 
compared to control (79.34±8.19nmol/mg), nor did LPS alone or with aspirin 
(72.13±2.84nmol/mg and 70.18±12.06nmol/mg respectively) (Figure 3.4B).
A B
Saline Saline + LPS +
Aspirin Aspirin
Saline Saline +
Aspirin Aspirin
Figure 3.4: The effect of aspirin on LPS-induced hepatotoxicity in male C57BL/6 mice.
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with or without aspirin (0.06mg/ml) in drinking water for 3 days before 
administration of LPS (5mg/kg; 24hr). Data is given as mean ± SD of 5 mice per group. 
Statistical significance was assigned relative to respective controls with or without aspirin.
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Aspirin pretreatment (0.06mg/ml) caused no inflammation as assessed by cytokine and 
HMGB1 release (Figure 3.5). LPS (5mg/kg) caused a significant increase in the serum level 
of TNF-a at 24hr (540.95±71.24pg/ml) (Figure 3.5A). IL-6 also increased at 24hr after LPS 
(1575.35±284.73pg/ml) (Figure 3.5B) as well as levels of IL-lp (238.67±23.13) (Figure 
3.5C). Serum levels of HMGB1 were also significantly increased at 24hr after LPS 
(1093.36±338.50ng/ml) (Figure 3.5D). Pretreatment with aspirin (0.06mg/ml) did not 
significantly reduce LPS-induced cytokine or HMGB1 release.
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Figure 3.5: Effect of aspirin on serum cytokine levels and HMGB1 during LPS-induced 
hepatotoxicity in C57BL/6 mice.
C57BL/6 mice were pretreated with or without aspirin (0.06mg/ml) in drinking water for 3 
days before administration of LPS (5mg/kg; 24hr) and serum levels of TNF-a (A), IL-6 (B), 
IL-lp (C) and serum HMGB1 (D) were determined. Data is given as mean ± SD of 3 mice 
per group. Statistical significance was assigned relative to respective controls with or without 
aspirin. ***p< 0.001.
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The histological examination confirmed the biochemical findings. There were no findings 
indicating that aspirin had any effect on the liver. However, it also appeared not to have an 
effect on the LPS-induced changes, i.e. neutrophil recruitment into the liver and individual 
hepatocyte death (Table 3.2)
Table 3.2: Histological findings after aspirin and LPS treatment. C57BL/6 mice were 
pretreated with or without aspirin (0.06mg/ml) in drinking water for 3 days before 
administration of LPS (5mg/kg). Animals were examined 24hr post LPS treatment. The 
histological evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of 
Veterinary Science, University of Liverpool). The listed findings represent a summary of the 
changes observed in each of 5 animals per group.
Treatment Score Histological findings
Saline 0 Diffuse glycogen; no histological abnormality is recognised
(NHAIR)
Saline + Aspirin 0 Diffuse glycogen; NHAIR
LPS 0 Some leukocytes in vessel lumina, scattered neutrophils 
between hepatic cords, scattered degenerate/necrotic 
hepatocytes
LPS + Aspirin 0 Diffuse glycogen, several leukocytes in vessel lumina and 
between hepatic cords, some neutrophils surrounding vessels; 
occasional degenerate/necrotic hepatocyte
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3.3.3 Investigation into the effect of aspirin on GalN-induced hepatotoxicity and 
inflammation
The effects of aspirin on the reduction of toxicity by modulation of inflammation were 
investigated in the GalN mouse model of hepatotoxicity and inflammation characterised in 
Chapter 2. In this study a high dose of aspirin (1 mg/ml) was used as no significant effect on 
the inflammatory response was observed in the LPS model. GalN administered alone caused 
toxicity as assessed by serum ALT activity (714.15± 58.28U/1) (Figure 3.6A). Aspirin in the 
drinking water did not have any toxic effect (ALT activity of 81.85±63.55U/1) nor was it 
capable of reducing the GalN-induced liver injury (ALT activity of 625.05±100.91U/1). 
Aspirin pretreatment did not alter the hepatic GSH content compared to control 
(54.02±6.85nmol/mg), nor did GalN alone or in combination with aspirin 
(58.89±7.19nmol/mg and 59.22±7.20nmol/mg respectively) (Figure 3.6B).
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Figure 3.6: The effect of aspirin on GalN-induced hepatotoxicity in male C57BL/6 mice.
Serum ALT (A), hepatic GSH content (B) were measured in male C57BL/6 mice pretreated 
with or without aspirin (1 mg/ml) in drinking water for 3 days before administration of GalN 
(800mg/kg; 24hr). Data is given as mean ± SD of 5 mice per group. Statistical significance 
was assigned relative to respective controls with or without aspirin. ***p< 0.001.
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Aspirin pretreatment (1 mg/ml) did not initiate cytokine release (Figure 3.7), whereas GalN 
(800mg/kg) caused a significant increase in the serum level of TNF-a at 24hr 
(90.57±6.45pg/ml) (Figure 3.7A) and a significant increase in serum IL-6 (63.42±8.38pg/ml) 
(Figure 3.7B) as well as serum IL-lp (70.92±9.08pg/ml) at the same time point (Figure 
3.7C). Pretreatment with aspirin (1 mg/ml) did not significantly reduce GalN-induced 
cytokine release, although levels of serum TNF-a (82.72±7.81pg/ml), IL-6 
(57.24±6.83pg/ml) and IL-lp (64.50±5.87pg/ml) were each lower than those after GalN 
treatment alone.
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Figure 3.7: Effect of aspirin on serum cytokine levels during GalN-induced 
hepatotoxicity in C57BL/6 mice.
Male C57BL/6 mice were pretreated with or without aspirin (1 mg/ml) in drinking water for 3 
days before administration of GalN (800mg/kg; 24hr) and serum levels of TNF-a (A), IL-6 
(B) and IL-lp (C) were determined. Data is given as mean ± SD of 3 mice per group. 
Statistical significance was assigned relative to respective controls with or without aspirin. 
***/?< 0.001.
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3.3.4 Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
metabolism
The effects of aspirin on the reduction of toxicity and possible effects on APAP metabolism 
were investigated in the APAP mouse model of hepatotoxicity characterised in Chapter 2. 
This study was repeated with an aspirin dose identical to the previously published dose 
(0.06mg/ml in drinking water; Imaeda et al.} 2009) and a similar time course (lOhr) to 
directly compare results. Aspirin in the drinking water caused no toxicity as assessed by 
serum ALT activity (24.17±3.88U/1) nor did it reduce APAP hepatotoxicity compared to 
APAP-treated mice with normal drinking water (3143.15±215.23U/1 and 3276.01±305.45U/1 
respectively) (Figure 3.8A). Aspirin pretreatment did not alter hepatic GSH levels compared 
to control (47.52±9.66nmol/mg and 47.29±8.17nmol/mg respectively) (Figure 3.8B). At lOhr 
post dosing the GSH content was lower in APAP-treated mice compared to control mice 
(40.17±5.56nmol/mg) although this reduction was not statistically significant. Aspirin 
pretreatment did not cause any difference in GSH recovery after APAP overdose, with levels 
returning to those of controls (43.47±11.71nmol/mg). To investigate the effect of aspirin on 
APAP metabolism the hepatic GSH content was measured Ihr after APAP-treatment 
(530mg/kg). At Ihr, aspirin pretreatment did not alter hepatic GSH levels compared to 
control (72.70±3.13nmol/mg) whereas APAP caused a significant decrease in GSH levels 
(15.11±3.61 nmol/mg) (Figure 3.9). Aspirin did not affect APAP metabolism as GSH levels 
were significantly decreased similar to those after APAP treatment alone 
(17.48±2.07nmol/mg).
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Figure 3.8: The effect of aspirin pretreatment on APAP-induced hepatotoxicity in fasted 
C57BL/6 mice.
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with or without aspirin (0.06mg/ml) in drinking water for 3 days before 
administration of APAP (530mg/kg; lOhr). Data is given as mean ± SD of 5 mice per group. 
Statistical significance was assigned relative to respective controls with or without aspirin.
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Figure 3.9: The effect of aspirin on bioactivation of APAP.
Hepatic GSH content was evaluated in male C57BL/6 mice were pretreated with or without 
aspirin (1 mg/ml) in drinking water for 3 days before administration of APAP (530mg/kg; 
1 hr). Data is given as mean ± SD of 5 mice per group. Statistical significance was assigned 
relative to saline control. ***p < 0.001.
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3.3.5 Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
inflammatory infiltration in fasted C57BL/6 mice at lOhr
The effects of aspirin on the reduction of toxicity by modulation of inflammation were 
investigated in the fasted APAP C57B1/6 model. At a similar time point to that previously 
published (lOhr) an increasing dose of aspirin (0.06-lmg/ml) was used to assess if any dose 
dependent modulation of inflammation and potential subsequent effects on APAP-induced 
hepatotoxicity would occur. Aspirin pretreatment of increasing dose caused no toxicity as 
measured by serum ALT activities (Figure 3.10A). A significant decrease of APAP-induced 
toxicity was observed with aspirin concentrations of 0.3 and 0.6mg/ml (3008.90±309.06U/1 
and 2988.05±103.57U/1 respectively) compared to mice treated with APAP alone (530mg/kg; 
3390.83±291.42U/1). Aspirin did not alter the hepatic GSH content compared to control 
animals (44.00±2.27nmol/mg) whereas APAP caused a significant decrease 
(29.95±2.31 nmol/mg) (Figure 3.1 OB). Aspirin (0.06-0.6mg/ml) did not aid GSH content 
recovery in APAP-treated groups compared to their respective controls, whereas at 1 mg/ml 
there was an observable difference in GSH content between control and APAP dosed mice 
but the difference was not significant (44.07±1.78nmol/mg and 31.73±2.85nmol/mg 
respectively).
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H20 ml ml ml
Figure 3.10: The effect of increasing dose of aspirin on APAP-induced hepatotoxicity in 
fasted C57BL/6 mice at lOhr.
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with or without aspirin (0.06-lmg/ml) in drinking water for 3 days before 
administration of APAP (530mg/kg; lOhr). (Saline, black; APAP, grey). Data is given as 
mean ± SD of 5 mice per group. Statistical significance was assigned relative to respective 
controls with or without aspirin. *p < 0.05, **/? < 0.01, ***/? < 0.001.
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Aspirin pretreatment (Img/ml) did not induce cytokine release into the serum (Figure 3.11). 
APAP (530mg/kg) caused a significant increase in the serum level of TNF-a at lOhr 
(223.74±20.28pg/ml) (Figure 3.11A). IL-6 also increased at lOhr post APAP dose 
(149.63±14.74pg/ml) (Figure 3.1 IB) as well as levels of IL-lf3 (48.42±6.49pg/ml) (Figure 
3.11C). Pretreatment with aspirin (Img/ml) significantly reduced levels of APAP-induced 
TNF-a release after lOhr (183.56±16.51pg/ml) but did not significantly alter levels of IL-6 or 
IL-lp (123.41±13.36pg/ml and 39.46±4.99pg/ml respectively) despite an observed trend of 
reduction for both cytokines.
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Figure 3.11: Effect of aspirin pretreatment on serum cytokine levels during APAP- 
induced hepatotoxicity in fasted C57BL/6 mice at lOhr.
Fasted male C57BL/6 mice were pretreated with or without aspirin (Img/ml) in drinking 
water for 3 days before administration of APAP (530mg/kg; lOhr) and serum levels of TNF-a 
(A), IL-6 (B) and IL-ip (C) were determined. Data is given as mean ± SD of 3 mice per 
group. Statistical significance was assigned relative to respective controls with or without 
aspirin. *p < 0.05, **/? < 0.01, ***/? < 0.001.
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The histological examination confirmed that aspirin does not have an effect on neutrophil 
recruitment into the liver after APAP-induced injury. Instead the average scores of mice 
treated with the different doses of aspirin were higher than in mice treated with APAP alone 
(Table 3.3).
Table 3.3: Histological findings after aspirin and APAP treatment in fasted mice at lOhr. 
Fasted male C57BL/6 mice were pretreated with or without aspirin (0.6-1 mg/ml) in drinking 
water for 3 days before administmtion of APAP (530mg/kg), Animals were examined lOhr 
after APAP treatment. The histological evaluation was undertaken by Prof Anja Kipar 
(Veterinary Pathology, School of Veterinary Science, University of Liverpool). The listed 
findings represent a summary of the changes observed in each of 5 animals per group.
Treatment Score 
lav era gel
Histological findings
Saline 0 Diffuse glycogen; no histological abnormality is 
recognised (NHAIR)
APAP (530mg/kg) 1-2
[1.5]
Affected areas surrounded by rim of glycogen loss and 
some degree of hydropic degeneration; several 
neutrophils and individual necrotic cells in some affected 
areas
Aspirin (0.6mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (0.6mg/kg)
+ APAP
2-4
[3.3]
Affected areas with extensive hydropic degeneration and 
necrosis, surrounded by rim of hydropic degeneration 
and some neutrophils in affected areas; no glycogen
Aspirin (1 mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (1 mg/kg)
+ APAP
2-4
[2.6]
Affected areas with extensive hydropic degeneration and 
necrosis, relatively numerous neutrophils (also as small 
aggregates and in central veins); some hydropic 
degeneration of hepatocytes outside affected areas; no 
glycogen
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3.3.6 Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
inflammation in fasted C57BL/6 mice at 24hr
The previous study investigating the effects of increasing levels of aspirin on APAP-induced 
toxicity and modulation of inflammation in fasted C57BL/6 mice was repeated with an 
extended time course of 24hr to assess if potential effects of aspirin are more pronounced at a 
later time point. Similar to 1 Ohr, aspirin pretreatment of increasing dose at 24hr post APAP 
dose (530mg/kg) caused no toxicity as measured by serum ALT activities (Figure 3.12A). 
Aspirin (0.06-1 mg/ml) did not alter the hepatic GSH content compared to control animals 
(36.80±24.49nmol/mg) (Figure 3.12B). APAP caused a significant decrease in hepatic GSH 
content at an aspirin concentration of 0.3mg/ml (30.99±12.77nmol/mg) with the other APAP- 
aspirin treated groups returning to control levels. The histological examination confirms that 
aspirin does not have an effect on APAP-induced hepatotoxicity and inflammatory cell 
recruitment at 24hr post treatment (Table 3.4).
A B
5000
® 3000
Normal Aspirin Aspirin Aspirin Aspirin
Drinking 0.06mg/ 0.3mg/ 0.6mg/ Img/ml 
H20 ml ml ml
Normal Aspirin Aspirin Aspirin Aspirin
Drinking 0.06mg/ O.Bmg/ 0.6mg/ Img/ml 
HjO ml ml ml
Figure 3.12: The effect of increasing dose of aspirin on APAP-induced hepatotoxicity in 
fasted C57BL/6 mice at 24hr.
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with or without aspirin (0.06-Img/ml) in drinking water for 3 days before 
administration of APAP (530mg/kg; 24hr). (Saline, black; APAP, grey). Data is given as 
mean ± SD of 5 mice per group. Statistical significance was assigned relative to respective 
controls with or without aspirin. *p < 0.05, ***p< 0.001.
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Aspirin pretreatment (1 mg/ml) did not induce cytokine release into the serum (Figure 3.13). 
APAP (530mg/kg) caused a significant increase in the serum level of TNF-a 
(247.4l±24.58pg/ml; Figure 3.13A), IL-6 (208.51±11.82pg/ml; Figure 3.13B) and IL-1(3 
(45.75±4.76pg/ml Figure 3.13C) at 24hr. Pretreatment with aspirin (1 mg/ml) did not 
significantly alter the serum levels of the three cytokines.
A B
* * *
a iso
Saline Saline-f APAP 
Aspirin
APAP + 
Aspirin
r ioo
Saline Saline + APAP
Aspirin Aspirin
c
Saline Saline-f APAP APAP +
Aspirin Aspirin
Figure 3.13: Effect of aspirin on serum cytokine levels during APAP-induced 
hepatotoxicity in fasted C57BL/6 mice at 24hr.
Fasted male C57BL/6 mice were pretreated with or without aspirin (1 mg/ml) in drinking 
water for 3 days before administration of APAP (530mg/kg; 24hr) and serum levels of TNF-a 
(A), IL-6 (B) and IL-1(3 (C) were determined. Data is given as mean ± SD of 3 mice per 
group. Statistical significance was assigned relative to respective controls with or without 
aspirin. *p < 0.05, **/? < 0.01, ***/? < 0.001.
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Table 3.4: Histological findings after aspirin and APAP treatment in fasted mice at 24hr. 
Fasted male C57BL/6 mice were pretreated with or without aspirin (0.06-1 mg/ml) in drinking 
water for 3 days before administration of APAP (530mg/kg; 24hr). The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed in each of 5 animals per group.
Treatment Score
[average]
Histological findings
Saline 0 Diffuse glycogen; no histological abnormality is recognised 
(NHAIR)
AP AP (530mg/kg) 2-4
[2.63]
Hydropic degradation in affected areas and surrounding 
these; some neutrophils in affected areas and central veins; 
diffuse glycogen outside affected areas
Aspirin
(0.06mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin
(0.06mg/kg)
+ APAP
0-5
[2.5]
No glycogen; sharply delineated affected areas with 
hydropic degeneration of intact cells surrounding these and 
coagulative necrosis (several individual and groups of 
necrotic cells; occasional apoptotic cells); a few neutrophils 
in affected areas (also in central veins)
Aspirin (0.3 mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (0.3mg/kg)
+ APAP
2-5
[3.25]
No glycogen; sharply delineated affected areas with 
hydropic degeneration and coagulative necrosis (numerous 
individual necrotic and apoptotic cells, at border to 
unaltered tissue); a few neutrophils
Aspirin (0.6mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (0.6mg/kg)
+ APAP
2-4
[3.5]
No glycogen; hydropic degeneration of cells surrounding 
affected areas; numerous necrotic/apoptotic cells in 
affected areas; relatively numerous neutrophils
Aspirin (1 mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (1 mg/kg)
+ APAP
2-5
[3.83]
No glycogen; sharply delineated affected areas with 
hydropic degeneration and coagulative necrosis (numerous 
individual necrotic and apoptotic cells, at border to 
unaltered tissue); some hydropic degeneration surrounding 
affected areas; some neutrophils in affected areas
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3.3.7 Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
inflammation in non-fasted C57BL/6 mice at lOhr
The effects of aspirin on the reduction of APAP-induced toxicity by modulation of 
inflammation were investigated this time in the non-fasted C57B1/6 model at the lOhr time 
point to see if potential effects of aspirin on APAP-induced hepatotoxicity are more 
pronounced in fed animals. Aspirin pretreatment of increasing dose caused no toxicity as 
measured by serum ALT activities (Figure 3.14A). A significant decrease of APAP-induced 
toxicity was observed with an aspirin concentration of 0.6mg/ml (1654.02±224.49U/1) 
compared to mice treated with APAP alone (530mg/kg; 2031.77±181.27U/1). Aspirin did not 
alter the hepatic GSH content compared to control animals (72.93±8.42nmol/mg) whereas 
APAP caused a significant decrease (47.00±4.05nmol/mg) (Figure 3.14B). No significant 
reduction in GSH content was observed in APAP-treated groups of higher concentrations of 
aspirin (0.6-lmg/ml) (50.12±8.57nmol/mg and 50.1 l±9.63nmol/mg respectively). The 
histological examination confirms that aspirin pre-treatment does not have an effect on 
APAP-induced hepatotoxic changes and neutrophil recruitment into the liver lOhr post 
treatment (Table 3.5).
A ,--------- *--------- , B
■2 1500
E 1000
Normal Aspirin Aspirin Aspirin Aspirin 
Drinking 0.06mg/ 0.3mg/ 0.6mg/ Img/ml
HjO ml ml ml
Drinking 0.06mg/ 0.3mg/ 0.6mg/ Img/ml
H,0 ml ml ml
Figure 3.14: The effect of increasing dose of aspirin on APAP-induced hepatotoxicity in 
non-fasted C57BL/6 mice at lOhr.
Serum ALT (A) and hepatic GSH content (B) were measured in non-fasted male C57BL/6 
mice pretreated with or without aspirin (0.06-Img/ml) in drinking water for 3 days before 
administration of APAP (530mg/kg; lOhr). (Saline, black; APAP, grey). Data is given as 
mean ± SD of 5 mice per group. Statistical significance was assigned relative to respective 
controls with or without aspirin. *p < 0.05, ***p< 0.001.
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Aspirin pretreatment (1 mg/ml) did not induce cytokine release into the serum (Figure 3.15). 
APAP (530mg/kg) caused a significant increase in the serum level of TNF-a 
(78.31±6.54pg/ml; Figure 3.15A), IL-6 (78.85±7.09pg/ml; Figure 3.15B) and IL-1(3 
(24.54±4.06pg/ml Figure 3.15C) at lOhr. Pretreatment with aspirin (1 mg/ml) significantly 
reduced APAP-induced serum TNF-a levels after lOhr (65.91±3.26pg/ml) but did not 
significantly alter serum levels of IL-6 or IL-ip (69.97±4.80pg/ml and 18.26±2.98pg/ml 
respectively) despite an observed trend of reduction for both cytokines.
A B
100 *
Saline Saline + APAP
Aspirin Aspirin
Saline Saline + APAP 
Aspirin
APAP + 
Aspirin
c
Saline Saline * APAP APAP +
Aspirin Aspirin
Figure 3.15: Effect of aspirin on serum cytokine levels during APAP-induced 
hepatotoxicity in non-fasted C57BL/6 mice at lOhr.
Non-fasted male C57BL/6 mice were pretreated with or without aspirin (1 mg/ml) in drinking 
water for 3 days before administration of APAP (530mg/kg; lOhr) and serum levels of TNF-a 
(A), IL-6 (B) and IL-ip (C) were determined. Data is given as mean ± SD of 3 mice per 
group. Statistical significance was assigned relative to respective controls with or without 
aspirin. *p < 0.05, ***^? < 0.001.
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Table 3.5: Histological findings after aspirin and APAP treatment in non-fasted mice at lOhr. 
Male C57BL/6 mice were pretreated with or without aspirin (1 mg/ml) in drinking water for 3 
days before administration of APAP (530mg/kg; lOhr). The histological evaluation was 
undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary Science, 
University of Liverpool). The listed findings represent a summary of the changes observed in 
each of 4 animals per group.
Treatment Score
[averagel
Histological findings
Aspirin (1 mg/kg)
+ Saline
0 No glycogen; no histological abnormality is recognised 
(NHAIR)
Aspirin (1 mg/kg)
+ APAP
0-5 No glycogen; hydropic degeneration;surrounding areas of 
cell loss; occasional apoptotic/necrotic hepatocytes; a few 
neutrophils in affected areas (border of cell loss)
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3.3.8 Investigation into the effect of aspirin on APAP-induced hepatotoxicity and 
inflammation in non-fasted C57BL/6 mice at 24hr
The previous study on the effects of increasing levels of aspirin on APAP-induced toxicity 
and modulation of inflammation in non-fasted C57B1/6 mice was repeated with an extended 
time course of 24hr. Aspirin pretreatment of increasing dose (0.06-0.6mg/ml) at 24hr post 
APAP dose (530mg/kg) caused no toxicity as measured by serum ALT activities (Figure 
3.16A). Aspirin (0.06-0.06mg/ml) did not alter the hepatic GSH content compared to control 
animals (71.42±3.42nmol/mg) (Figure 3.16B). The histological examination confirms that 
aspirin treatment does not have a distinct effect on APAP-induced hepatotoxic changes and 
the degree of neutrophil recruitment into the liver 24hr post treatment (Table 3.6).
A B
3000 100
Normal Aspirin Aspirin Aspirin 
Drinking O.OGmg/ 0.3mg/ml 0.6mg/ml
2500
H 1500
E 1000
Normal Aspirin Aspirin Aspirin 
Drinking O.OGmg/ 0.3mg/ml 0.6mg/ml
H2° ml H20 ml
Figure 3.16: The effect of increasing dose of aspirin on APAP-induced hepatotoxicity in 
non-fasted C57BL/6 mice at 24hr.
Serum ALT (A) and hepatic GSH content (B) were measured in non-fasted male C57BL/6 
mice pretreated with or without aspirin (0.06-0.6mg/ml) in drinking water for 3 days before 
administration of APAP (530mg/kg; 24hr). (Saline, black; APAP, grey). Data is given as 
mean ± SD of 5 mice per group. Statistical significance was assigned relative to respective 
controls with or without aspirin. ***£>< 0.001.
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Aspirin pretreatment (0.6mg/ml) did not induce cytokine release into the serum (Figure 3.17). 
APAP (530mg/kg) caused a significant increase in the serum level of TNF-a 
(86.16±7.22pg/ml; Figure 3.17A), IL-6 (122.89±12.21pg/ml; Figure 3.17B) and IL-ip 
(18.56±6.55pg/ml Figure 3.17C) at 24hr post dose. Pretreatment with aspirin (0.6mg/ml) did 
not significantly alter the levels of the three cytokines after APAP treatment.
A
100
Saline Saline-t- APAP APAP +
Aspirin Aspirin
B
Saline Saline + APAP 
Aspirin
APAP + 
Aspirin
c
d 10
Saline Saline + APAP 
Aspirin
APAP + 
Aspirin
Figure 3.17: Effect of aspirin on serum cytokine levels during APAP-induced 
hepatotoxicity in non-fasted C57BL/6 mice at 24hr.
Non-fasted male C57BL/6 mice were pretreated with or without aspirin (0.6mg/ml) in 
drinking water for 3 days before administration of APAP (530mg/kg; 24hr) and serum levels 
of TNF-a (A), IL-6 (B) and IL-lp (C) were determined. Data is given as mean ± SD of 3 
mice per group. Statistical significance was assigned relative to respective controls with or 
without aspirin. **p <0.0\,***p < 0.001.
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Table 3.6: Histological findings after aspirin and APAP treatment in non-fasted mice at 24hr. 
Male C57BL/6 mice were pretreated with or without aspirin (0.06-0.6mg/ml) in drinking 
water for 3 days before administration of APAP (530mg/kg; 24hr). The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed in each of 4 animals per group.
Treatment Score
[average]
Histological findings
Saline 0 Diffuse glycogen; no histological abnormality is 
recognised (NHAIR)
APAP (530mg/kg) 0-4
[2.25]
No glycogen; hydropic degeneration of remaining 
hepatocytes in affected areas; some neutrophils in blood- 
filled centrilobular areas and central veins
Aspirin
(0.06mg/kg)
+ Saline
0 Diffuse glycogen, often low amount; NHAIR
Aspirin
(0.06mg/kg)
+ APAP
0-4
[2.43]
In affected areas often inner area of cell loss with 
haemorrhage, surrounded by coagulative necrosis of 
hepatocytes and rim of glycogen loss
Aspirin (0.3mg/kg)
+ Saline
0 Variable amount of hepatocytes with glycogen; NHAIR
Aspirin (0.3mg/kg)
+ APAP
0-4
[1.63]
Centrolobular cell loss and coagulative necrosis; no 
glycogen; some neutrophils in affected areas
Aspirin (0.6mg/kg)
+ Saline
0 Diffuse glycogen; NHAIR
Aspirin (0.6mg/kg)
+ APAP
0-4
[2]
Area of cell loss surrounded by cells with hydropic 
degeneration; no glycogen or broad centrilobular rim of 
glycogen loss; a few neutrophils in affected areas
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3.3.9 Comparison of the effects of aspirin on APAP-induced hepatotoxicity and 
inflammation in fasted and non-fasted C57BL/6 mice
Table 3.7 shows a comparison of the effects of high dose aspirin on APAP-induced 
hepatotoxicity and inflammation in fasted and non-fasted C57BL/6 mice at lOhr and 24hr 
post APAP treatment. The table illustrates that APAP-induced hepatotoxicity as assessed by 
serum ALT activity was significantly greater in fasted C57BL/6 mice compared to fed mice 
(3390.83±291.42U/1 and 2031.77±181.27U/1 respectively) at lOhr post APAP (530mg/kg). 
The trend was also similar' at 24hr post APAP with significantly higher ALTs in fasted mice 
(3747.27±301.90U/1) than in fed mice (2214±266.82U/1). Pretreatment with aspirin reduced 
serum ALT activity by 16% in fed mice compared to 9.3% in fasted mice at lOhr post APAP 
dose. At 24hr post APAP dose, aspirin reduced ALT activity by a greater extent in fasted 
mice than in fed mice (6.9% and 3.3% respectively) although the extent of this reduction for 
both fasted and fed mice at 24hr was less than that observed at lOhr and the overall effect of 
aspirin on APAP toxicity were not significant. Pretreatment with aspirin reduced serum 
protein levels of TNF-a by 17.9% in fasted mice with a similar trend in fed mice (15.8%) at 
lOhr post APAP dose. At 24hr post APAP dose, aspirin reduced serum TNF-a in fasted mice 
by 4.1% and fed mice by 3.8%. Similar to TNF-a, aspirin pretreatment reduced levels of 
serum IL-6 by 17.5% in fasted mice compared to 11.3% in fed mice at lOhr post APAP dose 
and the same trend was observed 24hr post APAP. In fed mice the serum protein levels of IL- 
1(3 were reduced to a greater extent compared to fasted mice at both lOhr (25% fed and 
18.5% fasted) and 24hr (13.7% fed and 3.5% fasted). The results show the trend of a greater 
level of reduction of serum cytokine levels with aspirin pretreatment at the lOhr time point 
compared to 24hr post APAP dose. While it can be seen that the levels of toxicity and 
cytokine release are greater in fasted than in fed mice, the effect of aspirin on reducing 
toxicity and inflammation in both fasted and fed animals was not significant.
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3.4 DISCUSSION
There has recently been controversy reported regarding the role of the innate immune system 
in the overall outcome of drug-induced hepatotoxicity with conflicting literature reports 
concerning progression and exacerbation of toxicity (Liu et ah, 2006; Masson et ah, 2008; 
Williams et ah, 2011). Questions about the effects that the solvent DMSO has on APAP- 
induced liver injury have been raised. Therefore, the aim of one of the studies described 
within this chapter was to determine if DMSO can be the main cause of hepatic immune cell 
infiltration during APAP-induced hepatotoxicity through the use of the APAP model of 
toxicity characterised in Chapter 2. In order to test whether APAP or DMSO is responsible 
for immune cell infiltration, high doses of APAP were compared to DMSO treatments. The 
second objective of this chapter was to further investigate the contribution of the immune 
system in DILI by using aspirin, as it was reported to be a pharmacological inhibitor of the 
Nalp3 inflammasome in mice (Imaeda et al., 2009).
The use of DMSO to facilitate the dissolution of APAP has been implicated as a major factor 
in the pathogenic role of NK and in particular, NKT cells in AP AP-induced liver injury 
(Masson et ah, 2008). DMSO was implicated as the main cause of hepatic immune cell 
infiltration with increased numbers of cytotoxic NKT cells in the liver, both in the presence 
of APAP or alone. It was shown that in addition to affecting the role of NK and NKT cells in 
AP AP-induced hepatotoxicity, the presence of DMSO also decreased the severity of liver 
injury at equivalent doses of APAP. This effect was thought to be likely due to the inhibition 
of APAP bioactivation by DMSO (Masson et al., 2008).
A comparison of APAP and DMSO treatments in mice was conducted in order to determine 
if the use of the solvent DMSO is the main factor involved in immune cell infiltration rather 
than from APAP alone. As it has been well documented that high levels of DMSO can have 
an inhibitory effect on CYP450 metabolism and toxicity (Park et al., 1988; Lind et al., 2000; 
Dunphy et ah, 2007) and that DMSO has anti-oxidant activity (Yamasaki et al., 1988; 
Dunphy et al., 2007), the effect of DMSO on APAP toxicity was also assessed. At 24hr, mice 
that were administered DMSO alone (1 mg/ml in saline) showed no toxicity as assessed by 
serum ALT levels and histology, whereas mice that were treated with a dose of APAP shown
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to cause liver toxicity (530mg/kg) showed a significantly higher level of ALT activity (Figure 
3.1 A). DMSO, when administered simultaneously with APAP lead to complete abrogation of 
toxicity, with ALT levels similar to those after DMSO alone, however, when DMSO was 
dosed 2hr after APAP, APAP hepatotoxicity was observed. This data is in concordance with 
previous work (Masson et al., 2008) which suggested that high levels of DMSO could inhibit 
APAP bioactivation when given at the same time, with toxicity being observed if DMSO 
treatment was delayed by 2hr, giving time for APAP to become metabolised into its reactive 
metabolite and cause cell damage. At the equivalent time point (24hr) however, the levels of 
hepatic GSH content in each dose group were similar to control levels. When DMSO was 
administered 2hr after APAP, despite ALT levels being high, the GSH content was similar to 
levels when DMSO was given simultaneously (Figure 3.IB). GSH levels may have been 
returning to normal after 24hr as a result of liver regeneration and repair. Depletion would 
have occurred at an earlier time point as a result of oxidative stress caused by APAP, but the 
cellular levels of GSH would be replenished 24hr after the initial toxic insult. As it was 
observed that a high level of DMSO (Iml/kg) abrogated APAP-induced hepatotoxicity, a 
DMSO dose response was used in order to determine what levels could cause this inhibition 
(Figure 3.2). To assess whether ALT inhibition was also associated with a reduction of 
biochemical oxidative stress, the level of hepatic GSH content was measured 5hr after APAP 
exposure, so GSH levels would not have returned to normal. It was seen by serum ALT 
activity that toxicity was significantly reduced compared to APAP alone when DMSO levels 
were greater than O.lml/kg (Figure 3.2A). At the maximum level of DMSO used (Iml/kg), 
toxicity was completely abrogated at 5Ins suggesting that bioactivation of APAP was 
inhibited in the presence of DMSO. GSH levels were significantly reduced in all DMSO dose 
groups compared to DMSO alone (Figure 3.2B), however, levels increased in a dose 
dependent manner compared to APAP alone, most notably at levels greater than O.lml/kg 
DMSO. This was in parallel to the reduction in ALT levels at equivalent doses suggesting 
that some bioactivation was occurring. The time dependent effect of DMSO (Iml/kg) 
administration on bioactivation and toxicity was also explored (Figure 3.3). As seen with the 
previously described study, when DMSO was administered concurrently or Ihr after APAP, 
toxicity was abrogated as shown by the level of ALT activity (Figure 3.3A). The levels of 
ALT were similar to those of the control groups and significantly lower than with APAP 
alone. Administration of DMSO 2hr and 4hr after APAP lead to a significant increase in ALT 
activity compared to control, however, there was still a significant decrease with both time 
points compared to APAP alone although levels were above the threshold of toxicity. The
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levels of hepatic GSH content were significantly reduced in all APAP and DMSO treated 
groups compared to control, however when DMSO was administered concurrently and Ihr 
after APAP, the GSH level was significantly higher than after APAP treatment alone 
suggesting some inhibition of bioactivation (Figure 3.3B). The reduction of bioactivation and 
toxicity seen within these studies can be attributed to the high levels of DMSO used. The 
observation that APAP bioactivation is not completely inhibited by DMSO could be 
accounted for by the fact that APAP is metabolised by multiple CYP450 enzymes. APAP is 
primarily bioactivated by CYP2E1 and also CYP3A4 and CYP1A2 (Dahlin et al., 1984). A 
study investigating the effect of organic solvents on GYP enzymes have shown that DMSO 
can inhibit CYP2E1 and partially CYP3A4 (Easterbrook et ah, 2001) which could result in 
some APAP being bioactivated by any remaining uninhibited CYP3A4 or CYP1A2 enzymes. 
The histological examination confirmed the biochemical findings, as concurrent 
administration of DMSO with APAP showed no histological abnormality normally associated 
with APAP treatment, however, cell loss was evident when DMSO was administered 2hr post 
APAP treatment.
It was hypothesised that aspirin is capable of inhibiting the Nalp3 inflammasome and it was 
reported that pretreatment with aspirin in drinking water reduced APAP-induced liver injury 
(Imaeda et ah, 2009). It was concluded that aspirin protected due to inhibition of cytokine 
transcriptional activation (i.e. IL-lp, IL-18, TNF-a and IFN-y) and also inhibition of Nalp3, 
which processes the pro-form of IL-lp and IL-18 (Imaeda et ah, 2009). The assumption was 
that the reduced cytokine formation attenuates liver injury through reduced inflammatory cell 
activation and recruitment. In this chapter a study was undertaken to repeat the published one 
and with the aspirin dose previously published (0.06mg/ml in drinking water) as well as with 
higher doses (0.3mg/ml, 0.6mg/ml and 1 mg/ml) in the three animal models established in 
Chapter 2. The aims of these studies were to see if aspirin could act as a pharmacological 
inhibitor of the Nalp3 inflammasome and subsequently, reduce inflammation and toxicity in 
our LPS, GalN and APAP animal models.
The effect of LPS, GalN and APAP on toxicity, metabolism and inflammation were 
investigated in Chapter 2, therefore, the effects of a pharmacological agent used to modulate 
these factors could be evaluated. The LPS model of hepatotoxicity and inflammation was first 
utilised to examine the effect of aspirin on inflammation as LPS produces a substantial
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inflammatory response. Using the dose previously published, aspirin in the drinking water of 
mice caused no liver injury as assessed by serum ALT activity and histology, nor did LPS on 
its own over a 24hr period (Figure 3 A A), which is in concordance with the findings in 
Chapter 2. Aspirin pretreatment and LPS alone did not alter hepatic GSH content (Figure 
3.4B) or serum cytokine levels (Figure 3.5). Aspirin caused a trend of decreasing LPS 
induced cytokine release, but the reduction was not statistically significant. The levels of each 
cytokine produced after administration of LPS were consistent with the levels observed in 
Chapter 2. Pretreatment of aspirin in the GalN mouse model showed a slight decrease in 
serum ALT activity compared to GalN alone but the reduction was not significant (Figure 
3.6A). In a similar finding to the LPS model, there was a trend of decreasing serum cytokine 
levels in aspirin pretreated animals with GalN compared to GalN alone but the decrease was 
again not significant (Figure 3.7). These results with GalN were observed using a much 
higher dose of aspirin than previously published (Img/ml; Imaeda et al., 2009). These 
findings suggest that aspirin was ineffective in our LPS and GalN models at reducing the 
level of toxicity and inflammation. The latter was also confirmed by histology, since there 
was no obvious difference in the degree of inflammatory cell recruitment into the liver.
Using the same pretreatment regimen as described by Imaeda et al. (2009) no significant 
effect of aspirin on APAP-induced hepatotoxicity was observed after lOhr when compared to 
APAP alone in the APAP C57BL/6 mouse model (Figure 3.8A). APAP metabolism was 
shown to be unaffected by aspirin pretreatment in our investigation as hepatic GSH levels 
were significantly reduced from control in APAP with aspirin treated groups, comparable to 
the level of reduction seen with APAP alone (Figure 3.9), although this was not assessed in 
the previous study (Imaeda et al., 2009). The APAP-aspirin study was expanded to see if 
higher doses of aspirin, different time points of APAP exposure and fasting had any effect on 
the overall effectiveness of aspirin as a protector of toxicity and inflammation. Mice were 
given a dose range of aspirin (0.06-1 mg/ml) prior to APAP administration and examined lOhr 
or 24hr and had been either fasted or fed. Aspirin pretreatment showed a slight dose- 
dependent trend to reduce toxicity and cytokine release but the overall effect was not 
statistically significant. This was further confirmed by the histological examination, where 
there was no distinct effect on APAP-induced liver changes or inflammatory cell recruitment 
into the liver. Increasing the time course of APAP-exposure from lOhr to 24hr also did not 
alter the overall effect of aspirin on toxicity and inflammation, hi Chapter 2 it was observed
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that at the later time point of 24hr, the extent of toxicity and inflammation in the APAP 
model was greater than at preceding time points. The resulting hypothesis was that at this 
later time point, aspirin may have more of an impact on reducing toxicity and inflammation. 
If the overall protective effect of aspirin was negligible, it might not have been detectable in a 
model with a lesser toxicological and inflammatory response. A similar hypothesis was 
formed regarding whether mice were fasted or fed, as the findings from Chapter 2 showed 
that fasting of APAP-treated mice increased the level of toxicity and cytokine release 
compared to fed animals, and therefore the effect of aspirin may be detectable in the fasted 
model. However, the results of the present study showed no significant effect of aspirin on 
APAP-induced toxicity and inflammation.
These data further support the concept that aspirin pretreatment has no significant effect on 
the overall extent of experimental APAP hepatotoxicity. These results were also in 
concordance with data recently published by Williams et al. (2011) who looked at the genetic 
elimination of the Nalp3 inflammasome as well as pharmacological inhibition of Nalp3 with 
aspirin in APAP-treated mice. Their data demonstrated that no significant alteration of 
APAP-induced liver injury occurred in Nalp3 inflammasome knockout mice or wild-type 
mice treated with aspirin. However the results presented in this Chapter and by Williams et 
al. (2011), are not consistent with the results and conclusions presented by Imaeda et al. 
(2009). The only differences in the methods used in this chapter and that of Imaeda were that 
Imaeda’s group used a slightly smaller dose of APAP (500mg/kg) as opposed to 530mg/kg, 
and that they euthanized their animals at 12hr post APAP treatment, whereas the time points 
explored in this chapter were lOhr and 24hr post APAP dose. The same dose of aspirin by 
Imaeda (0.06mg/ml) was used and even increased, but with no bearing on the overall 
outcome. There are no obvious explanations for the discrepancies in these results, although 
an important aspect of our study was to show that the use of aspirin as a pharmacological 
modulator of the inflammatory response in our model did not alter the bioactivation of 
APAP, something which Imaeda’s group did not confirm.
In summary the data presented in this chapter suggest that the effect of DMSO on 
exacerbation of APAP-toxicity by recruitment of inflammatory cells such as NK/NKT cells is 
minimal as the inhibitory effect of DMSO on the enzymatic bioactivation of APAP and 
subsequent reduction of hepatotoxicity is more prominent when DMSO is administered
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within Ihr of APAP. The use of DMSO to facilitate the dissolution of compounds in studies 
involving the hepatic immune system must therefore be carefully considered. The data also 
strongly supports recent literature evidence and the conclusion that the activation of the 
Nalp3 inflammasome and subsequent involvement of neutrophils has no relevant impact on 
APAP hepatotoxicity and therefore may not be a viable therapeutic target to treat APAP 
overdose. Caution must be exercised in translating this concept to man with respect to aspirin 
acting as a hepatoprotective agent against APAP-induced liver injury.
123
Chapter 4
CHAPTER FOUR
INVESTIGATION OF THE EFFECT OF ANTI-HMGB1 ANTIBODY AND ETHYL 
PYRUVATE ON DRUG-INDUCED HEPATOTOXICITY AND LPS-MEDIATED
INFLAMMATION
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4.1 INTRODUCTION
The innate immune response has been shown to play an important role in the exacerbation of 
liver injury during APAP hepatotoxicity downstream of drug metabolism (Ju et ah, 2002; Liu 
et ah, 2004; Liu et ah, 2006). The contribution to the severity and progression of APAP- 
induced liver injury is understood to be mediated by recruitment of inflammatory cells into 
the liver and production of proinflammatory cytokines (Blazka et ah, 1995; Scaffidi et al, 
2002; Laskin et al., 2003; Liu et al.} 2004) which are released from macrophages, neutrophils 
and other cells of the imiate immune system. Chapter 3 focused on the modulation of 
inflammatory cell recruitment to the liver after initial hepatocyte damage. Along with 
proinflammatory cytokines such as TNF-a, IL-6, IL-lp, a variety of molecules released from 
necrotic cells were identified that can induce further cytokine formation. These molecules, 
collectively termed damage-associated molecular patterns (DAMPs) include DNA fragments, 
heat shock proteins and HMGB1 (Bianchi et al., 2007).
HMGB1 is a late mediator of lethal systemic inflammation in animal models of cytokine- 
mediated disease initiated by LPS (Wang et al., 1999). It is passively released by necrotic 
cells and secreted by activated immune cells but not by cells dying via apoptosis. Following 
release it acts as a potent inflammatory mediator that has been shown to link the necrotic cell 
death of hepatocytes to the inflammatory response (Scaffidi et al., 2002) by targeting TLR 
(Toll-like receptor) and RAGE (Receptor for Advanced Glycation End products) (Kokkola et 
al., 2005; Yu et al., 2006). HMGB1 is actively released by macrophages after a delay of 12- 
18hr dining endotoxaemia (Wang et al., 1999). Antibodies that neutralise HMGB1 have been 
shown to protect against the lethal effects of LPS-induced endotoxaemia in mice when 
administered 2hr after the onset of endotoxaemia. The proinflammatory activity of HMGB1 
stimulates the release of TNF-a, IL-lp and other inflammatory cytokines from macrophages 
and mediates lethality of mice (Wang et al., 1999; Andersson et al., 2000). Moreover, in 
patients with sepsis, increased serum HMGB1 levels correlated with mortality (Wang et al, 
1999). Anti-HMGBl antibodies have also been shown to be successful at attenuating the 
inflammatory response associated with APAP hepatotoxicity (Scaffidi et al., 2002). It has 
also been demonstrated that levels of serum HMGB1 in patients increased with APAP- and 
non-APAP-induced acute liver injury (Craig et al., 2011). These results suggest that HMGB1
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is an important mediator in inflammation and APAP-induced liver injury and that its 
inhibition may be a key to improving clinical outcomes.
Ethyl pyruvate (EP) is a stable lipophilic pyruvate derivative of the endogenous metabolite 
pyruvic acid. The lipophilicity of EP thereby enables it to diffuse readily into cells, where it 
acts as a potent antioxidant and free-radical scavenger and has also been shown to be an 
effective anti-inflammatory agent in a variety of in vitro and in vivo model systems (Fink et 
al., 2007). EP has been shown to improve survival and ameliorate organ dysfunction in a 
wide variety of animal models of severe sepsis (Ulloa et al, 2002; Venkataraman et al, 
2002), haemorrhagic shock (Yang et al, 2002b; Cai et al, 2009), hepatic 
ischaemia/reperfusion injury (Tsung et al, 2005), bacterial peritonitis (Ulloa et al, 2002; Su 
et al, 2007), and ethanol-induced acute liver injury (Yang et al, 2003). EP was shown to 
inhibit EPS-induced NF-kB activation in cultured RAW264.7 murine macrophage-like cells, 
and reduces HMGB1 release and TNF-a gene expression both in vitro and in vivo (Sims et 
al, 2001; Ulloa et al, 2002; Yang et al, 2002b).
To date there has not been a report of EP being used as an experimental pharmacological 
agent that could modulate APAP-induced hepatotoxicity and inflammation. Therefore, the 
overall aim of this chapter was to test the hypothesis that treatment with EP would be 
protective in our APAP model of hepatotoxicity and inflammation. We reasoned that EP 
might be protective in APAP-induced liver injury, depending on its inhibition of early (TNF- 
a, IL-6, IE-Iff) and late (HMGB1) inflammatory cytokines. The aims of the studies in this 
chapter were to define if EP reduces hepatotoxicity in our model of APAP-induced 
hepatotoxicity as assessed by serum ALT activity and histological assessment, and if EP 
reduced inflammation in our APAP and EPS models, including modulation of HMGB1. The 
studies were designed to evaluate whether pretreatment or delayed treatment of EP could be 
beneficial in our mouse models of EPS and APAP hepatotoxicity associated inflammation. 
Pretreatment of EP was designed to test if its pharmacological effects were due to the 
inhibition of early cytokines, whereas delayed treatment of EP was tested to see if EP could 
modulate the late acting HMGB1 and see if it had an effect after the onset of toxicity and 
inflammation.
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4.2 MATERIALS AND METHODS
4.2.1 Materials
Infinity ALT liquid kits were purchased from ALPHA Laboratories (Eastleigh, U.K). 
HMGB-1 neutralising antibody and control IgY antibody were from Shino-Test Corporation 
(Tokyo, Japan). Unless otherwise stated, all other chemicals and materials were purchased 
from Sigma-Aldrich (Poole, U.K).
4.2.2 Experimental animals
The protocols described were in accordance with criteria outlined in a licence granted under 
the Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool 
Animal Ethics Committee. Animals were purchased from Charles River laboratories and had 
a 5 day acclimatisation period prior to experimentation. Animals were also maintained in a 
12hr light/dark cycle with free access to food and water.
4.2.3 Animal dosing regime
Male C57BL/6 (18-23g) mice were either fasted overnight with free access to water or had 
free access to food and water prior to experimentation. Mice received an i.p injection of 0.9% 
saline or ethyl pyruvate (EP; sodium 130mM, potassium 4mM, calcium 2.7mM, chloride 
139mM and EP 28mM, pH 7.0) 30min prior to administration of APAP (530mg/kg, i.p.) in 
0.9% saline or with LPS (5mg/kg, i.p.) in 0.9% saline then were euthanized after 24hr. 
Control animals received 0.9% saline. Other groups of mice received an i.p injection of 0.9% 
saline or EP 4hr after administration of APAP (530mg/kg, i.p) in 0.9% saline or LPS 
(5mg/kg, i.p.) in 0.9% saline and were then euthanized after 24hr. To determine the role 
played by circulating HMGB1 released after APAP treatment, male CD-I mice (25-35g) 
were fasted overnight before intravenous administration of 200jag of neutralising chicken 
polyclonal antibody to HMGB1 or 200pg of a control IgY antibody. Antibody treatment was 
conducted 2hr after APAP administration (530mg/kg; i.p). Animals were then euthanized 
after 24hr as described by Antoine et al. (2010).
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4,2.4 Assessment of hepatotoxicity in male C57BL/6 mice
Animals were sacrificed by CO2 inhalation and cervical dislocation and blood was collected 
by cardiac puncture. Hepatotoxicity was assessed by serum ALT activity and histology as 
described in Chapter 2.
4.2.5 Determination of hepatic glutathione levels in C57BL/6 mouse whole liver during 
drug-induced hepatotoxicity
Total hepatic GSH levels were determined as described previously in Chapter 2. Levels of 
GSH were normalised to hepatic protein content using Bio-Rad protein assay reagent 
according to the manufacturer’s instructions.
4.2.6 Histological examination of C57BL/6 mouse liver
Hepatotoxicity and leukocyte infiltration was assessed as part of the histological examination 
of HE-stained sections as described in Chapter 2. The assessment was undertaken by Prof A 
Kipar, Veterinary Pathology, School of Veterinary Science, University of Liverpool.
4.2.7 Measurement of cytokines in serum from animals dosed with LPS and APAP 
using Luminex Analysis
Serum was collected from control and treated animals. Concentrations of TNF-a, IL-6 and 
IL-ip were measured using the Bio-Plex Assay kit (Bio-Rad Laboratories, Inc) as described 
in Chapter 2. The lower range of the assay is <5,8 pg/ml for TNF-a, <0.74pg/ml for IL-6 and 
<10.36pg/ml for IL-lp. Levels below these values were assigned a value of zero.
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4.2.8 Measurement of HMGB1 in serum from animals dosed with LPS and APAP
HMGB1 measurements were carried out using an ELISA according to the manufacturer’s 
instructions. A chicken anti-HMGBl antibody was used as a catcher antibody (IjagAvell 
compared to known standards using 3,3’,5s5’-tetramethyl-benzidine turnover by a peroxidise- 
linked anti-HMGBl antibody. The limit of detection was O.lng/ml.
4.2.9 Statistical analysis
All results are expressed as mean ± standard deviation (S.D). Values to be compared were 
analysed for non-normality using a Shapiro-Wilk test. The unpaired t-test was used when 
non-normality was indicated. A Mami-Whitney U test was used for non-parametric data. 
Comparisons between multiple groups were performed with one-way ANOVA or, where 
appropriate, by two-way ANOVA, followed by a post hoc Bonferroni test. All calculations 
were performed using SPSS statistical software, results were considered significant when 
/K0.05.
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4.3 RESULTS
4.3.1 Investigation into the effect of EP pretreatment on LPS-induced inflammation
A study by Ulloa et al., (2002) demonstrated that EP was an effective strategy to 
pharmacologically inhibit HMGB1 and could subsequently attenuate lethal systemic 
inflammation caused by endotoxaemia and sepsis. This study was repeated using the EP dose 
previously published (40mg/kg; Ulloa et al., 2002). An initial evaluation of EP as a 
therapeutic agent for inflammation and hepatotoxicity in our EPS model was conducted. 
C57BL/6 mice received a single dose of EP (40mg/kg; i.p.) followed 30min later by EPS 
(5mg/kg; i.p.) and then were euthanized after 24hr. Pretreatment with EP conferred a 
significant decrease of serum HMGB1 levels in EPS-dosed animals (701.32±162.43ng/ml) 
compared to mice treated with EPS alone (954.37±75.18ng/ml) (Figure 4.1). EP alone did not 
result in HMGB1 release (11.32±6.00ng/ml).
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Figure 4.1: The effect of EP pretreatment on LPS-induced HMGB1 release
HMGB1 was measured in fasted male C57BL/6 mice pretreated with saline or EP (40mg/kg), 
30min before administration of EPS (5mg/kg) (- EP; black; + EP, grey). Mice were 
euthanized after 24hr. Data is given as mean ± SD of 4 mice per group. Statistical 
significance was assigned relative to respective controls with or without EP. *p < 0.05, ***p 
<0.001.
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Pretreatment with EP caused no hepatotoxicity as assessed by serum ALT activity 
(17.07±7.24U/1) (Figure 4.2A). LPS administered alone or with EP did not cause 
hepatotoxicity either (14.38±7.31U/1 and 16.43±8.57U/1 respectively). EP pretreatment did 
not alter hepatic GSH content compared to control (46.97±6.50nmol/mg), nor did LPS alone 
or with EP (45.12±5.95nmol/mg and 46.20±5.81 nmol/mg respectively) (Figure 4.2B).
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Figure 4.2: The effect of EP pretreatment on LPS-induced toxicity
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with saline or EP (40mg/kg), 30min before administration of LPS (5mg/kg) (- EP; 
black; + EP, grey). Mice were euthanized after 24hr. Data is given as mean ± SD of 6 mice 
per group. Statistical significance was assigned relative to respective controls with or without 
EP.
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EP pretreatment (40mg/kg) caused no cytokine release into the serum (Figure 4.3), whereas 
EPS (5mg/kg) caused a significant increase in the serum level of TNF-a 
(581.22±32.77pg/ml) (Figure 4.3A), the serum level of IL-6 (1825.57±342.23pg/ml) (Figure 
4.3B) and the level of IL-1(3 (239.12±25.40pg/ml) at 24hr post EPS dose (Figure 4.3C). 
Pretreatment with EP significantly decreased serum levels of EPS-induced TNF-a 
(416.82±54.63pg/ml), IL-6 (1107.46±145.64pg/ml) and IL-lp (155.60±19.12pg/ml) after 
24hr.
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Figure 4.3: The effect of EP pretreatment on serum cytokine levels post LPS treatment
Fasted male C57BL/6 mice were pretreated with saline or EP (40mg/kg), 30min before 
administration of LPS (5mg/kg) and serum levels of TNF-a (A), IL-6 (B) and IL-lp (C) were 
determined at 24hr post treatment (- EP; black; + EP, grey). Data is given as mean ± SD of 3 
mice per group. Statistical significance was assigned relative to respective controls with or 
without EP. * */? < 0.01, * * */? < 0.001.
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The histological examination confirmed the biochemical findings. There were no findings 
indicating that EP had any effect on the liver. EP also appeared not to have an effect on the 
EPS-induced changes, i.e. neutrophil recruitment into the liver and individual hepatocyte 
death (Table 4.1).
Table 4.1: Histological findings after EP pretreatment of EPS treated mice. Male C57BL/6 
mice were pretreated with saline or EP (40mg/kg) 30min before administration of EPS 
(5mg/kg), Animals were examined 24hr after EPS treatment. The histological evaluation was 
undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary Science, 
University of Liverpool). The listed findings represent a summary of the changes observed in 
each of 6 animals per group.
Treatment Score* Histological findings
Saline predose +
Saline
0 Diffuse glycogen; no histological abnormality is recognised 
(NHAIR)
Saline predose +
EPS
0 Diffuse glycogen; mild increase of neutrophils between 
hepatic cords; some small random neutrophil aggregates
EP predose +
Saline
0 Diffuse glycogen; no histological abnormality is recognised
EP predose +
EPS
0 No glycogen; mild increase of neutrophils between hepatic 
cords, some neutrophils in central veins and sinuses 
surrounding these; scattered small random neutrophil 
aggregates
* The scoring system for APAP-induced hepatotoxicity was applied (see Chapters 2 and 3).
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4.3.2 Investigation into the effect of delayed administration of EP on LPS-induced 
inflammation
The therapeutic efficacy of EP when first administered after the onset of LPS-induced 
inflammation was assessed. Treatment with EP was initiated 4hr after EPS, a time when LPS- 
induced toxicity and inflammation would already be evident (as shown in Chapter 2; Figures 
2.1 and 2.2). Delayed treatment of EP (40mg/kg) significantly reduced serum HMGB1 levels 
in LPS-dosed animals (790.77±136.60ng/ml) compared to mice treated with LPS alone 
(1055.92±176.48ng/ml) (Figure 4.4). EP alone did not result in HMGB1 release 
(1 L65±5.10ng/ml).
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Figure 4.4: The effect of delayed administration of EP on LPS-induced HMGB1 release
HMGB1 was measured in fasted male C57BL/6 mice treated with saline or EP (40mg/kg), 
4hr after administration of LPS (5mg/kg) (- EP; black; + EP, grey). Mice were euthanized 
after 24hr. Data is given as mean ± SD of 4 mice per group. Statistical significance was 
assigned relative to respective controls with or without EP. *p < 0.05, ***/? < 0.001.
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Delayed treatment with EP (40mg/kg) caused no hepatotoxicity as assessed by serum ALT 
activity (9.14±2.20U/1) (Figure 4.5A). LPS administered alone or with EP did not cause 
hepatotoxicity either (26.76±12.16U/1 and 27.15±7.94U/1 respectively), although ALT was 
significantly higher than in controls. Delayed treatment with EP did not alter hepatic GSH 
content compared to control (44.52±3.75nmol/mg), nor did LPS alone or with EP 
(49.34±9.55nmol/mg and 48.64±3.02nmol/mg respectively) (Figure 4.5B).
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Figure 4.5: The effect of delayed administration of EP on LPS-induced toxicity
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
treated with saline or EP (40mg/kg), 4hr after administration of LPS (5mg/kg) (- EP; black; + 
EP, grey). Mice were euthanized after 24hr. Data is given as mean ± SD of 6 mice per group. 
Statistical significance was assigned relative to respective controls with or without EP. **p < 
0.01.
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Delayed treatment with EP (40mg/kg) caused no cytokine release into the serum (Figure 4.6). 
EPS (5mg/kg) caused a significant increase in the serum level of TNF-a 
(621.62±36.98pg/ml) (Figure 4.6A), IL-6 (1786.14±194.1 Ipg/ml) (Figure 4.6B) and IL-lp 
(301.18±20.93pg/ml) (Figure 4.6C) at 24hr post EPS dose. Delayed treatment with EP did 
not significantly decrease serum levels of EPS-induced TNF-a (540.16±61.03pg/ml) or IL-6 
(1504.02±286.19pg/ml) after 24hr whereas a significant reduction in IE-1(3 serum levels was 
observed (238.96±25.66pg/ml).
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Figure 4.6: The effect of delayed administration of EP on serum cytokine levels post 
EPS treatment
Fasted male C57BL/6 mice were treated with saline or EP (40mg/kg), 4hr after 
administration of EPS (5mg/kg; 24hr) and serum levels of TNF-a (A), IL-6 (B) and IL-lp (C) 
were determined at 24hr post treatment. (- EP; black; + EP, grey). Data is given as mean ± 
SD of 3 mice per group. Statistical significance was assigned relative to respective controls 
with or without EP. *p < 0.05, ***p< 0.001.
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The histological examination confirmed that delayed treatment with EP did not appeal’ to 
have an effect on the LPS-induced changes, i.e. neutrophil recruitment into the liver and 
individual hepatocyte death (Table 4.2).
Table 4.2: Histological findings after delayed administration of EP to EPS treated mice. 
Male C57BL/6 mice were treated with saline or EP (40mg/kg) 4hr after administration of 
EPS (5mg/kg). Animals were examined 24hr after EPS treatment. The histological evaluation 
was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary Science, 
University of Liverpool). The listed findings represent a summary of the changes observed in 
each of 6 animals per group.
Treatment Score* Histological findings
Saline +
EP post dose
0 Diffuse glycogen; no histological abnormality is recognised
EPS +
EP post dose
0 Diffuse glycogen (low amount); increased neutrophils 
between hepatic cords, some degree of central vein 
endothelial cell activation; several neutrophils within lumen 
of central veins and within sinuses surrounding central veins
* The scoring system for APAP-induced hepatotoxicity was applied (see Chapters 2 and 3).
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4.3.3 Investigation into the effect of EP pretreatment on APAP-induced hepatotoxicity 
and inflammation
The efficacy of EP in reducing inflammation and toxicity in the APAP-model was tested 
next. Pretreatment with EP conferred a significant decrease of serum HMGB1 levels in 
APAP-dosed animals at 24hr post APAP (74.99±19.56ng/ml) compared to mice treated with 
APAP alone (125.27±30.17ng/ml) (Figure 4.7). EP alone did not result in HMGB1 release 
(11.32±6.00ng/ml).
*
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Figure 4.7: The effect of EP pretreatment on APAP-induced HMGB1 release
HMGB1 was measured in fasted male C57BL/6 mice pretreated with saline or EP (40mg/kg), 
30min before administration of APAP (530mg/kg; 24hr) (- EP; black; + EP, grey). Mice were 
euthanized after 24hr. Data is given as mean ± SD of 4 mice per group. Statistical 
significance was assigned relative to respective controls with or without EP. *p < 0.05, **p< 
0.01, ***/?< 0.001.
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Pretreatment with EP caused no hepatotoxicity as assessed by serum ALT activity 
(17.07±7.24U/1) (Figure 4.8A) nor did it reduce APAP hepatotoxicity compared to APAP- 
treated mice given a predose of saline (3307.72±501.05U/1 and 3615.66±454.62U/1 
respectively). EP pretreatment did not alter hepatic GSH content compared to control 
(46.97±6.50nmol/mg). GSH content was lower in APAP-treated mice compared to control 
(35.51±4.03nmol/mg and 43.95±5.93nmol/mg respectively) although this reduction was not 
statistically significant. EP pretreatment did not cause any difference in GSH recovery after 
APAP overdose, with levels returning to control (38.12±5.58nmol/mg) (Figure 4.8B).
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Figure 4.8: The effect of EP pretreatment on APAP-induced hepatotoxicity
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
pretreated with saline or EP (40mg/kg), 30min before administration of APAP (530mg/kg; 
24hr) (- EP; black; + EP, grey). Mice were euthanized after 24hr. Data is given as mean ± SD 
of 6 mice per group. Statistical significance was assigned relative to respective controls with 
or without EP. ***p < 0.001.
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EP pretreatment (40mg/kg) caused no cytokine release into the serum (Figure 4.9). APAP 
(530mg/kg) caused a significant increase in the serum level of TNF-a (292.4l±32.68pg/ml) 
(Figure 4.9A), IL-6 (159.43±30.56pg/ml) (Figure 4.9B) and IL-lp (61.40±11.51pg/ml) 
(Figure 4.9C) at 24hr post APAP. Pretreatment with EP significantly decreased serum levels 
of APAP-induced TNF-a (215.96±17.46pg/ml) and IL-1(3 (28.15±7.26pg/ml) release after 
24hr. Serum IL-6 levels were not reduced with EP pretreatment at 24hr post APAP 
(170.18±20.83pg/ml).
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Figure 4.9: The effect of EP pretreatment on serum cytokine levels post APAP dose
Fasted male C57BL/6 mice were pretreated with saline or EP (40mg/kg), 30min before 
administration of APAP (530mg/kg; 24hr) and serum levels of TNF-a (A), IL-6 (B) and IL- 
1 p (C) were determined at 24hr post treatment (- EP; black; + EP, grey). Data is given as 
mean ± SD of 3 mice per group. Statistical significance was assigned relative to respective 
controls with or without EP. **/? < 0.01, ***/? < 0.001.
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The histological examination identified the typical APAP-induced changes in APAP-treated 
animals and confirmed that EP pretreatment does not have an effect on neutrophil recruitment 
into the liver after APAP-induced injury (Table 4.3).
Table 4.3: Histological findings after EP pretreatment on APAP treated mice. Male C57BL/6 
mice were pretreated with saline or EP (40mg/kg), 30min before administration of APAP 
(530mg/kg). Animals were examined 24hr after APAP treatment. The histological evaluation 
was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary Science, 
University of Liverpool). The listed findings represent a summary of the changes observed in 
each of 6 animals per group.
Treatment Score* 
[average |
Histological findings
Saline predose +
Saline
0 Diffuse glycogen; no histological abnormality is 
recognised
Saline predose +
APAP
2-5
[3.5]
No glycogen; centrilobular coagulative necrosis and 
apoptosis with hydropic degeneration of hepatocytes 
surrounding affected areas; some neutrophils in affected 
areas
EP predose +
Saline
0 Diffuse glycogen; no histological abnormality is 
recognised
EP predose +
APAP
2-5
[3.75]
No glycogen; almost diffuse hydropic degeneration 
(variable intensity); coagulative necrosis and apoptosis of 
remaining hepatocytes in affected areas; some neutrophils 
in affected areas
* The scoring system for APAP-induced hepatotoxicity was applied (see Chapters 2 and 3).
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4.3.4 Investigation into the effect of delayed administration of EP on APAP-induced 
hepatotoxicity and inflammation
The efficacy of EP on APAP-induced hepatotoxicity and inflammation when administered 
after the onset of toxicity in the APAP model was tested. Delayed treatment with EP 
(40mg/kg) significantly reduced serum HMGB1 levels in APAP-dosed animals 
(97.28±20.40ng/ml) compared to mice treated with APAP alone (154.01 ±23.95ng/ml) 
(Figure 4.10). EP alone did not result in HMGB1 release (11.65±5.10ng/ml).
* *
Saline APAP
Figure 4.10: The effect of delayed administration of EP on APAP-induced HMGB1 
release
HMGB1 was measured in fasted male C57BL/6 mice treated with saline or EP (40mg/kg), 
4hr after administration of APAP (530mg/kg; 24hr) (- EP; black; + EP, grey). Mice were 
euthanized after 24hr. Data is given as mean ± SD of 4 mice per group. Statistical 
significance was assigned relative to respective controls with or without EP. **/? < 0.01, ***/7 
<0.001.
143
Chapter 4
Delayed treatment with EP (40mg/kg) caused no hepatotoxicity as assessed by serum ALT 
activity (9.14±2.20U/1) (Figure 4.11 A). EP significantly reduced APAP hepatotoxicity 
compared to APAP treatment with a post dose of saline (2917.94±354.13U/1 and 
3441.89±380.05U/1 respectively). Delayed treatment with EP did not alter hepatic GSH 
content compared to control (44.52±3.75nmol/mg). GSH content was significantly lower in 
APAP-treated mice compared to control (36.38±6.10nmol/mg and 47.96±5.06nmol/mg 
respectively). Delayed treatment with EP did not cause any difference in GSH recovery after 
APAP overdose, with decreased levels observed similar to APAP-alone 
(32.45±5.77nmol/mg) (Figure 4.1 IB). The histological examination showed that delayed EP 
treatment does not have an effect on APAP-induced hepatotoxic changes and neutrophil 
recruitment into the liver 24hr post treatment (Table 4.4).
A I- EP B
*
50001
***^ 4000
* * *
® 3000
Saline APAP Saline APAP
Figure 4.11: The effect of delayed administration of EP on APAP-induced 
hepatotoxicity
Serum ALT (A) and hepatic GSH content (B) were measured in fasted male C57BL/6 mice 
treated with saline or EP (40mg/kg), 4hr after administration of APAP (530mg/kg; 24hr) (- 
EP; black; + EP, grey). Mice were euthanized after 24hr. Data is given as mean ± SD of 6 
mice per group. Statistical significance was assigned relative to respective controls with or 
without EP. *p < 0.05, **/? < 0.01, ***/? < 0.001.
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Delayed treatment with EP (40mg/kg) caused no cytokine release into the serum (Figure 
4.12). APAP (530mg/kg) caused a significant increase in the serum level of TNF-a 
(286.05±17.52pg/ml) (Figure 4.12A), IL-6 (224.44±26.91pg/ml) (Figure 4.12B) and IL-1(3 
(66.67±19.97pg/ml) (Figure 4.12C) 24hr post APAP dose. Delayed treatment with EP 
significantly reduced serum levels of APAP-induced TNF-a after 24hr (238.44±19.75pg/ml) 
whereas there was no significant reduction observed for IL-6 (190.70±17.02pg/ml) or IL-lp 
(46.67± 10.25pg/ml).
A *
Saline APAP
B
_ 200
150
_!i ioo
Saline APAP
c
100 I
Saline APAP
■ -EP 
□ + EP
Figure 4.12: The effect of delayed administration of EP on serum cytokine levels post 
APAP dose
Fasted male C57BL/6 mice were treated with saline or EP (40mg/kg), 4hr after 
administration of APAP (530mg/kg; 24hr) and serum levels of TNF-a (A), IL-6 (B) and IL- 
ip (C) were determined at 24hr post treatment (- EP; black; + EP, grey). Data is given as 
mean ± SD of 3 mice per group. Statistical significance was assigned relative to respective 
controls with or without EP. */? < 0.05, **/? < 0.01, ***/? < 0.001.
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Table 4.4: Histological findings after delayed administration of EP on EPS treated mice. 
Male C57BL/6 mice were treated with saline or EP (40mg/kg), 4hr after administration of 
APAP (530mg/kg). Animals were examined 24hr after APAP treatment. The histological 
evaluation was undertaken by Prof Anja Kipar (Veterinary Pathology, School of Veterinary 
Science, University of Liverpool). The listed findings represent a summary of the changes 
observed in each of 6 animals per group.
Treatment Score*
[averagel
Histological findings
Saline + 0 Diffuse glycogen; no histological abnormality is
EP post dose recognised
APAP + 2-4 Centrilobular coagulative necrosis and apoptosis; hydropic
EP post dose [3] degeneration of hepatocytes surrounding affected areas; 
some neutrophils in affected areas; no glycogen or rim of 
glycogen loss around affected areas
* The scoring system for APAP-induced hepatotoxicity was applied (see Chapters 2 and 3).
4.3.5 Investigation into the effect of HMGB1 neutralisation on APAP-induced 
hepatotoxicity and inflammation
To enable the evaluation of a pharmacological inhibitor of HMGB1 as a modulator of 
inflammation and toxicity, a standard model with complete inhibition of HMGB1 was 
required. The antibody-mediated neutralisation of the inflammatory potential of HMGB1 has 
previously been reported (Scaffidi et ah, 2002). This study was adapted and repeated in male 
CD-I mice. Treatment of animals with a neutralising antibody to HMGB1 resulted in 
complete inhibition of serum HMGB1 levels after APAP challenge compared with that 
observed in IgY-treated animals (Figure 4.13 A). There was significant reduction in the level 
of toxicity as assessed by serum ALT activity in the APAP + anti-HMGBl antibody group 
compared with the APAP + control IgY group (Figure 4.13B). In both APAP-treated groups 
significant elevation in the serum level of TNF-a was observed (Figure 4.13C); however, the 
level of TNF-a was greater in the control group receiving APAP + IgY (232.3±54.2pg/ml) 
compared with the APAP + anti-HMGBl group (121.0±16.7pg/ml). Mice treated with APAP 
+ anti-HMGBl also showed significant elevations in the serum level of IL-6 
(246.2±36.8pg/ml) (Figure 4.13D).
146
Chapter 4
B
D
350
300
— 250
E
g 200 
2 150
100 
50 
0
IgY Anti- APAP+ APAP +
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Figure 4.13: The effect of HMGB1 neutralisation on APAP-induced hepatotoxicity
Male CD-I mice were treated with an HMGB1-neutralising antibody or a control IgY 
antibody 2hr after APAP (530mg/kg) treatment. Serum HMGB1 content (A), serum ALT 
activity (B), serum TNF-a (C) and serum IL-6 levels (D) were measured at 24hr post 
treatment. Data is given as mean ± SD of 6 mice per group. Statistical significance was 
assigned between groups as appropriate. *p < 0.05, **/? < 0.01, ***/? < 0.001.
147
Chapter 4
4.4 DISCUSSION
EP has been shown to be an effective anti-inflammatory agent in a wide variety of in vivo 
and in vitro model systems of inflammation-mediated cellular or tissue injury, including 
severe sepsis, (Ulloa et al., 2002; Venkataraman et al., 2002), haemorrhagic shock (Yang et 
al., 2002; Cai et al., 2009), hepatic ischemia/reperfusion injury (Tsung et al., 2005), bacterial 
peritonitis (Ulloa et al., 2002; Su et al., 2007) and ethanol-induced acute liver injury (Yang et 
al., 2003). The molecular basis of EP action has previously been reported as interfering with 
signal transduction through the p38 MAPK and NF-kB signal transduction pathways and to 
target directly the p65 subunit of the transcription factor (Ulloa et al., 2002; Han et al., 2005). 
EP inhibition of the p38 MAPK and NF-kB signalling effectively prevents the release of 
early (TNF-a, IL-lp and IL-6) and late (HMGB1) inflammatory mediators. In a previous 
study by Ulloa et al. (2002), EP was shown to inhibit secretion of HMGB1 and improve the 
survival of mice in a model of endotoxaemia. The survival advantage was apparent when EP 
was administered 30min before EPS infusion, and when administered 24hr after the onset of 
disease.
The studies presented in this chapter were designed to test if EP can inhibit the release of 
both early (TNF-a, IL-lp and IL-6) and late (HMGB1) cytokines in our LPS and APAP 
models and subsequently, modulate the associated hepatotoxicity and inflammation. This was 
to be assessed alongside anti-HMGBl antibody treatment, which offers a standard to which 
complete inhibition of HMGB1 is observed. Also, in both models a pre- and delayed 
treatment of EP was investigated to see if either treatment had a greater modulatory effect on 
hepatotoxicity and inflammation. In the LPS model of inflammation, the levels of both early 
and late cytokines in the serum were increased in mice 24hr after LPS administration 
compared to control mice. The results were in accordance with the findings in Chapter 2. 
Pretreatment with EP significantly inhibited the release of HMGB1 in LPS dosed animals 
although it is worth noting that this was not a complete inhibition compared to the level of 
inhibition observed with the anti-HMGBl antibody. EP pretreatment also significantly 
reduced the serum levels of the cytokines TNF-a, IL-lp and IL-6 in LPS-treated mice. EP 
pretreatment had no effect on hepatotoxicity as assessed by serum ALT activity or hepatic 
GSH content. LPS alone did not cause hepatotoxicity or alter the level of GSH. Overall, the
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early dose of EP significantly reduced both the early and late acting cytokines released after 
LPS administration.
Following the early treatment of EP, the therapeutic efficacy of EP was next assessed when 
administered after the onset of endotoxaemia and inflammation. Treatment with EP was 
initiated 4hr after the onset of endotoxaemia, a time at which clinical signs of LPS-induced 
toxicity, including diarrhoea, piloerection and depressed activity were already evident. 
Similarly to the outcome of pre-treating with EP, delayed administration led to a significant 
decrease in serum HMGB1 but not complete inhibition. However, delayed treatment only led 
to reduction that was statistically significant for IL-1(3, not TNF-a or IL-6 serum levels. One 
possible explanation for this could be that EP was administered after an early peak in TNF-a 
and IL-6 levels, which has been seen to occur l-3hr after the onset of endotoxemia (Hesse et 
al., 1988; Taudorf et al., 2007). The histological examination confirmed the biochemical 
findings. There were no findings indicating that pre- or delayed treatment with EP had any 
effect on the LPS-induced changes, i.e. neutrophil recruitment into the liver and individual 
hepatocyte death.
The pre- and delayed EP treatment regime was repeated in the APAP model of hepatotoxicity 
and inflammation. As reported in the literature, inhibition of HMGB1 using an anti-HMGBl 
antibody modulated the inflammatory response associated with APAP. With HMGB1 
partially inhibited by EP in our LPS model, which also led to modulation of cytokine levels, 
it was hypothesised that EP could protect against APAP-induced hepatotoxicity. Pretreatment 
with EP resulted in a significant decrease in HMGB1 post APAP-dose. The inhibition, as 
with the LPS model, was not absolute when compared to using anti-HMGBl antibodies, 
however, a similar trend was observed regaining TNF-a and IL-6 serum levels. Both TNF-a 
and IL-lp serum levels were significantly lower in EP pretreated groups with APAP 
compared to APAP alone. IL-6 however, showed a slight increase although this was not 
statistically significant (Figure 4.9), The reduction of both early and late inflammatory 
mediators by pretreatment of EP suggests that EP had a prolonged effect after administration. 
This is supported by a study that showed pretreating mice with EP provided durable 
protection against some of the deleterious effects of LPS, even when the duration between the 
last dose of EP and the endotoxic challenge was 6hr (Sappington et al., 2003). Pretreatment 
with EP gave no protection in terms of APAP toxicity, as there was no significant decrease in
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serum ALT activity compared to APAP alone (Figure 4.8). Further investigation is required 
to deduce why an early dose of EP did not protect against APAP hepatotoxicity. As EP is 
widely accepted as a potent antioxidant and free-radical scavenger (Varma et al., 1998; Sims 
et al, 2001), and that antioxidant treatment has been shown to protect against APAP 
hepatotoxicity (Oz et al., 2004), it could be hypothesised that early treatment of EP could 
protect via its antioxidant and free radical scavenger activities. The lack of protection is 
furthermore of interest when considering that EP is a lipophilic compound and thereby can 
diffuse readily into cells, potentially acting on both intracellular and extracellular radicals.
Delayed treatment with EP significantly reduced HMGB1 in APAP-treated mice compared to 
APAP alone. There was a frend showing a decrease in APAP-induced cytokine release but 
only TNF-a was statistically significant. Delayed treatment with EP, however, conveyed 
significant protection to APAP toxicity. As treatment with EP began after the initial toxicity, 
the results suggest that the significant protection conveyed by EP may be due to it targeting 
the late acting mediator of inflammation as observed by the significant reduction in HMGB1, 
rather than the earlier acting cytokines. Thus, overall these studies indicate that EP can 
significantly inhibit the release of both early (TNF-a, IL-1(3 and IL-6) and late (HMGB1) 
cytokines that mediate inflammation and toxicity. Furthermore, delayed treatment with EP 
can protect against APAP-induced hepatotoxicity. The histological examination showed that 
both pre- and delayed treatment of EP did not have an effect on APAP-induced hepatotoxic 
changes and neutrophil recruitment into the liver as there was no obvious difference in the 
degree of inflammatory cell recruitment into the liver.
HMGB1 is regarded as a late mediator of inflammation, because its release during 
endotoxaemia is delayed in comparison with the rapid increase of early pro-inflammatory 
cytokines such as TNF-a, IL-6 and IL-1J3 (Wang et al., 1999; Ulloa et al., 2002; Ulloa et al., 
2003). The antibody-mediated neutralisation of the inflammatory potential of HMGB1 in a 
murine model of endotoxin lethality and protection has previously been reported (Wang et 
al., 1999). In this study HMGB1 increased in the circulation starting at 8hr, further increased 
until 16hr, and thereafter remained at a high level until 36hr during endotoxaemia. The 
administration of anti-HMGBl antibodies reduced lethality, increasing the survival rate to 
30% and conferring significant protection to a lethal dose of LPS. Likewise, we found that 
antibody neutralisation of HMGB1 in mice modulated the inflammatory response associated
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with APAP hepatotoxicity. These findings are in accordance with data reported in a model of 
APAP hepatotoxicity by Scaffidi et al. (2002). Anti-HMGBl administered 2hr after APAP 
completely abrogated the release of HMGB1 in mice, which was in parallel to a reduction in 
the level of hepatotoxicity as assessed by serum ALT activity and serum levels of TNF-a 
(Figure 4.13). However, the observed increase in IL-6 after anti-HMGBl treatment with 
APAP requires further investigation. One possibility is that HMGB1 sequesters the hepatic 
IL-6 by direct protein-protein binding. The binding of HMGB1 and the alteration of cytokine 
function has previously been described (Sha et al., 2008). The delayed kinetics of actively 
released HMGB1 could provide a wider therapeutic window during which anti-HMGBl 
antibodies or pharmacological inhibitors could be administered downstream of the initial cell 
damage and inflammatory response.
Investigating the level of protection afforded by completely inhibiting HMGB1 in APAP 
hepatotoxicity by using anti-HMGBl antibodies allowed us to compare the effects of 
partially inhibiting HMGB1 by a pharmacological agent such as EP. The complete inhibition 
of HMGB1 by neutralising antibodies gave greater protection against APAP hepatotoxicity 
compared to partial inhibition of HMGB1 provided by EP. Moreover, a significant reduction 
in serum ALT was observed when EP treatment was delayed to a point when toxicity had 
already occurred.
Together, these results suggest that EP may have therapeutic potential for APAP-induced 
hepatotoxicity along with other potential conditions mediated by the release of the 
proinflammatory cytokines TNF-a, IL-lp and IL-6 and HMGB1. Although not absolute, EP 
is an effective inhibitor of HMGB1 release in our in vivo models of LPS and APAP 
hepatotoxicity and inflammation. EP warrants further evaluation as it may have a therapeutic 
potential in the clinic for inflammation associated with APAP-induced hepatotoxicity. EP has 
been tested in human volunteers and shown to be safe at clinically relevant doses (Fink, 
2008). The consequence of HMGB1 signalling and its interaction with its receptors 
downstream of APAP-induced hepatotoxicity is another potential area of investigation to 
elucidate its role in the exacerbation of inflammation and toxicity.
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CHAPTER FIVE
INVESTIGATION INTO THE EXPRESSION OF RECEPTOR FOR ADVANCED 
GLYCATION END PRODUCTS (RAGE) DURING ACETAMINOPHEN-INDUCED
HEPATOTOXICITY
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5.1 INTRODUCTION
The immune system has evolved to respond not only to pathogens, but also signals released 
from dying cells. Severe injury to the liver, such as that induced by toxic doses of APAP, 
triggers a cascade of events leading to hepatic cell death. This initial cell stress or necrosis 
leads to the release of endogenous molecules such as SI00 proteins, DNA and HMGB1 into 
the extracellular milieu. These molecules then act as Damage-Associated Molecular Pattern 
molecules (DAMPs), inducing activation of intracellular signalling pathways via interaction 
with at least three pattern recognition receptors; TLR-2, TLR-4 and the receptor for advanced 
glycation end products (RAGE) (Park et al., 2004).
The RAGE protein is a cell-surface molecule belonging to the immunoglobulin superfamily 
(Neeper et al., 1992). Its biological activity appeal's to be mainly dependent on the presence 
of its various ligands, including Advanced Glycation End products (AGEs) (Neeper et al., 
1992; Schmidt et al., 1992), SI00 calcium binding protein/calgranulins (Hofinann et al, 
1999), amyloid-p-peptides (Du Yan et al, 1997) and HMGB1 (Hori et al, 1995), all known 
to be elevated in inflammatory diseases. RAGE is composed of three immunoglobulin 
domains located in the extracellular space, a single membrane spanning domain and a short 
cytoplasmic tail. RAGE exists as a full-length isofonn (flRAGE) that is bound to the 
membrane and has several isoforms including soluble forms deriving from alternate splicing 
(known as endogenous secretory RAGE or esRAGE) or from proteolytic cleavage of the 
membrane-bound forms (soluble RAGE or sRAGE). The full-length form of RAGE contains 
the intracellular cytoplasmic domain, which is necessary for RAGE signalling. sRAGE lacks 
both the membrane and intracellular’ domains and appears to function as a decoy receptor that 
neutralises circulating ligands, subsequently preventing RAGE overactivation (Bucciarelli et 
al, 2002; Wendt et al, 2006). RAGE is now recognised as a key player in modulating the 
innate immune response. Ligand engagement of RAGE leads to prolonged inflammation by 
induction of NF-kB and MARK kinases, resulting in RAGE-dependent expression of 
proinflammatory mediators such as cytokines and chemokines (Figure 5.1). RAGE-mediated 
signalling leads to the perpetuation of the initial signal both through de novo synthesis of p65 
subunits of NF-kB and a positive feedback effect on RAGE expression (Schmidt et al, 2000; 
Bierhaus et al, 2001).
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Figure 5.1: RAGE signal transduction pathways.
RAGE-induced signalling pathways. The engagement of ligands to RAGE results in the 
activation of a cascade of signalling pathways, including mitogen activated protein kinases 
(MARK), such as extracellular regulated kinase (ERK)-l/2, p38 and c-Jun N-terminal kinase 
(JNK), Jak/STAT, and members of the Rho GTPase signalling pathway (Cdc42 and Rac-1), 
which converge to the activation of nuclear transcription factors, including nuclear factor 
(NF)-kB, subsequently leading to gene activation and cellular effects. Activation of RAGE 
also leads to increased oxidative stress (adapted from Xu et al., 2003).
RAGE is highly expressed and associated with many inflammation-based pathological 
diseases such as atherosclerosis (Park et al., 1998; Wendt et al., 2003), cancer (Taguchi et al., 
2000), neurodegeneration (Yan et al., 1996; Yan et al., 1997) and diabetes (Wautier et al., 
1996; Park et al., 1998b). The current opinion regarding the role of RAGE in the 
pathogenesis of inflammation associated conditions is that RAGE-mediated inflammation is 
deleterious and therefore RAGE inhibition may be potentially beneficial. In order to further
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define a potential role of RAGE in immunity and inflammation RAGE signalling has been 
blocked or intercepted by using recombinant sRAGE and RAGE-deficient mice. Several 
studies investigating the role of RAGE in inflammatory diseases have used sRAGE to 
scavenge ligands in the extracellular space and prevent them Rom interacting with RAGE 
present at the cellular- membrane (Hofmann et ah, 1999; Taguchi et ah, 2000; Hou et ah, 
2004). In animal models of hepatic ischaemia and massive liver resection, administration of 
sRAGE increased survival (Zeng et ah, 2004; Cataldegirmen et al., 2005). The use of RAGE' 
/_ mice has also been demonstrated to have a protective effect in a model of caecal ligation 
puncture (CLP), where RAGE'7' mice were better protected from the lethal effects of septic 
shock than wild-type controls (Liliensiek et al., 2004).
Experimental studies have given rise to the discussion that RAGE and its interaction with 
HMGB1 contribute to the pathophysiology of inflammatory conditions. It has been 
demonstrated in animal models that RAGE and HMGB1 play a key role in inflammation and 
oxidative stress-induced tissue injury, where the use of RAGE"7' mice, sRAGE, 
pharmacological inhibitors and antibodies or peptides targeted at RAGE or HMGB1 attenuate 
the lethal effects of endotoxin, ischaemia-reperfusion and APAP (Yang et al., 2004; Zeng et 
al., 2004; Kokkola et al., 2005; Ekong et al., 2006; Lutterloh et al, 2007a; 2007b; Zhang et 
al., 2008). The study by Ekong et al. (2006) looked at the effect of blocking RAGE using 
sRAGE on survival, generation of oxidative stress and expression of proinflammatory 
cytokines after APAP administration. They hypothesised that RAGE activation contributes to 
the generation of oxidative stress and inflammation within the livers of mice subjected to a 
lethal dose of APAP. They found that blockade of RAGE led to increased survival and a 
reduction in oxidative stress in APAP-treated animals.
The observations from Chapter 4 and in the literature that administration of anti-HMGBl 
antibodies protected mice from sepsis lethality and APAP-induced hepatotoxicity (Wang et 
al., 1999; Scaffidi et al., 2002), and that blockade of RAGE could protect against APAP- 
induced hepatotoxicity (Ekong et al., 2006), suggests that the engagement of RAGE by 
HMGB1 may play an important role in mediating the pathogenic effects of HMGB1 during 
APAP-induced liver injury. Chapter 4 focused on the effect of inhibiting HMGB1 on APAP 
hepatotoxicity and inflammation, whereas the focus in this chapter is on the downstream 
signalling by HMGB1 via RAGE.
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Despite reports that RAGE is upregulated in the presence of its ligands, to the best of our 
knowledge, no data is currently available for comparison between RAGE expression in 
APAP-treated livers and normal tissue. The aim of this chapter was to evaluate the expression 
of RAGE in the tissues of APAP-treated mice and its relationship to the pathophysiology of 
APAP hepatotoxicity at the mRNA, protein and tissue level. Our hypothesis is that RAGE is 
upregulated in response to danger signals such as HMGB1 that are released by necrotic cells 
during APAP-induced hepatotoxicity.
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5.2 MATERIALS AND METHODS
5.2.1 Materials
Infinity ALT liquid kits were purchased from ALPHA Laboratories (Eastleigh, U.K). Unless 
otherwise stated, all other chemicals and materials were purchased from Sigma-Aldrich 
(Poole, U.K). RAGE antibodies (RAGE H-300 and RAGE C-20) were purchased from 
Santa-Cruz Biotechnology.
5.2.2 Experimental animals
The protocols described were in accordance with criteria outlined in a licence granted under 
the Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool 
Animal Ethics Committee. Animals were pm-chased from Charles River laboratories and had 
a 5 day acclimatisation period prior to experimentation. Animals were also maintained in a 
12hr light/dark cycle with free access to food and water.
5.2.3 Animal dosing regime
Male C57BL/6 mice (18-23g) were either fasted overnight with free access to water or had 
free access to food and water prior to experimentation. Mice (18-23g) were administered a 
single Ip. injection of APAP (530mg/kg) in 0.9% saline for 0-24hr. Control animals received 
0.9% saline. Treatment groups consisted of 4 individual animals.
5.2.4 Isolation of total RNA from murine liver tissue
For each sample approximately 50-100mg of liver tissue was placed in an RNase free 
microtube (1.5ml). 200j.il of Trizol Reagent was added to each microtube and using an 
eppendorf micropestle, the tissue was homogenised thoroughly. A further 800jal was added to 
each tube and the lysate was passed through a pipette tip to ensure homogenisation. The 
samples were then incubated at room temperature for 5min to permit dissociation of
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nucleoprotein complexes. 200pi of chloroform was then added to each tube, after which each 
tube was vigorously shaken by hand for 15sec. The tubes were left to incubate for 2-3min at 
room temperatm-e and then centrifuged for 15min (12,000 x g, 4°C) which separates the 
solution into an RNA-containing aqueous phase and an organic phase containing DNA and 
protein. 500pi of isopropyl alcohol was then added to the aqueous phase in a new tube and 
left to incubate at room temperature for lOmin. After which, samples were centrifuged for 
lOmin (12,000 x g, 4°C). The supernatant was discarded and 1ml of 74% EtOH was added to 
each tube, vortexed for 15sec and centrifuged for 5min (7,500 x g, 4°C). The supernatant was 
again discarded and the pellet was allowed to air dry for 5-10min. Finally, 44pl RNase-ffee 
H20 was added to each tube to dissolve the pellet. The resultant RNA was stored at -80°C 
until DNase treatment could be performed.
5.2.5 DNase treatment of isolated RNA
DNA-free kit (Ambion) was used to eliminate DNA contamination in RNA extracts. To each 
tube containing 44pl of RNA, 5 pi of lOx DNase buffer and Ipl of DNase I were added. The 
tubes were spim briefly (3,000rpm, lOsec) to reconstitute any bubbles and then placed on a 
heating block for 30min at 37°C. 5 pi of DNase inactivation reagent was added to each tube 
and agitated gently to mix. The tubes were incubated for 2min at room temperature and then 
centrifuged for Imin (14,000rpm at room temperature). The resultant supernatant was 
transferred into new RNase-ffee tubes (0.6ml) and stored at -80°C until Reverse 
Transcription (RT) could be performed. An aliquot of supernatent was used to quantify RNA 
on an ND 1000 spectrophotometer (Nanodrop).
5.2.6 Reverse transcription of isolated RNA
The ImProm-II reverse transcriptase kit (Promega) was used to produce cDNA from total 
RNA. 2.5pg of DNA-free RNA was incubated with Oligo (dT16) and nuclease-free H20 at 
70°C for 5min. The samples were put on ice and the remaining RT components were added: 
5x RT buffer, 25mM MgCl2, dNTPs, reverse transcriptase and nuclease-free H20. The 
samples were then incubated in a thermocycler for 5min at 20°C, followed by Ih at 42°C,
160
Chapter 5
then 15min at 70°C and held at 4°C. 200(11 of nuclease-free H2O was added to each tube and 
the cDNA was stored at -20°C until real time PCR could be performed.
5.2.7 Real time PCR of RAGE genes with SYBR Green
The mRNA sequence for RAGE was obtained at NCBI Nucleotide. Primers were designed 
using the PrimerB website and were blasted for specificity using the NCBI nucleotide blast 
database. Each primer set was designed to be between 18-22 bases, with a G/C content of 
60%, a Tm of around 60°C and with the desired amplicon being between 100 and 180 bases. 
The sequences of the primer used for each gene were:
Endogenous secretory RAGE forward: 
Endogenous secretory RAGE reverse: 
Total RAGE forward:
Total RAGE reverse:
Full length RAGE forward:
Full length RAGE reverse:
GAPDH forward:
GAPDH reverse:
5'-GATGAGGGCACCTATAGCTGC-3' 
5'-TCCAGTCCCTCACCTTCAGC-3' 
5'-GCTCTATGGGGAGCTGTAGC-3' 
5'-C AGTTTCCATTCTAGCTGCTGG-3' 
5'-AGGATGAGGAGGAACGTGC-3'
5 -GCTCTAGGGCCAT C AC ACAG-3'
5'-TGTCCGTCGTGGATCTGAC-3'
S'-CCTGCTTCACCACCTTCTTG-B'
The primers for each gene were custom synthesised by Eurofins MWG Operon. Real-Time 
PCR was performed using the SYBR Green JumpStart Taq ReadyMix kit (Sigma). Real- 
Time PCR reactions were set up in a thermo-fast 96-well detection plate to a final volume of 
25pi. lOpg of cDNA was added to individual wells with 2 x SYBR Green, ROX, nuclease- 
free H2O and 0.2pM of both forward and reverse primers for a specific gene. The 
thermocycler conditions of 95°C for 2min (1 cycle), 95°C for 15sec, 60°C for Imin (40 
cycles) and held at 4°C. RAGE and GAPDH transcripts were quantified relative to GAPDH 
using SYBR green reagents (Sigma) and the ABI prism 7000 Sequence Detection System 
(applied biosystems). Dissociation curves were set up to confirm that primer products were
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specific and that the SYBR Green fluorescence was a direct measure of accumulation of the 
product of interest.
5.2.8 Crude membrane isolation of murine whole liver tissue
Liver tissue (lOOmg) was washed twice in 1ml PBS then centrifuged at 2000rpm for lOmin. 
The supernatant was discarded and the pellet was resuspended in hypotonic lysis buffer 
(lOmM Tris pH 7.5, lOmM NaCl, ImM MgCL, ImM DTT and 1:500 protease inhibitor 
cocktail). The samples were frozen at -80°C then thawed out and left on ice (30-40min). The 
samples were then douce homogenised (50 strokes) and 2-fold hypotonic lysis buffer added. 
The samples were then spun down (500 x g, lOmin, 4°C). The low speed supernatant was 
transferred into a centrifuge tube and disrupted with a 25 gauge needle and syringe (x 20). 
The membrane was collected by centrifugation (53,000rpm, 60min) and resuspended in 
lOmM Tris pH 7.5 and protease inhibitor cocktail.
5.2.9 RAGE immunoblotting in murine whole liver membrane
Membrane protein (5pg) was denatured via the addition of loading buffer containing 70% 
(v/v) NuPAGE sample loading buffer, 30% (v/v) NuPAGE reducing agent and was incubated 
at 80°C for 5min. Samples were loaded onto 4-12% NuPAGE bis-tris gels and resolved with 
3-(N-morpholino)propanesulphonic acid (MOPS) and transferred to nitrocellulose 
membranes. Membranes were blocked with 10% (w/v) non-fat dried milk for 15min and then 
incubated overnight with a RAGE antibody (RAGE H-300, 1:2000 in 0.1% Tween-TBS with 
2% (w/v) non-fat (hied milk). Membranes were washed 3 times (5min/wash) with 0.1% 
Tween-TBS and incubated with an anti-rabbit secondary antibody conjugated to horse radish 
peroxidise for Ihr (1:10,000 in 0.1% Tween-TBS with 2% (w/v) non-fat dried milk). 
Immunoblots were visualised with western lighting chemiluminescence reagent and exposed 
to ECL Hyperfilm.
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5.2.10 Immunohistology for RAGE
3-5jum thick paraffin-embedded liver sections were dewaxed in xylene (2 x 5min) and then 
submersed twice in 100% EtOH (2min) and again in 96% EtOH (2min). Endogenous 
peroxidise was blocked (360ml MeOH and 6ml 30min) followed by two washes with 
water. For antigen retrieval, sections were then incubated with citrate buffer pH 6 for 30min 
in a water bath at 95°C then cooled on bench (15min), prior to a wash with dH20. Non­
specific antibody binding was blocked by incubation with normal horse serum (lOmin), 
followed by overnight incubation with the primary antibody, goat polyclonal anti-mouse 
RAGE C-20 (1:200 in TBS; Santa-Cmz Biotechnology). The sections were washed in TBS 
for 5min and then a horse anti-goat secondary antibody (biotinylated anti-goat IgG, 
Vectastain) was added (0.9pl in 100pi TBS). After 30min incubation, sections were washed 
for 5min in TBS before incubation for 30min with ABC (Vectastain ABC-kit). The sections 
were washed for 5min in TBS, and then rinsed 4 times in dH20 before incubation with 
diaminobenzidine hydrochloride (DAB; Fluka Analytical) for lOmin to develop. After 
incubation, the sections were washed in dH20 (3 x 5min) and then counterstained with 
Papancolaou’s haematoxylin (Merck) for Imin. The sections were rinsed under running tap 
water for 5min then dehydrated and cleared by a series of steps (96% EtOH for Imin, 100% 
EtOH for 2min, 100% EtOH for 3min, xylene for 2min, xylene for 3min, xylene for 3min), 
then mounted with DPX (BHD). Sections of lung from a control mouse served as a positive 
control for RAGE expression. Negative controls were represented by consecutive sections 
that were incubated without the primary antibody.
5.2.11 RAGE RNA in s/Yw-hybridisation
5.2.11.1 Polymerase chain reaction (PCR) for amplification of RAGE DNA
A 517-bp fragment for RAGE DNA was amplified with
RAGE forward (GAGGGAAGGAGGTCAAGTCC) Tm 61.4, GC 60% and
RAGE reverse (GGTGCACCATCCTTTATCCA) Tm 57.3, GC 50%
PCR was used to amplify DNA fragments for cloning. For cloning purposes the Expand High 
FidelityPLUS PCR System (Roche) was used. 50pi PCR mix contained 5 pi of lOx buffer 2, Ipl 
of lOpM dNTPs, 2pl of both forward and reverse primers (lOpM stock) and 2.5pi of 
template cDNA (50ng stock).
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5.2.11.2 Ligation of RAGE DNA into vector
Ligation of the insert/PCR product into pCRII-TOPO vector (Invitrogen) was carried out with 
a 4:1 insert-vector ratio. In a total reaction volume of 3pi, 2pi of insert, 0.5pi of vector and 
0.5pi of salt solution was used. The ligation was carried out at room temperature for 30min.
5.2.11.3 Cloning and transformation of RAGE DNA vector in bacteria
One Shot TOP 10 Chemically Competent E. coli cells (Invitrogen) were used for cloning and 
transformation purposes. Transformation of competent E. coli cells was carried out by 
thawing three tubes containing 50 pi of cells on ice and adding the entire ligation mix (3 pi) to 
one tube, 0.5pl of TOPO-vector to another and 0.5pl of pUC18 vector (positive control) to 
the third tube. The cells were gently shaken by hand before incubating on ice for 30min, heat 
shocked at 42°C for exactly 30sec and put on ice for Imin before 250pi of SOC medium was 
added to the tube. The cells were incubated at 37°C for Ihr at 250rpm in a shaking incubator, 
before 50pi and 150pl were plated on agar plates containing lOOpg/ml ampicillin and 
incubated at 37°C overnight. Colonies represent bacteria with ampicillin resistance and 
sufficient ligation of PCR product. Discrete colonies were dabbed with filtered pipette tips 
which were then dropped into 20ml sterilin tubes containing 2ml LB broth and supplemented 
with Ipg/ml ampicillin. The tubes were incubated at 37°C at 250rpm overnight in a shaking 
incubator. Small yield plasmid DNA preparations from 1.5ml bacterial cultures (Mini­
preparations) were done with the QIAprep spin Miniprep Kit (Qiagen) as per manufacturer’s 
instructions, to obtain high quality DNA. Large yield plasmid DNA preparations from 150ml 
bacterial cultures (Maxi-preparations) were done with the Qiagen plasmid Maxi Kit to 
prepare stocks of plasmid DNA.
5.2.11.4 Restriction enzyme digestion of RAGE DNA
Plasmid DNA was linearised by restriction enzyme digestion. Two separate reactions were 
set up using two different restriction enzymes for sense and antisense riboprobes, EcoRV (cut 
site 5’-GATAATC-3’) and Sad (cut site 5’-GAGCTAC-3’) respectively. For each reaction 
5pg plasmid DNA was added to 5 pi of the appropriate restriction enzyme, 5 pi of lOx
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restriction enzyme buffer and made up to a total volume of 50pl with ddH20. The reaction 
mix was incubated at 37°C for 2hi\
5.2.11.5 Phenol-chloroform extraction and ethanol precipitation of RAGE DNA
To remove salts and protein, template DNA was subjected to phenol-chloroform extractions 
followed by ethanol precipitations. An equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) was added to the DNA templates. The tubes were then vortexed vigorously and 
centrifuged at 14,000rpm at room temperature for Imin. The upper aqueous phase was 
transferred into a new tube and the steps repeated once more. An equal volume of 
chloroform:isoamyl was added and the tubes were again vortexed vigorously and centrifuged 
at 14,000rpm at room temperature for Imin with a fresh tube used for the upper aqueous 
phase. The DNA was precipitated with 1/10 volume of 3M NaOAc and 3x volume of ice cold 
100% EtOH. DNA was then precipitated by incubating at -20°C for Ihr or overnight 
followed by centrifugation for lOmin (14,000rpm, room temperature). The supernatant was 
discarded and the pellet was washed with an equal volume of 70% EtOH. The tube was 
centrifuged for lOmin (14,000rpm, room temperature), before the remaining EtOH was 
removed. The pellet was air-dried for lOmin and then dissolved in 30pi of MQ H20.
5.2.11.6 RAGE RNA probe preparation
The labelling of RNA was done by in vitro transcription using digoxigenin-ll-UTP as the 
label molecule. Ipg of linearised template DNA was added to an RNase-free tube and MQ 
H20 was added to make a final volume of 13 pi. DNA templates were mixed with lOx 
transcription buffer, RNase inhibitor, lOx NTP labelling mixture (lOmM ATP, CTP, GTP, 
6.5mM UTP, 3.5mM Digoxigenin-ll-UTP (pH 7.5)) and SP6 (sense) or T7 (antisense) 
RNase polymerase. The mixture was centrifuged briefly at 5,000 x g and then incubated at 
37°C for 2h. 2pl RNase-free RQ1 DNase was added with Ipl RNase inhibitor to digest the 
DNA template to leave purified RNA probes, and the mixture was further incubated at 37°C 
for 15min, The reaction was stopped by adding 0.2M EDTA. 1 mg/ml of yeast tRNA was 
added to the DNase digested probes, and the RNA was precipitated by addition of 1/10 
volume of 3M NaOAc pH 5.2 and 2.5x volume 100% EtOH. The mixture was incubated at -
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80°C for 30min then spun at room temperature for 20min. The supernatant was discarded and 
the pellet was washed with 70% EtOH followed by centrifugation for 5min at room 
temperature. The supernatant was then carefully removed and the pellet was air-dried for 
lOmin before being resuspended in 45 pi of nuclease-free H20. Alkaline hydrolysis was then 
used to generate a shorter probe from 500bp to 350bp. 5pi of 0.4M NaHCO3/0.6M Na2C03 
pH 10.2 was added to the probe and incubated for exactly 7min 48sec at 60°C. The mixture 
was neutralised by adding 5pi of 3M NaAc pH 4.6 and the previous ethanol precipitation and 
wash step was repeated. The pellet was air-dried for lOmin before being resuspended in 50pl 
nuclease-ffee H20. To test the efficiency of DIG labelling of the newly synthesised probe as 
series of dilutions were prepared using yeast tRNA as the diluent (1:10-1:100,000). 5pi of 
each dilution was spotted onto a nylon membrane (Amersham) and allowed to dry before 
cross linking using a UV Stratalinker. The membrane was incubated on a shaker in washing 
buffer (0.1M maleic acid, 0.15M NaCl, pH 7.5, 0.3% v/v Tween 20) for 2min and then 
blocked in blocking solution (lx blocking solution in maleic acid buffer) for 30min. The 
membrane was then incubated with an anti-digoxigenin antibody (Anti-DIG-AP, 1:5000 in 
blocking solution) for 30min. It was rinsed twice for 15min in washing buffer and then a 
further 3min in detection buffer (0.1M Tris HC1, 0.1M NaCl, pH 9.5), followed by 
incubation. The membrane was then incubated in 10ml of colour substrate BCIP/NBT tablets 
(1 per 10ml) in the dark without shaking until the colour precipitate formed and reached the 
required concentration. The reaction was stopped using 50ml TE buffer (lOmM Tris-HCl, 
ImM EDTA pH 8).
5.2.11.7 Pretreatment of murine liver tissue sections
In order to improve signal and reduce background, sections were subjected to several 
pretreatment steps before the hybridisation probes were applied, 3-5 pm thick paraffin- 
embedded liver sections were prepared on polylysine coated slides. They were dewaxed in 
xylene (2 x 5min) and then submersed twice in 100% alcohol (5min) and again in 96% 
alcohol in DEPC ddH2G (1 x 5min) followed by 70% alcohol in DEPC ddH2G (1 x 5min). 
The sections were then submersed in an autoclaved glass tank containing ddH20 with DEPC 
(5min) before being transferred into an autoclaved coplin jar containing ddH20 with DEPC 
(Imin). The sections were washed in lx PBS for 5min and then left to stand for 20min at 
room temperature in 0.2M HC1. After, the sections were washed twice with 2x SCC plus
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5mM EDTA at 50°C for 30min each and then incubated with proteinase K (1M Tris, 0.1M 
CaCl2, ddH20 with DEPC, proteinase K) at 37°C for 15min. The proteinase K reaction was 
stopped by washing slides in 0.2% glycine in PBS at room temperature for 5min. Slides were 
immersed in 4% PFA at room temperature for 4min and then washed twice in lx PBS for 
Imin. Slides were washed in lx PBS plus 5mM MgCl2 at room temperature for 15min. The 
sections were immersed into 0.25% acetanhydride in 0.1M triethanolamide (pH 7.5) for 
lOmin and then rinsed twice in lx PBS at room temperature for Imin each before washing in 
lx PBS at room temperature for 15min.
5.2.11.8 Hybridisation of RAGE riboprobe to murine liver tissue
Sections were treated with prehybridisation buffer-mix (prehybridisation buffer, RNA, 
ssDNA) for 1 hr at 52°C. The digoxigenin-labelled riboprobe was diluted 1:100 in 
hybridisation buffer-mix (hybridisation buffer, RNA, ssDNA, dextransulphate). 40 pi of 
probe/hybridisation mixture was added on each slide under a plastic coverslip to prevent 
evaporation then placed in a hybridisation chamber and incubated overnight at 37°C to allow 
the probe to hybridise to targets. The coverslip was removed and the sections were washed 
with a series of SCC with decreasing concentrations to further remove unbound probes. For 
this purpose the sections were rinsed twice in 6x SCC plus 45% formamide at 42°C for 
15min at a time then twice in 2x SCC at room temperature for 5min each and then washed 
twice in 0.2x SCC at 50°C for 15min each.
5.2.11.9 Staining of RAGE riboprobe signals
The slides were incubated in Buffer 1 (lOOmM Tris, lOOmM NaCl, ddH20, pH 7.5) for Imin. 
To prevent non-specific binding, sections were blocked in blocking solution (NSS, 10% triton 
X-100, Buffer 1) at room temperature for 30min. Slides were then incubated in blocking 
solution containing AP-conjugate antibody (Anti-DIG-AP) at the concentration of 1:200 at 
room temperature for 2hr. After incubation with antibody, sections were washed twice with 
Buffer 1 at room temperature for 15min before washing in Buffer 3 (lOOmM Tris, lOOmM 
NaCl, 50mM MgCl2.6H20, dd^O, pH 9.5) for 2min. The sections were then incubated with 
staining solution (Buffer 3 containing NBT, X-phosphate, levamisole). The development of
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the sections was followed using a microscope. The reaction was stopped by submerging the 
sections in Buffer 4 (lOmM Tris, ImM EDTA, ddH20, pH 8) and rinsing a few times in 
ddH20 for 5min. The sections were then stained using Papanicolaou’s haematoxylin 
counterstain for lOsec before bluing in tap water for 5min. The slides were dried by blotting 
on a clean paper towel before adding a drop of prewaimed (37°C) glycer-gel to the slides and 
covered using a coverslip. The slides were left to dry in the dark until analysis.
5.2.12 Statistical analysis
All results are expressed as mean ± standard deviation (S.D). Values to be compared were 
analysed for non-normality using a Shapiro-Wilk test. The impaired t-test was used when 
non-normality was indicated. A Mann-Whitney U test was used for non-parametric data. 
Comparisons between multiple groups were performed with one-way ANOVA followed by a 
post hoc Bonferroni test. All calculations were performed using SPSS statistical software, 
results were considered significant whenp<§.§5.
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5.3 RESULTS
5.3.1 Quantification of RAGE mRNA expression during APAP-induced hepatotoxicity
The expression of RAGE in the hepatic tissue of APAP-treated C57BL/6 mice was first 
evaluated at the mRNA level. Mice were either fasted or fed prior to administration of APAP 
(530mg/kg; 0-24hr). Purified mRNA from mouse lung encoding total RAGE as well as a full- 
length (flRAGE) and endogenous secretory isoform (esRAGE) was identified in RNA 
extracts from mouse livers and quantified using RT-PCR. RT-PCR analysis revealed a 
significant 3-fold increase of total RAGE mRNA post-APAP in fed mice at 3hr compared to 
the corresponding time-matched control (Figure 5.2A). In fasted mice, total RAGE mRNA 
increased after APAP-dose as early as Ihr (4-fold) and peaked at 5hr with an 8-fold increase 
over control levels (Figure 5.2B). In both fasted and fed mice, total RAGE mRNA levels had 
returned to normal by 24hr.
A B
Time (hr)
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Figure 5.2: Total RAGE mRNA expression in response to APAP-induced hepatotoxicity 
in fed and fasted mice
The level of total RAGE mRNA expression was assessed by RT-PCR. Male C57BL/6 mice 
were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 0-24hr) or 
0.9% saline. Results were normalised to the house-keeping gene, GAPDH and expressed 
relative to time-matched saline controls, using the comparative Ct method. Data is given as 
mean ± SD of 4 mice per group. Statistical significance was assigned relative to time- 
matched controls. **p < 0.01, ***/? < 0.001.
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The hepatic mRNA expression of the full-length RAGE isoform was determined next. In fed 
mice, flRAGE significantly increased 2.5-fold compared to saline control at 3hr and returned 
to control levels at both 5hr and 24hr time points (Figure 5.3A). In contrast to the findings in 
fed mice, flRAGE mRNA in fasted animals significantly increased at the earlier time point of 
Ihr (2.5-fold), continued to increase at 3hr (4.8-fold) and peaked at 5hr (5.2-fold) before 
returning to control levels at 24hr (Figure 5.3B).
A B
Time (hr)
* * *
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Time (hr)
Figure 5.3: Full-length RAGE mRNA expression in response to APAP-induced 
hepatotoxicity in fed and fasted mice
The level of full-length RAGE mRNA expression was assessed by RT-PCR. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 0-24hr) or 
0.9% saline. Results were normalised to the house-keeping gene, GAPDH and expressed 
relative to time-matched saline controls, using the comparative Ct method. Data is given as 
mean ± SD of 4 mice per group. Statistical significance was assigned relative to time- 
matched controls. *p < 0.05, ***p< 0.001.
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The final RAGE gene that was evaluated was the endogenous secretory isoform. In fed mice, 
there was a significant 1.8-fold increase in esRAGE mRNA at Ihr compared to saline control 
(Figure 5.4A). At 3hr, esRAGE had further increased and peaked (2.3-fold) before returning 
to control levels at 5hr and 24hr. In fasted mice, esRAGE mRNA also increased at Ihr, 
however, the increase was 2.5-fold greater when compared to fed mice (4.7-fold) (Figure 
5.4B). esRAGE mRNA further increased at 3hr (6.2-fold) and peaked at 5hr (11.2-fold), 
before returning to control levels at 24hr.
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Figure 5.4: Endogenous secretory RAGE mRNA expression in response to APAP- 
induced hepatotoxicity in fed and fasted mice
The level of endogenous secretory RAGE mRNA expression was assessed by RT-PCR. Male 
C57BL/6 mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 
0-24hr) or 0.9% saline. Results were normalised to the house-keeping gene, GAPDH and 
expressed relative to time-matched saline controls, using the comparative Ct method. Data is 
given as mean ± SD of 4 mice per group. Statistical significance was assigned relative to 
time-matched controls. **/? < 0.01, ***/? < 0.001.
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5.3.2 Quantification of RAGE protein during APAP-induced hepatotoxicity
The expression of RAGE protein in membrane fractions of whole liver was assessed by 
western blot analysis. Male C57BL/6 mice were either fed or fasted prior to administration of 
either APAP (530mg/kg) or saline and examined 0 to 24hr after dosing. On visual inspection 
of western blot analyses, and densitometric analysis, membrane expression of RAGE protein 
in APAP-treated livers in both fasted and fed mice appeared the same as that in livers from 
saline-treated controls at Ohr (Figure 5.5A and 5.5B). Similar* to the findings at Ohr, RAGE 
protein expression in APAP-treated livers of both fed and fasted mice appeared the same as 
that in the livers of the respective saline treated controls at 0.5hr (Figure 5.6A and 5.6B), Ihr 
(Figure 5.7A and 5.7B), 3hr (Figure 5.8A and 5.8B), 5hr (Figure 5.9A and 5.9B) and 24hr 
(Figure 5.10A and 5.1 OB). There appeared to be no significant change in level of RAGE 
protein expression as assessed by visual inspection and densitometric analysis of western blot 
analyses.
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Figure 5.5: RAGE protein expression at Ohr during APAP-induced hepatotoxicity in fed 
and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; Ohr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were carried out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
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Figure 5.6: RAGE protein expression at 0.5hr during APAP-induced hepatotoxicity in 
fed and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 0.5hr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were carried out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
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Figure 5.7: RAGE protein expression at Ihr during APAP-induced hepatotoxicity in fed 
and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; Ihr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were earned out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
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Figure 5.8: RAGE protein expression at 3hr during APAP-induced hepatotoxicity in fed 
and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 3hr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were carried out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
176
Chapter 5
Saline
1 r
RAGE
(45kD)
Ponceau i I t I \
APAP
JL
B
RAGE
(45kD)
Ponceau I I I in I I
Figure 5.9: RAGE protein expression at 5hr during APAP-induced hepatotoxicity in fed 
and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 5hr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were carried out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
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Figure 5.10: RAGE protein expression at 24hr during APAP-induced hepatotoxicity in 
fed and fasted mice
The level of RAGE protein expression was assessed by western blot analysis. Male C57BL/6 
mice were either fed (A) or fasted (B) prior to administration of APAP (530mg/kg; 24hr) or 
0.9% saline. Liver membrane extracts were prepared from frozen liver extracts. Ponceau 
stains were carried out to ensure equal loading. Data is given as mean ± SD of from 
densitometric analysis of individual animals (n=4). Statistical significance was assigned 
relative to respective time-matched control.
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5.3.3 Cellular expression and localisation of RAGE during APAP-induced 
hepatotoxicity
To address the cellular localisation of RAGE in the liver of APAP-treated mice, 
immunohistology and in RNA-situ hybridisation (RNA-ISH) were performed. The 
histological examination showed the typical APAP-associated centrilobular cell loss at 24hr 
post-APAP (530mg/kg). RAGE protein expression was seen in the cytoplasm of hepatocytes 
where it was generally weak, with strongest expression in hepatocytes in periportal areas. 
RAGE expression was patchy but appeared more intense in remaining cells in areas of 
centrilobular cell loss (Figure 5.11). This was often associated with a weak nuclear reaction 
in centrilobular apoptotic hepatocytes (Figure 5.1 IB). RAGE mRNA expression was 
represented by a nuclear/cytoplasmic signal in centrilobular apoptotic hepatocytes and in 
occasional endothelial cells (Figure 5.12). In animals at 3hr post APAP treatment, the RAGE 
protein and mRNA expression pattern and intensity was similar. In comparison, control livers 
at 24hr showed constitutive RAGE expression, represented by a variably intense, moderately 
granular cytoplasmic reaction in a large number of hepatocytes (Not shown). ISH revealed 
patchy and random distribution of RAGE mRNA, mainly around portal areas and in bile duct 
epithelial cells (Not shown).
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Figure 5.11: Immunohistological demonstration of RAGE protein expression at 24hr 
post APAP treatment
Male C57BL/6 mice were administered APAP (530mg/kg) and examined 24hr post dosing. 
RAGE expression is represented by finely granular to patchy cytoplasmic brown staining. A. 
Most intense expression is seen in intact hepatocytes surrounding areas of centrilobular cell 
loss. B. Apoptotic hepatocytes exhibit weak nuclear RAGE expression (arrow). CV: central 
vein.
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Figure 5.12: RNA in 5i/M-hybridisation for RAGE mRNA expression at 24hr post APAP 
treatment
Male C57BL/6 mice were administered APAP (530mg/kg) and examined 24hr post 
treatment. The RAGE signal is represented by a dark purple to black nuclear and cytoplasmic 
staining. Scattered individual hepatocytes (arrows) and scattered endothelial cells (arrow, EC) 
are positive. CV: central vein.
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5.4 DISCUSSION
RAGE is commonly associated and often cited as a molecule that can mediate and exacerbate 
inflammatory conditions. It is well known that in several pathological states such as diabetes, 
atherosclerosis and neurodegenerative diseases, RAGE expression is elevated in response to 
the increased level of its newly formed ligands such as AGEs, SlOO/calgranulins, amyloid-p- 
peptides and HMGB1 (Hofmann et al, 1999; Schmidt et al, 2001). As HMGB1 is released 
by necrotic cells during APAP hepatotoxicity, we reasoned that RAGE may be upregulated in 
the presence of this ligand. The aims of the experiments presented in this chapter was to 
provide evidence for the possible participation of RAGE in APAP-induced liver injury by 
analysis of hepatic expression of RAGE at the mRNA, protein and tissue level in our 
established model of APAP hepatotoxicity and inflammation.
RAGE is expressed both constitutively and inducibly in a wide variety of cell types such as 
vascular* smooth muscle cells, neurons, lung alveolar epithelial cells, endothelial cells and 
mononuclear phagocytes (Brett et al., 1993; Katsuoka et al., 1997). However, except for 
mouse lung tissue, where RAGE is abundant, a number of reports indicate that RAGE mRNA 
and protein are expressed at low or barely detectable levels respectively, in a variety of 
different cell types such as monocytes/macrophages, endothelial cells, smooth muscle cells, 
fibroblasts and neuronal cells (Brett et al., 1993; Bierhaus et al., 2005; Demling et al, 2006; 
Raucci et al., 2008). While basal levels of RAGE are seen to be low, these cells can be 
induced to express RAGE in conditions in which inflammatory mediators and ligands 
accumulate (Huttunen et al., 1999). Despite its very low expression level, the ubiquitously 
expressed RAGE has been reported to mediate HMGB1 signalling responses by a number of 
cell types, including macrophages, myoblasts and neutrophils (Kokkola et al., 2005; Riuzzi et 
al., 2006; Muhammad et al., 2008; van Zoelen et al., 2009). RAGE has been seen to increase 
in the presence of HMGB1 in mouse embryonic fibroblast cells (Penzo et al., 2010). Also, a 
recent study showed that macrophage expression of RAGE mRNA is upregulated in response 
to conditioned medium containing HMGB1, collected 24hr after treatment of mouse 
hepatocytes with APAP (Dragomir et al., 2011). To the best of our knowledge, there have 
been no reports that determine the expression of RAGE in vivo in situations such as APAP- 
induced liver injury.
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RAGE mRNA expression was compared in our fasted and fed APAP model over a time 
course of APAP treatment (530mg/kg) ranging from 0-24hr, similar to the APAP time course 
studies performed in Chapter 2. The comparison of the dietary state of mice was employed as 
the findings in Chapter 2 showed that fasted mice were more susceptible to the toxic effects 
of APAP due to increased bioactivation and subsequently invoked a greater inflammatory 
response (Figure 2.11 and 2.12 respectively). It was hypothesised that the greater the 
inflammatory response, the more likely it would be that RAGE would be induced and 
subsequently expressed. Real-time PCR experiments were performed with a set of RAGE 
PCR primers that would detect all RAGE mRNA isoforms (total RAGE), full-length RAGE 
and endogenous secretory RAGE in whole liver preparations of mice. Total RAGE mRNA 
expression was upregulated in fed mice in response to APAP treatment compared to saline 
treated controls at 3hr. The time points before and after 3hr showed no upregulation and 
remained at basal levels. However, in fasted mice, total RAGE mRNA upregulation occurred 
at an earlier time point of Ihr and continued to increase until 5hr, suggesting a more 
prolonged induction (Figure 5.2). Next, the expression of the full-length RAGE isoform was 
assessed. flRAGE is bound to the cell membrane and contains the cytosolic domain that 
appears essential for intracellular signalling (Huttunen et al, 1999). flRAGE mRNA 
expression in fed animals exhibited a similar trend to that observed with total RAGE in that 
upregulation occurred at only the 3hr time point. Fasted animals also continued the trend in 
which upregulation of flRAGE occurred earlier at Ihr and was sustained imtil 5hr where the 
expression levels had peaked (Figure 5.3). Finally the expression of endogenous secretory 
RAGE mRNA was determined. esRAGE is a variant that encodes a secreted form lacking the 
transmembrane and cytosolic domains, which appeal's to function as a decoy receptor that 
neutralises circulating ligands. Upregulation of esRAGE mRNA expression in fed mice 
occurred at Ihr, earlier than that observed with total and full-length RAGE, and continued to 
increase at 3hr. After 3hr expression went back to basal levels. In fasted mice, the familiar 
trend of total and full-length RAGE was observed with expression increasing at Ihr and 
continuing to increase until 5hr, in which peak upregulation occurred (Figure 5.4).
The time course dynamics of each of the RAGE isoforms in response to APAP may be 
explained when comparing alongside the toxicity and inflammation dynamics established in 
the APAP model in Chapter 2. In fed animals, toxicity occurred at 3hr post APAP-dose along 
with a trend of increasing serum inflammatory cytokines levels (Figure 2.9 and 2.10). At this
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point upregulation of total RAGE, flRAGE and esRAGE occurred. However, toxicity and 
cytokine levels persisted at both 5In’ and 24hr whereas RAGE mRNA expression in all three 
forms had returned to basal levels. In fasted mice, toxicity also occurred at 3hr but at a 
greater level than in fed (Figure 2.11). Similarly, serum levels of cytokines increased at this 
time point and were also at a greater level in fasted animals than in fed (Figure 2.12). The 
level of expression of RAGE mRNA exhibited the same trend as the fold increase of each 
RAGE form was much greater in fasted animals than in fed at the equivalent time points. 
These results suggest that RAGE mRNA is upregulated to a greater level in more pronounced 
toxic and inflammatory conditions, however the physiological or pathological role of RAGE 
in APAP-induced liver injury may be mediated through complex inteiplay between the 
RAGE isoforms, and may not be mediated solely by full-length RAGE. flRAGE was reported 
to be the most predominant form of RAGE (Kalea et ah, 2009) and is responsible for 
producing sustained cellular activation. The presence of more flRAGE presumably results in 
greater and more sustained signalling through the flRAGE receptor. In this scenario, esRAGE 
may be upregulated in response to APAP toxicity to act as a negative feedback mechanism, to 
stop ligands interacting with full-length RAGE and therefore suppressing overexpression and 
continuous perpetuation of inflammatory signalling.
In contrast to the mRNA data, RAGE showed a different protein expression pattern as shown 
by western blot analysis in isolated membrane fractions of livers in APAP-treated mice. At 
each of the time points post APAP-dose there was no upregulation or change in expression 
levels of RAGE protein. Basal levels of RAGE protein could be detected in control animals at 
each time point and there was no difference between them and time-matched APAP-treated 
groups. The full extent of RAGE expression has yet to be fully deciphered. It is known 
however, that the frill-length form of RAGE may be proteolytically cleaved proximal to the 
membrane to generate a soluble form of RAGE (sRAGE) that will have the same decoy 
capacity as esRAGE (Raucci et ah, 2008). Ectodomain cleavage, also known as ‘shedding’ 
regulates the functions of many membrane-bound proteins (Schlondorff et al., 1999; Huovila 
et ah, 2005; Garton et al., 2006; Reiss et al., 2006). The proteases responsible for shedding 
belong to the family of metalloproteases, in particular, the ADAM (a disintigrin and 
metalloproteinases) family. Generally, shedding occurs constitutively but can be induced by 
ligand binding (Raucci et al., 2008). Moreover, binding of HMGB1 has been reported to 
promote RAGE shedding (Raucci et al., 2008). The RAGE antibody used in this investigation
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detected full-length RAGE only, with no evidence for cross-reactivity to other forms of 
RAGE as the western blot data showed only one band with a molecular weight of 45kD. 
Further investigation would be required to monitor sRAGE levels in the serum, as sRAGE 
may be shed dining APAP hepatotoxicity and thereby would not be detected in membrane 
fractions of the liver using a flRAGE specific antibody. It has also been demonstrated that 
RAGE can be internalised by engagement of its ligands. A study by Sevillano et al. (2009) 
showed that binding of RAGE with its ligand AGEs led to internalisation and that this 
process was needed for the generation of intracellular responses mediated by AGEs. So far it 
is unknown if internalisation of RAGE via HMGB1 is required to generate an intracellular 
response but evidence exists that RAGE is internalised with HMGB1-DNA complexes (Tian 
et al., 2007). Internalisation of membrane-bound RAGE may prevent its detection by western 
blot analysis, however if RAGE is concurrently being upregulated then any change in the 
level of surface RAGE may not be detected. Together, these results could be a valid reason 
why there was no observable difference in RAGE protein expression and why there was no 
correlation between mRNA and protein expression. HMGB1 alone may promote the increase 
and upregulation of RAGE levels by direct interaction but may also help maintain the balance 
of cell surface RAGE levels simultaneously subject to rapid depletion by HMGB1 
engagement resulting in RAGE shedding and internalisation. The physiological and/or 
pathological factors that regulate shedding and internalisation of flRAGE in vivo require 
further examination.
Both immunohistological and in situ detection of RAGE protein and mRNA confirmed 
constitutive RAGE production in the liver, which was mainly seen in hepatocytes. Expression 
was highly variable and often patchy, but also appeared random in control mouse livers. 
There was evidence of upregulation in degenerating cells post APAP treatment. An 
interesting finding seen with immunohistology was that RAGE protein was found to be 
localised in the nucleus of apoptotic hepatocytes post APAP treatment. This finding requires 
further investigation to determine if this is a functional response by cells to sequester RAGE 
in the nucleus of hepatocytes following APAP hepatotoxicity to prevent further inflammatory 
signalling, thereby acting as a negative feedback loop to prevent prolonged inflammation.
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The contribution of RAGE activation to APAP hepatotoxicity has been touched upon 
previously in one study (Ekong et aL, 2006). The authors found that blockade of RAGE using 
sRAGE led to increased survival and a reduction in oxidative stress in APAP-treated animals. 
However, the full extent of RAGE expression and the molecular mechanisms that control it 
have not been evaluated adequately. Gaining further knowledge about the molecular 
mechanisms underlying RAGE and esRAGE regulation may provide new diagnostic and 
therapeutic options to pursue the reduction of RAGE-mediated exacerbation of APAP- 
induced liver injury. Continuation of this work to elucidate the contribution of RAGE in 
APAP toxicity, such as use of RAGE'7' mice and antibodies and pharmacological inhibitors 
targeted at neutralising RAGE may provide a clearer picture and a novel approach to 
reducing APAP hepatotoxicity.
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6.1 Background
Drug-induced liver injury (DILI) has proven to be a major problem for both the 
pharmaceutical industry and regulatory authorities and is the most frequent cause for 
withdrawal of approved drugs and attrition of drug development (Lazarou et al., 1998; 
Jaeschke et al., 2002; Pinnohamed et al., 2004). The key to predicting and preventing DILI is 
by having a thorough understanding of all the underlying mechanisms. The overall aim of the 
work presented within this thesis was to explore the mechanism of inflammation associated 
with DILI with the ultimate aim of applying these findings to further understand the various 
inflammatory pathways during DILI and their contribution to the progression of liver injury. 
Figure 6.1 shows a general overview of the mechanisms of inflammation associated with 
DILI, highlighting the intracellular’ mechanisms that have been explored in this thesis. These 
were investigated by;
• Developing suitable models of DILI and inflammation. The characterisation of these 
animal models in Chapter 2 enabled their use in further studies presented in chapters 
3, 4 and 5 with the aim to assess the effect of modulating certain parts of the 
inflammatory pathway associated with DILI such as leukocyte infiltration and 
signalling (Chapter 3), signalling by dying hepatocytes and immune cells (Chapter 4) 
and the receptors associated with these danger signals (Chapter 5). Collectively, the 
models provided useful experimental systems for the investigation of the underlying 
mechanisms of DILI-associated inflammation. Also, the effect of fasting on APAP- 
hepatotoxicity and inflammation was addressed.
• Evaluating the contribution of the innate immune response in the pathogenesis of 
APAP-induced liver injury. The APAP model was employed in Chapter 3 to identify 
the role DMSO played in modulation of leukocyte accumulation as well as using 
aspirin as a pharmacological inhibitor of the Nalp3 inflammasome in our models of 
hepatotoxicity and inflammation that were established in Chapter 2. This work served 
to assess the potential of aspirin as a modulator of the inflammatory response in our 
models by its reported effect on the Nalp3 inflammasome in neutrophils.
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• Exploring the downstream signalling events triggered by DILI and by LPS exposure. 
The work conducted in Chapter 4 investigated the potential protective effect of 
inhibiting early (TNF-a, IL-6 and IL-lp) and late (HMGB1) inflammatory cytokines 
in our APAP and LPS models. This was investigated using ethyl pyruvate (EP) as a 
pharmacological inhibitor of these cytokines and the outcome was compared to the 
effects of complete HMGB1 inhibition by the use of an anti-HMGBl antibody.
• Evaluating the expression of the HMGB1 receptor RAGE in the tissues of APAP- 
treated mice. The work in Chapter 5 was conducted with the intent to deduce its 
relationship to the pathophysiology of APAP hepatotoxicity as the expression of 
RAGE was investigated in our APAP model at the mRNA, protein and tissue level 
using RT-PCR, Western blot analysis, immunohistology and in situ hybridisation.
The work undertaken was to assess the contribution of inflammation towards DILI by 
targeting certain points in the signalling pathway between dying hepatocytes and cells of the 
innate immune system. Further investigation of this mechanism of inflammation associated 
with DILI will aid the development of effective methods of therapeutic intervention and 
assessment of novel mechanisms by understanding the relationship between inflammation 
and toxic outcome.
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Figure 6.1: Schematic overview of the inflammatory pathway during DILI and sterile 
inflammation.
Drugs or chemicals cause cell injury and necrosis, which results in the release of cellular 
contents including DNA, RNA, and proteins (HMGB1). These DAMPs, can bind to innate 
immune cells, triggering cytokine and chemokine production. Innate immune cells can then 
be activated and/or recruited to the liver where they produce pro- and anti-inflammatory 
mediators, ROS and acetylated HMGB1. Signalling of HMGB1 through receptors RAGE and 
TLRs can lead to prolonged inflammation and subsequent liver damage. Signalling through 
RAGE can lead to a positive feedback loop in which the RAGE signal is maintained and 
amplified. Orange highlighted boxes represent mechanisms and factors that have been 
explored in this thesis either by modulation or measurement.
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6.2 Animal models of DILI-associated inflammation
Currently, sufficient data to support an unequivocal role for inflammation in DILI for drugs 
are lacking, and mechanistic details are unknown. Evidence to support the hypothesis that 
DILI triggers the activation of the innate immune system within the liver has been obtained 
from experimental in vivo models. The advantages of investigating inflammation in animal 
models of DILI are the stable genetic, molecular and immunological backgrounds of inbred 
strains. This lack of valuation, compared to the clinical situation, enables a more complete 
exploration and determination of possible inflammatory mechanisms contributing to the 
overall pathophysiology downstream from drug metabolism or accumulation. Several 
different models of DILI in which inflammation has been modulated have been investigated 
in an attempt to dissect the processes of inflammation from those of direct drug-induced 
hepatocyte cell death. However, the use of different strains of mice, species, compounds and 
the varying doses and pretreatments in in vivo models in the literature, have led to conflicting 
reports regarding the role that the inflammatory response plays in the pathogenesis of DILI, 
most notably, in APAP-induced liver injury.
The initial studies presented within this thesis were designed to define a set of in vivo models 
of DILI that could produce an inflammatory response which could be assessed and 
characterised by a chosen set of observable or measurable parameters. The use of these 
models in this thesis allowed for the investigation of various inflammatory pathways during 
DILI and by modulating these pathways, their contribution to the progression of liver injury 
could be examined. Primarily the development of an APAP model that could consistently 
provide reproducible levels of toxicity and inflammation was the main focus, so that further 
studies involving modulation of inflammation could be compared back to the original model 
as well as comparisons to other models of hepatotoxicity and inflammation with different 
mechanistic pathways. LPS was used as a systemic innate immune system activating agent, to 
produce a potent inflarmnatory response without causing hepatic cell damage, while two 
model hepatotoxins, APAP and GalN were utilised to produce combinations of toxicity and 
an inflammatory response. Both APAP and GalN provide a toxicological endpoint in an 
integrated animal model and require metabolic activation to initiate toxicity, however, there is 
a biochemical difference in the initiation of hepatotoxicity between APAP and GalN as 
APAP hepatotoxicity requires GSH depletion but GalN toxicity does not (Mitchell et al.,
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1973b; Decker and Keppler, 1974). High doses of GalN are known to cause hepatic necrosis 
by UTP depletion, leading to inhibition of RNA synthesis (Decker and Keppler, 1974). GalN 
was chosen as a model hepatotoxin as it has been frequently used to induce experimental 
liver injury (Keppler et al., 1968), has a different mechanism of toxicity to APAP and has 
been shown to produce an inflammatory response (Strachlewitz et al., 1999). Using these 
different agents was aimed at generating multiple models so we could characterise the type of 
immune and inflammatory activation that APAP caused and then compare with both LPS and 
GalN. This would give mechanistic data to help understand the nature of the immune 
response to APAP. APAP-induced liver injury is a widely studied model of DILI in mice and 
has been extensively used to investigate the involvement of inflammation. Table 6.1 shows a 
general overview of the inflammatory models used in APAP hepatotoxicity and highlights 
just how many different models have been used to determine the role of inflammation with 
APAP. The use of different doses of APAP, along with different strains and genetic 
backgrounds of mice has made it difficult to fully define an inflammatory response or the 
subsequent role it plays in DILL Once validated, the APAP model used in this thesis 
produced relatively consistent levels of toxicity and inflammation, reducing variability 
between studies. Also, in an attempt to further reduce variability the C57BL/6 mouse strain 
was chosen due to its inbred background and common use in the literature for APAP, LPS 
and GalN investigations (Bahrami et al„ 1994; Nowak et al., 2000; Masubuchi et al., 2003; 
Liu et al., 2004; Liu et al., 2006; Bourdi et al, 2007; Maddox et al, 2010; Zurita et al, 2010).
The comparison of the toxicological response to APAP and GalN is important as both 
compounds initiate toxicity via different mechanisms, as mentioned previously, and this was 
reflected by the level of inflammation induced by each. Both compounds were used as tools 
to induce a specific response. The results generated by dose response studies in Chapter 2 has 
shown that APAP and GalN induced dissimilar1 levels of a toxicological response and that 
LPS caused no toxicity, but all three agents resulted in an inflammatory response. The GalN 
model was characterised by mild hepatocellular1 death and moderate inflammation whereas 
APAP produced a more severe pattern of hepatocellular1 death and a systemic inflammatory 
response. LPS, despite apparent lack of toxicity, not inducing hepatocyte cell death induced a 
potent systemic inflammatory response as characterised by cytokine release into the serum. 
This supports findings in the literature that no hepatotoxicity was observed in mice that 
received LPS alone (Maddox et al,, 2010). Administration of LPS induces systemic
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inflammation characterised by the production of a range of cytokines (Wong et al., 2000). 
LPS has been used more as an adjuvant to DILI in recent studies, as it has been shown that 
mice treated with an inflammatory dose of LPS became more sensitive to APAP-induced 
liver injury. LPS co-administration caused a leftward shift in the dose-response curve for 
APAP hepatotoxicity, causing normally nontoxic doses of APAP to become hepatotoxic 
(Maddox et al., 2010). The inflammation produced in this model is likely to have been by 
activated immune cells rather than the release of inflammatory contents by damaged or dying 
hepatocytes. Having an inflammatory model based predominantly on activation of the innate 
immune system as opposed to cell damage enabled the investigation of the mechanism of 
inflammation by means of modulating the inflammatory pathway and apportioning the level 
of toxicity associated caused by inflammation or the direct deleterious effect of the model 
hepatotoxins.
The conflicting reports in the literature regarding the role of the inflammatory response 
induced by APAP could also be a consequence of fasting experimental animals. Previous 
literature reports using histology noticed that a common feature in mice fasted prior to 
investigation of the APAP-induced inflammatory response was the inability of these mice to 
recover from APAP damage at 24hr (Bourdi et al., 2002; Liu et al., 2006). Moreover, within 
the investigations in Chapter 2, fasted animals responded differently to non-fasted animals 
post APAP with a much greater toxicological and inflammatory response observed, 
suggesting that fasting caused animals to be more susceptible to toxic agents and 
subsequently more inclined to induce a greater inflammatory response. Fasting of animals 
can profoundly affect the toxicological response by decreasing hepatic GSH (Shimizu et al., 
1992), and ATP (Lee et al., 1988), altering CYP450 expression (Hu et al., 1995) and 
downregulating gene expression associated with apoptosis (Bauer et al., 2004). Further 
investigations are required to fully determine why fasting prior to experimental DILI elicits a 
greater inflammatory response in animals. One hypothesis is that fasting causes a shift 
towards necrosis as the predominant mode of cell death as fasting leads to depletion of 
inftacellular ATP, inhibiting the energy-dependent process of apoptosis (Kim et al., 2003). 
Increasing the level of necrosis would lead to the release of more inflammatory signals and 
mediators, promoting a greater inflammatory response. By considering the dissimilar 
toxicological and inflammatory responses to APAP in fasted and fed mice, the results in 
Chapter 2 highlight important implications for the planning and execution of mechanistic
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inflammatory studies in in vivo models. Work carried out previously by Antoine et al. (2010) 
supports the current finding in this thesis that fasting promotes the induction of inflammation 
by a more severe toxicological response. This is advantageous in models designed to evaluate 
and measure inflammatory outputs, however, caution is required when interpreting results in 
fasted animals when studying biological and physiological mechanisms leading to cell death 
and organ failure. This is further highlighted when considering that the ultimate goal of 
animal models is the prediction of human DILI during drug development (Dixit and 
Boelsterli, 2007). A combination of factors in the literature, such as fasting mice, using 
different doses of APAP and using different strains and genetic backgrounds of mice could 
offer an explanation for the controversy and inconsistency in reports for the role of 
inflammation in APAP-induced liver injury. Therefore the initial aim in this thesis was to 
produce a set of in vivo models that could aid further investigations involving modulation of 
inflammatory pathways, including a consistent and reproducible model of APAP-induced 
liver injury and inflammation.
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Table 6.1: Summary of inflammatory models used in APAP-induced hepatotoxicity.
References Inflammatory model(s) Reported effect
Ju et al., 2002; KC depletion Protection against liver injury at early
Goldin et al, 1996 time points, more susceptible at later 
time points
Liu et al, 2006 Neutrophil depletion Significantly protected against liver 
injury
Liu et al, 2004 NK/NKT cell depletion Significantly protected against liver
injury
Blazkaet al, 1995 Anti-TNF-a/IL-1 -a/IL-1 ra Increased susceptibility to liver injury
Isliida et al, 2004 Anti-TNF-a,TNF-p55 
receptor l"7" mice
Reduced mortality and liver injury
Chiu et al, 2003 TNFRl-7" mice Increased susceptibility to liver injury
Ishida et al, 2002 IFN-y"7' mice Significantly protected against liver
injury
Masubuchi et al,
2003
IL-6"7" mice Increased susceptibility to liver injury
Bourdi et al 2007 IL-10/4/6''’ mice Significantly protected against liver
injury
IL-10/4'a mice Increased susceptibility to liver injury
Yee et al, 2007 IL-13'7' mice Increased susceptibility to liver injury
Imaeda et al, 2009 Anti-TLR9, TLR9"7', Nalp3‘
7" mice
Reduced mortality and liver injury
Williams et al, 2011 Nalp3‘7’ mice No protection against liver injury
Ekong et al, 2006 Soluble RAGE Reduced mortality and liver injury
Maddox et al, 2010 LPS Increased susceptibility to liver injury
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6.3 Immune cell infiltration and modulation
Growing evidence suggests that the innate immune system can contribute to the severity and 
progression of DILI for certain drugs through the production of cytokines and recruitment of 
inflammatory cells into the liver downstream from cell damage (Blazka et al., 1995; Laskin et 
ah, 2003; Ishibe et al., 2009). The controversy regarding the role of the innate immune 
system in the overall pathogenesis of DILI stems from conflicting literature reports 
concerning the importance of various leukocyte populations for the progression and 
exacerbation of APAP induced liver injury (Liu et al, 2006; Masson et al, 2008). It is 
important to better understand the mechanisms by which cells of the immune system are 
activated and recruited into the liver during drug-induced hepatotoxicity and how these cells 
cause hepatocellular injury. One of the aims of this thesis was to modulate the recruitment 
and signalling of imiate immune cells during drug-induced toxicity and assess the relative 
contribution of these immune cells to liver injury.
The pathological role of NK/NKT cells in a murine model of APAP-induced liver injury was 
reported to be secreting IFN-y, modulating chemokine production, accumulation of 
neutrophils, and up-regulating FasL expression in the liver, all of which may promote the 
inflammatory response of liver imiate immune system (Liu et al, 2004). It was also reported 
in the same study that depletion of these cells in the liver exerted a protective effect against 
APAP hepatotoxicity by substantially reducing the formation of cytokines (notably IFN-y), 
chemokines and neutrophil recruitment. However, it was later determined that the presence of 
DMSO as a solvent in these studies activated NK and NKT cells, which does not occur 
without DMSO (Masson et al, 2008). It was found that DMSO used in these initial studies 
increased the activation of these NK/NKT cells and that their depletion did not affect APAP 
hepatotoxicity unless the cells were activated by DMSO prior to APAP. One of the studies 
carried out in this thesis was designed to evaluate the effect of DMSO on infiltrating immune 
cells in our- APAP animal model and if this affected the progression of APAP hepatotoxicity. 
The results generated in Chapter 3 showed that the APAP model demonstrated a 
toxicological response consistent with that seen in Chapter 2. APAP, when administered 
concurrently with DMSO, showed a complete inhibition of toxicity at 24hr but when DMSO 
was administered 2hr or later after APAP, the level of toxicity was significantly reduced. 
Moreover, DMSO demonstrated a dose dependent reduction in APAP toxicity when
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administered concurrently. The primary effect of DMSO in our APAP model was inhibition 
of toxicity, likely due to the inhibition of APAP bioactivation by DMSO as there was no 
hepatic GSH depletion when a high dose of DMSO (1 mg/ml) was administered concurrently 
with APAP. These findings are in support of literature evidence that report that high levels of 
DMSO can have an inhibitory effect on CYP450 metabolism and toxicity (Park et ah, 1988; 
Lind et al., 2000; Dunphy et ah, 2007), as APAP bioactivation is dependent on CYP450 
enzymes (Dahlin et al., 1984; Raucy et al., 1989; Thummel et ah, 1993). The study by 
Masson et al. (2008) did not confirm whether DMSO had an impact on APAP metabolism. 
Overall, the results presented in Chapter 3 suggest the effect of DMSO on exacerbation of 
APAP-toxicity by recruitment of inflammatory cells is minimal as the inhibitory effect of 
DMSO on the enzymatic bioactivation of APAP and subsequent reduction of hepatotoxicity 
is more prominent when DMSO is administered concurrently with APAP. These results are 
supported by a previous study in that high doses of DMSO inhibit metabolic activation of 
APAP, resulting in protection against APAP hepatotoxicity (Jaeschke et ah, 2006b). The use 
of DMSO to facilitate the dissolution of compounds in studies involving the hepatic immune 
system must be carefully considered, due to the ability of DMSO at high doses to inhibit 
bioactivation of compounds requiring CYP450 enzymes.
The pathogenic role of neutrophils has been established in cases of liver disease such as 
ischaemia-reperfusion mediated liver injury (Jaeschke et ah, 2003b; Hasegawa et ah, 2005), 
alcoholic hepatitis (Bautista., 1997), obstructive cholestasis (Gujral et ah, 2003b) and a- 
naphthylisothiocyanate (ANIT) toxicity (Hill et ah, 1999; Xu et ah, 2004). However, the 
evidence for the involvement in DILI has been limited to a few examples, such as halothane 
(You et al., 2006), concanavalin A (Bonder et ah, 2004) and a-naphthylisothiocyanate (Dahm 
et ah, 1991). Neutrophils have been implicated as having an active role in the pathogenesis of 
APAP hepatotoxicity in mice (Ishida et ah, 2006; Liu et ah, 2006), where depletion of 
neutrophils in mice led to reduced toxicity and improved survival. However, many other 
studies do not support a relevant contribution of neutrophils to exacerbation of liver injury. 
Recently, it was implied that neutrophil infiltration, partially mediated by IL-ip, could 
exacerbate liver injury after APAP (Imaeda et ah, 2009). The inflammatory pathway 
investigated in this study was the Nalp3 inflammasome that regulates activation of caspase-1 
that in itself regulates formation of IL-lp, leading to neutrophil recruitment and a subsequent 
inflammatory response. The investigators reportedly reduced APAP-induced liver injury by
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using gene knockout mice of each component of the inflammasome and also aspirin as a 
pharmacological inhibitor. However, the role of neutrophils in progression of APAP 
hepatotoxicity has been contested (Bauer et al, 2000; Lawson et al, 2000; Cover et ak, 
2006). It was suggested that even though neutrophil accumulation occurred in the livers of 
APAP-challenged animals, they did not contribute to the initiation and progression of APAP 
hepatotoxicity (Lawson et al., 2000). One of the studies performed in this thesis was to test if 
modulation of inflammatory cell recruitment by using aspirin as a pharmacological inhibitor 
in our APAP, GalN and LPS models of inflammation, could affect the levels of inflammation 
and toxicity and elicit protection. The aim being that aspirin may be a potential therapeutic 
tool in protecting against inflammation associated with APAP hepatotoxicity and other drugs 
associated with DILI. The results of these studies presented in Chapter 3 suggest that aspirin 
was ineffective in our APAP, LPS and GalN models at reducing the level of toxicity and 
inflammation and conferred no protection. However, these studies alone provided no 
evidence for inhibition of the Nalp3 inflammasome, but a collaborative study recently 
published also looked at the genetic elimination of the Nalp3 inflammasome as well as 
pharmacological inhibition of Nalp3 with aspirin in APAP-treated mice, found the same 
ineffective outcome with aspirin, and that elimination of the Nalp3 inflammasome did not 
protect against APAP hepatotoxicity (Williams et al., 2011). The data presented in Chapter 3 
strongly supports recent literature evidence and the conclusion that the activation of the 
Nalp3 inflammasome and subsequent involvement of neutrophils has no relevant impact on 
APAP hepatotoxicity and therefore may not be a viable therapeutic target to treat APAP 
overdose. However, confirmation of these results in the human pathophysiology is required 
before dismissing this as a therapeutic tar-get in APAP overdose patients. Caution must be 
exercised in translating this concept to man with respect to aspirin acting as a 
hepatoprotective agent against APAP-induced liver injury,
6.4 Effect of modulation of HMGB1 on DILI and inflammation
The release of damage-associated molecular- pattern (DAMP) molecules from damaged or 
dying cells following injury has been well described (Bianchi et al., 2007; Martin-Murphy et 
al., 2010). DAMPs that have been reported to be released in response to APAP hepatotoxicity 
are heat shock proteins (HSPs), DNA and HMGB1 (Jahr et al., 2001; Scaffrdi et al, 2002;
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Martin-Murphy et aL, 2010). HMGB1 can be passively released by necrotic cells in a hypo- 
acetylated form in the context of experimental DILI (Antoine et ah, 2009), or secreted by 
activated macrophages in a hyper-acetylated form (Bonaldi et ah, 2003). Both forms have 
been detected in the plasma after an overdose of APAP (Scaffidi et ah, 2002). Increased 
levels of serum HMGB1 have also been demonstrated in patients with APAP- and non- 
APAP-induced acute liver injury (Craig et al., 2011). Once released, HMGB1 can act as a 
potent inflammatory mediator which has been shown to link the necrotic cell death of 
hepatocytes to the inflammatory response (Scaffidi et al., 2002), by targeting TLRs (Yu et al., 
2006) and RAGE (Kokkola et al., 2005). It was therefore hypothesised that HMGB1 is an 
important modulator of inflammation and APAP-induced liver injury and that its inhibition 
may be a key to improving clinical outcomes.
The studies carried out in Chapter 4 involved using ethyl pyruvate (EP) as another potential 
pharmacological inhibitor of DILI and inflammation. EP is a potent antioxidant and free- 
radical scavenger and has been reported to be an effective anti-inflammatory agent in a 
variety of in vitro and in vivo model systems (Fink et al., 2007). EP was shown to inhibit 
LPS-induced NF-kB activation in cultured RAW264.7 murine macrophage-like cells, and 
reduces HMGB1 release and TNF-a gene expression both in vitro and in vivo (Sims et al., 
2001; Ulloa et al., 2002; Yang et al., 2002b). One of the studies presented in this thesis was to 
see if EP could reduce inflammation in both our LPS and APAP models and if it could 
subsequently protect against APAP hepatotoxicity by potentially modulating early (TNF-a, 
IL-6 and IL-1[3) and late (HMGB1) cytokine release. The effects of EP on APAP toxicity and 
inflammation were compared to those seen using an anti-HMGBl antibody in an APAP 
model.
Pretreatment with EP significantly reduced the release of HMGB1 in both LPS and APAP 
models, however, it was not complete inhibition compared to the level of inhibition observed 
with the anti-HMGBl antibody. EP pretreatment also significantly reduced LPS and APAP- 
semm cytokine release. However, despite the reduction in both HMGB1 and cytokine 
release, pretreatment with EP gave no significant protection in terms of APAP hepatotoxicity. 
This finding requires further investigation to deduce why the early dose of EP did not protect 
against APAP hepatotoxicity when EP is known to have antioxidant and free-radical
200
Chapter 6
scavenging properties. EP is a potent antioxidant and free-radical scavenger (Varma et al., 
1998; Sims et al., 2001), with antioxidant treatment reported to protect against APAP 
hepatotoxicity (Oz et al, 2004). EP had no effect on APAP-mediated hepatic GSH depletion 
in our APAP model. EP is lipophilic, thereby diffusing readily into cells, potentially acting on 
both intracellular and extracellular radicals. Also, EP is a stable derivative of pyruvate, 
potentially leading to prolonged effects of this compound after administration. This was 
confirmed by a study showing pre-treatment of mice with EP provided durable protection 
against some of the deleterious effects of LPS, even when the duration between the last dose 
of EP and the endotoxic challenge was 6hr (Sappington et al., 2003), This fact rules out the 
possibility of EP being rapidly eliminated and subsequently having insufficient levels to 
affect the release of late-appearing cytokines post LPS or APAP dose. Further studies 
conducted in Chapter 4 involved a delayed treatment of EP in the LPS and APAP models, to 
study if any pharmacological effects of EP can persist after waiting for a prolonged period 
(4hr) after the dose of LPS or APAP. The results showed that delayed treatment of EP 
conferred a significant reduction in HMGB1 release but not in the release of early cytokines 
in both LPS and APAP-treated animals. Delayed EP treatment, however, conveyed 
significant protection to APAP toxicity. A limitation of this work in these models is that the 
form of HMGB1 released is undetermined. As it has been shown that EP reduces actively 
released HMGB1 (Ulloa et al., 2002), a future study that incorporates mass spec analysis of 
HMGB1 in our models is required to show that the cell death released form of HMGB1 
(hypoacetylated) is not altered by EP. These findings could be accounted for by the fact that 
treatment began after the initial toxicity and early peak in cytokines, and that the protection 
by EP may be due to it targeting the late acting mediator of inflammation, HMGB1 and not 
by having an antioxidant effect early during APAP bioactivation. It is also worth noting that 
the protection against APAP hepatotoxicity was greater in anti-HMGBl treated animals that 
completely inhibited HMGB1, compared to the partial inhibition of HMGB1 by EP.
EP warrants further evaluation as it may have a therapeutic potential in the clinic for 
inflammation associated with APAP-induced hepatotoxicity. EP is likely to have a lower 
propensity to be harmful to humans, with its close similarity to the endogenous metabolite 
pyruvate, its safety profile in animals and its common use as a food supplement in humans. 
EP has been tested in human volunteers and shown to be safe at clinically relevant doses 
(Fink, 2008). Most importantly, from a clinical standpoint EP appears to have beneficial
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effects when it is administered after toxicity has become well established after APAP 
overdose. Overall, EP may be a useful adjuvant to other treatments for DILI, by targeting the 
inflammatory signalling pathway and thereby potentially protecting against the 
inflammatory-mediated exacerbation of liver injury.
6.5 Expression of RAGE in APAP hepatotoxicity
The observations in Chapter 4 and in the literature suggest that HMGB1 signalling may be an 
important factor in the progression of APAP-induced liver injury by activation of the immune 
response (Scaffidi et al., 2002). Chapter 4 focused on the release of HMGB1 and the 
therapeutic potential of blocking this signalling pathway. Downstream from this, 
experimental studies have given evidence that the interaction of HMGB1 with its receptor 
RAGE, contributes to the pathophysiology of inflammatory conditions. RAGE exists as a 
full-length isoform (flRAGE) that is bound to the membrane and as a soluble form derived 
from alternate splicing (esRAGE). RAGE is commonly associated and often cited as a 
molecule that can mediate and exacerbate inflammatory conditions such as diabetes, 
atherosclerosis and neurodegenerative diseases as ligand engagement of RAGE leads to 
prolonged inflammation by induction of NF-kB, resulting in RAGE-dependent expression of 
proinflammatory mediators. It is well known that RAGE expression is elevated in response to 
the increased level of its ligands and has the potential to perpetuate inflammation by a 
positive feedback effect on RAGE expression (Schmidt et al., 2000).
One of the aims of this thesis was to evaluate the expression of RAGE in the tissues of 
APAP-treated mice and its potential relationship to the pathophysiology of APAP 
hepatotoxicity. The results of a 24hr APAP time course study in Chapter 5 showed that in fed 
mice, RAGE mRNA of total, full-length and endogenous secretory forms of RAGE increased 
between Ihr and 3 hr, with basal levels of each form observed at preceding and later time 
points. A change in expression of RAGE mRNA was observed in fasted mice, with a more 
prolonged increase in expression of the three isoforms culminating in a peak of expression at 
5hr. A possible explanation for these findings is linked to the effect of fasting on 
inflammation observed in Chapter 2, in that fasted animals had a greater inflammatory 
response during APAP hepatotoxicity. These results suggest that the level of expression of
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RAGE mRNA increases in more pronounced toxic and inflammatory conditions. The 
pathological role of RAGE in APAP hepatotoxicity may be mediated through a complex 
interplay between the RAGE isoforms. The presence of more flRAGE presumably results in 
greater and more sustained signalling through the flRAGE receptor, whereby esRAGE may 
be upregulated in response to this to act as a negative feedback mechanism as esRAGE can 
act as a decoy for RAGE ligands and thereby inhibit the signalling pathway, suppress 
overexpression of flRAGE, and perpetuate inflammation. In contrast to the results of the 
expression of mRNA, RAGE showed a different pattern of expression with respect to protein. 
There was no difference in expression of RAGE protein between control and APAP-treated 
animals at any of the time points post APAP-dose. As the flRAGE form has been shown to be 
proteolytically cleaved to generate a soluble form (Raucci et al., 2008) and that the 
membrane-bound RAGE can be internalised (Sevillano et al., 2009), it could be that changes 
in RAGE expression at the protein level are not detected. As the dynamics of RAGE mRNA 
and protein turnover are not yet folly established, further investigation is needed, however, it 
is worth noting that analysis at the mRNA level does not always correlate well with changes 
in protein levels (Greenbaum et al., 2003).
The full extent of RAGE activation and expression in response to APAP hepatotoxicity 
requires further investigation in order to accurately evaluate the contribution of RAGE in the 
overall pathogenesis of APAP hepatotoxicity. The down-regulation of RAGE expression or 
blockade of RAGE downstream signalling may be a promising target for therapeutic 
intervention. There is evidence supporting a role of RAGE in the pathogenesis of APAP 
hepatotoxicity as it was shown that its inhibition by sRAGE resulted in increased survival and 
a reduction in oxidative stress in mice (Ekong et al., 2006). Further evaluation of the 
therapeutic potential of RAGE is required, however, the potential for inhibiting RAGE- 
mediated inflammation in human cases of DILI exists.
6.6 Perspectives on research and future investigations
The rationale of the work undertaken in this thesis was to provide further evidence for the 
role of inflammation during DILI using a variety of in vivo models. Support for the 
hypothesis that immune cells can play a critical role in drug-induced hepatotoxicity is
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steadily growing. There is increasing evidence to support that in many cases, the effects of 
drugs on cells within the liver can act as an initiating event for an immune response that can 
determine the overall extent of liver injury. Therefore, it is important for a greater 
understanding of the mechanisms by which cells of the innate immune system are activated 
and recruited into the liver during DILI and how they exacerbate the overall pathogenesis. 
The work presented in this thesis was aimed at using the current knowledge collected from 
the literature to develop a set of in vivo models that could be used to assess both basic and 
novel mechanisms of inflammation, with the aim of testing potential therapeutic strategies. 
Table 6.2 summarises the various models, therapies and mechanisms that were developed 
and/or assessed within this thesis.
Table 6.2: Overview of inflammatory models, therapies and mechanisms assessed within this 
thesis.
In vivo models of
inflammation
Potential therapies 
(Inhibitors)
Novel mechanisms
- APAP - Aspirin - RAGE expression
- GalN - Anti-HMGBl antibody - RAGE in nucleus
- LPS -EP
- Fasting
Aims Aims Aims
- Test mechanisms of 
inflammation
- Test potential therapies
- Assess new mechanisms
- Translate to human risk
assessment?
- Test/probe mechanisms
- Assess inflammatory 
suppressors
- Assess new mechanism
Our current knowledge of the mechanisms of DILI is that initial hepatocyte damage leads to 
downstream events such as the activation and recruitment of immune cells, release of 
inflammatory cytokines and chemokines and also initiation of an adaptive immune response. 
An effective way towards a greater understanding of these molecular and cellular mechanistic 
events is by developing animal models of DILI that incorporate many of the inflammatory
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pathways. The murine model of APAP hepatotoxicity has been widely studied to gain insight 
into the mechanisms of DILI as it has similar characteristics to human patients based on 
clinical, biochemical and histological observations (Hinson et al., 1981; Ishida et al., 2002). It 
has been shown that the concordance of hepatic toxicities between animals and humans is 
-50% (Olson et al., 2000) therefore, the development of models that more accurately 
represent the human physiological situation is required. APAP was used as a primary model 
of DILI in this thesis to evaluate the inflammatory response with the prospect that any 
observations could be translated to man. GalN and LPS were also used as models as both 
could induce a specific response. GalN was characterised as inducing part hepatotoxicity, part 
inflammation, whereas the LPS model had no hepatotoxic component but was mainly 
systemic inflammation. These models, when compared to APAP gave a wider view on the 
mechanisms of inflammation, which allowed for further exploration with regards to potential 
inhibitory mechanisms in later studies. APAP and GalN, served as useful models that could 
represent both a toxicological and inflammatory response in man, while the LPS model 
served as a positive control for inflammation, in which a potent systemic inflammatory 
response could be observed. The limitation of the LPS model is that it does not represent 
DILI in man, as it is a model of sepsis and endotoxaemia, but has been extensively used in 
rodent studies as a model to investigate innate immune mechanisms (Salojin et al., 2006; 
Roger et al., 2009; Wang et al., 2010). The models used in this thesis have given a broad 
spectrum for the evaluation of proinflammatory activity, each having a different mechanism 
of action for producing inflammation.
Some of the mechanisms explored in this thesis using these models were based on immune 
cell recruitment and signalling. Based on accumulating evidence in the literature, immune 
cells can play an important role in the progression of most but not all cases of DILI. While it 
is widely regarded that neutrophils play a detrimental role in conditions such as ischaemia- 
reperfiision or cholestasis (Gujral et al., 2003b; Jaeschke et al., 2003b; Hasegawa et al, 
2005), there has been controversy regarding their role in APAP hepatotoxicity (Bauer et al., 
2000; Lawson et al., 2000; Cover et al., 2006). While mouse models have been extensively 
used to dissect the mechanism of inflammation, it must be taken into consideration that there 
are differences between the innate immune system of mice and humans (Mestas et al, 2004; 
Fairbaim et al., 2011). An example of the differences can be highlighted by the cellular 
constituents of the blood, where 50-70% of the population of peripheral blood cells in
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humans is neutrophils but only 10-25% in the mouse (Doeing et ah, 2003; Mestas et al., 
2004). It is therefore important to consider that the results and conclusions of the mechanisms 
of inflammation drawn from these mouse models need to be investigated further and 
translated in DILI patients before therapeutic interventions can be successfully detennined. 
Preclinical in vivo models that incorporate inflammatory cells are critical to address all 
aspects of DILI. The work undertaken in this thesis aimed to address this by modulating 
immune cell recruitment and signalling. The evaluation of proinflammatory cytokine 
production is useful in assessing an inflammatory response as they can be easily measured in 
the serum. The limitation to evaluating these cytokines in the senun is that their release is not 
restricted to specific cells. Serum biomarkers that monitor the function of specific cells such 
as neutrophils and macrophages need to be identified and established in models of DILL 
DAMPs such as HMGB1 have potential as a biomarker of inflammation as the acetylated 
form is released from activated immune cells (Bonaldi et al., 2003). An improvement to the 
models used in this thesis would be to incorporate the measurement of HMGB1 alongside the 
existing cytokine and histopathological analysis. Evaluation of liver histopathology along 
with standard clinical pathology markers of liver injury currently represents the most reliable 
method for the assessment of hepatotoxicity in standard toxicology studies (Olson et al., 
2000). However, inconsistencies when comparing ALTs to histological findings were evident 
in some of the studies presented in this thesis. The need for biomarkers that better represent 
histological findings is evident. HMGB1 is a non-organ specific biomarker of necrosis and 
inflammation and is a potential non-invasive biomarker that correlates to histopathology 
(Antoine et al., 2009). Future investigations should incorporate the measurement of HMGB1 
alongside clinical chemistry parameters and histological assessment.
The need for improved animal models of DILI that more closely resemble the human 
physiological situation is evident. An increased understanding of the biological mechanisms 
of inflammation associated with DILI and their relevance to humans should lead to increased 
use and application of data from animal models to human health risk assessments. 
Developing models that use perturbed animals may more accurately predict and determine 
human risk. For example, the use of fasted animals in this thesis may represent a more 
clinically relevant model with respect to DILI and inflammation in human patients. The 
nutritional state of patients was shown to be an important factor in APAP hepatotoxicity 
(Whitcomb et al., 1994), where fasting enhanced the prospects of liver injury associated with
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therapeutic doses of APAP. Indeed, the results presented in Chapter 2 support this finding as 
APAP hepatotoxicity was greater in fasted animals compared to non-fasted. Fasting can 
decrease intracellular GSH, increasing the overall susceptibility to APAP toxicity (Pessayre 
et al., 1979). This situation can resemble human conditions in which malnutrition is 
associated such as chronic alcoholism and anorexia. An alcoholic or individual suffering 
from anorexia nervosa may already have reduced GSH levels in the liver and may therefore 
be at increased risk of developing toxic liver injury with APAP (Riordan et al„ 2002; Zenger 
et al., 2004). In these particular cases, the impact of fasted animal models on the mechanism 
of APAP-induced liver injury and the resulting inflammatory response may closely resemble 
the human situation and could have important implications in translating the results to the 
clinic and in the risk assessment for humans. Another perturbed animal model to take into 
consideration utilises LPS co-administration with hepatotoxic agents to induce an 
inflammatory background. In these models, LPS exposure induces a mild inflammatory 
response that can synergistically augment hepatotoxicity in the presence of hepatotoxic drugs, 
usually at non-injurious doses. Examples where this has been demonstrated include LPS-co- 
administration with APAP (Maddox et al., 2010) and GalN (Lawson et al., 1998). The 
mechanisms of these models are similar in which LPS-generated inflammation can lead to 
recruitment and activation of neutrophils in the liver, triggering exacerbation of injury. The 
relevance of these models to man is that the presence of inflammation may influence the 
pathogenic outcome of chemical exposure. Patients suffering from pre-existing inflammatory 
conditions or bacterial or viral infections may be at higher risk of developing hepatotoxicity 
at therapeutic doses of particular drugs. This model can mimic the inflammatory episodes that 
can occur in man and has the potential to aid human risk assessment although further 
investigation is required. LPS-co-administration would be a useful additional model to the 
work earned out in this thesis and should be considered for future investigations into 
mechanistic studies of DILI. The application of these perturbed animal models to human risk 
assessment will require interpretation of the data with respect to its relevance to humans, as 
well as recognition of the limitations of these models but overall could provide a more 
physiologically relevant model to human DILL
To further understand the activation of the innate immune system in response to DILI, the 
interaction between extracellular signals such as DAMPs and receptors must be addressed. 
Using the variety of models developed and characterised in this thesis, further exploration of
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these signalling pathways was conducted by testing potential therapies that target a specific 
part of the inflammatory pathway. Various agents were used to modulate either immune cell 
recruitment or their signalling, with the aim to determine if they could provide protection 
against DILL Aspirin and EP were selected as pharmacological inhibitors due to reports in 
the literature of their effects at modulating inflammation (Ulloa et ah, 2002; Imaeda et ah, 
2009). Also, as both are safe for human consumption, there was the potential to translate any 
beneficial effect to the clinic. Overall it was determined that aspirin had no significant effect 
on inflammation in our models, with no notable protection to DILI. These results were 
supported by a recent study by Williams et al. (2011). A potential future investigation to 
consider may involve changing the route of administration of aspirin, as well as delaying 
treatment until after hepatotoxicity is evident, as pretreatment in the drinking water for 3 days 
before drug treatment at a range of doses had no effect. Delaying treatment of aspirin may be 
more clinically relevant as pretreatment would not be feasible for intentional or non- 
intentional overdose patients. EP had a more promising outcome, as both pre- and delayed 
treatment resulted in a significant reduction in HMGB1 release. Mass-spec analysis is 
required to confirm that the HMGB1 being inhibited in our models is the acetylated fonn 
which is actively released by immune cells. Delayed treatment of EP appeared to reduce the 
level of APAP hepatotoxicity as determined by ALT activity, suggesting that EP could be a 
potential therapeutic treatment in APAP hepatotoxicity. It should be noted that EP treatment, 
compared to the effects of the more specific anti-HMGBl antibody was less effective in 
reducing toxicity. Further studies should be targeted towards testing a range of hepatotoxic 
agents with EP to see if there is a similar outcome. A limitation to the modulatory studies in 
this thesis was that, anti-HMGBl antibody aside, the pharmacological treatment strategies of 
aspirin and EP were not specific to the targets for which they were intended. While the off- 
target effects of these agents need to be investigated, the lack of specificity could result in 
poor efficacy if translated to the clinic.
One of the aims of the thesis was to investigate the novel mechanism of RAGE expression 
during APAP hepatotoxicity. In summary, RAGE interaction with its ligands leads to an 
inflammatory response resulting in RAGE-dependent expression of proinflammatory 
mediators and upregulation of RAGE by a positive feedback loop (Sclnnidt et al., 2000; 
Bierhaus et al., 2001). The studies performed in Chapter 5 aimed to address the hypothesis 
that RAGE expression was modulated in response to APAP toxicity. This work served to
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gain further mechanistic understanding of inflammation associated with DILI, using our 
APAP model. A novel finding in these studies was that RAGE was found to be localised in 
the nucleus of a small number of hepatocytes post APAP treatment. This finding requires 
further investigation to determine if this is a functional response by cells to sequester RAGE 
in the nucleus to prevent further inflammatory signalling, thereby acting as a negative 
feedback loop to prevent prolonged inflammation. Functional blockade of RAGE by 
application of recombinant RAGE significantly diminished liver damage according to a study 
by Ekong et al. (2006). Future studies should involve utilising recombinant RAGE and other 
low molecular- weight inhibitors of RAGE such as telmisartan (Nakamura et al., 2005) in our 
models to attempt to elucidate the effects of blocking this receptor on inflammation 
associated with DILI and the overall pathophysiology. Inhibition of the HMGB1/RAGE 
interaction may provide a new possibility for the treatment of DILI and requires further- 
investigation. Whether RAGE inhibitors will be useful at the later stages of APAP-induced 
liver injury or in other cases of DILI remains to be determined.
6.7 Concluding remarks
In summary, the experiments planned within this thesis were designed to further address our 
understanding of the role of the innate irmnune system and inflammatory response during 
DILI. In particular*, the aims of the investigations presented in this thesis were to assess the 
contribution of inflammation by tar-geting certain points in the signalling pathway between 
necrotic hepatocytes and cells of the imrate immune system. However, due to the continually 
increasing complexity of the innate immune and inflammatory-mediated liver injury 
mechanisms as well as some of the controversies in the literature, not all aspects of this field 
could be covered in depth. As DILI is a significant burden for drug development in addition 
to morbidity and mortality, a preclinical in vivo model to incorporate inflammatory cells to 
assess immune responses is essential to address all potential aspects of DILL One of the aims 
of this thesis was to have a set of in vivo models that could be utilised to investigate 
simultaneously the molecular- mechanisms involved in hepatotoxicity and inflammation. The 
use of model hepatotoxins APAP and GalN and the inflammation-inducing endotoxin LPS, 
as tools to induce a specific response, have proved capable of assessing the pathway 
associated with DILI and inflammation, and the potential of pharmacological agents to
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modulate inflammation by targeting specific parts of the signalling pathway. One novel 
finding in this thesis was the potential for EP to be used as a pharmacological inhibitor of 
DILI-associated inflammation in mice; however, further work is required to translate this to 
the clinic. Another was the expression of RAGE in the nucleus of hepatocytes during DILI. 
The full implications of the mechanism of the inflammatory response during DILI and the 
subsequent consequences in the liver still remain to be elucidated, but the work presented in 
this thesis has provided evidence to suggest that the overall conhibution of the innate immune 
and inflammatory responses during APAP induced hepatotoxicity is minimal.
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